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ABSI PAC T 
Much interest has been shown recently in the components 
of the surfaces of the rod and cone photoreceptor cells 
in the mammalian retina and in the constituents of the 
interphotoreceptor matrix (IPM) which interact with the 
surfaces of the photoreceptor cells. Such molecules 
are likely to assist in- maintaining the structures of 
the photoreceptor cells and /or to have functional roles 
in the continual interactions between the pigmented 
epithelium cell layer and the neural retina. 
Abnormalities in the composition of such molecules may 
lead to disease states in which such structures and 
functions have broken down. 
One approach to identifying constituents of the 
surfaces of cells is to use cell -specific probes in the 
form of monoclonal antibodies which can be raised 
against cell- specific surface molecules, and may be 
used to identify these molecules and to allow 
comparisons to be made between normal and diseased 
tissue. 
Mice immunised with partially purified surface 
molecules of photoreceptor outer segments or with a 
synthetic peptide corresponding to the N- terminus of a 
cone -specific rhodopsin -like protein, gave rise to the 
production of monoclonal antibodies with only general 
immunoreactivity against the retina. 
Immunisation with interphotor-eceptor matrix or crudr' 
photoreceptor outer segment preparations resulted in 
the production of hybridomas which secreted monoclonal 
antibodies 1001.A1 and .1001.A3. 
100l.A1 binds to the interstitial retino].- binding 
protein (IRBP), associated with the rod photoreceptor 
cells and the IPM, as demonstrated by immunohisto- 
chemistry and by Western blotting and dot blotting of 
IPM and purified IRBP. 
1001.A3 binds a soluble high molecular weight 
chondroitin sulphate proteoglycan. 
Immunohistochemistry indicated the antigen to be 
present in the form of distinct sheath -like structures 
surrounding the photoreceptor cells. Gel filtration 
chromatography both in native conditions and in the 
presence of guanidinium chloride showed the antigen to 
have an apparent molecular mass of greater than 
2000kDaltons and indicated the antigen was not a 
loosely associated aggregate of smaller components. 
Binding of .1007.A3 to fixed tissue sections of the 
bovine retina was completely abolished by their prior 
treatment with either chondroitinase ABC, 
chondroitinase AC, hyaluronidase (testicular) or 
trypsin. Prior treatment of tissue sections with 
either heparinase or neuraminidase had no effect on 
binding. Treatment of tissue sections with 
hyaluronidase (Streptomyces) had no effect on the 
ability of 1001.A3 to bind, but the structure of the 
antigen was altered. The sheath -like structure 
surrounding the photoreceptors was broken down and 
immunoreactivity was seen in the same area of the 1PM, 
adjacent to the photoreceptors but with no defined 
structure. In conclusion, the antigen is a chondroitin 
sulphate molecule which is associated with hyaluronic 
acid molecules and which together form a defined 
sheath -like structure surrounding the photoreceptor 
cells. 
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1.1. Structure of the mammalian neural retina. 
The mammalian neural retina contains five classes of 
neural cells: photoreceptor cells, bipolar cells, 
ganglion cells, horizontal cells and amacrine cells. 
Neural cells are found throughout the central nervous 
system and the retina is often used as a model for the 
studies of the central nervous system, being more 
accessible and simpler in organisation than brain 
tissue. 
Also present in the neural retina are glial cells, the 
major type being the Muller cells which are the only 
cells to span radially across the entire retina, from 
the outer to the inner limiting membranes. Also present 
are astrocytes, which are mainly confined to the 
ganglion cell layer. Each neural cell type forms a 
layer of cells across the retina, so giving it a very 
ordered structure, stratified in appearance (Figure 
1.1.). 
1.2. Development of the neural retina - 
In the vertebrate eye there are two neurally- derived 
tissues, the neural retina and the retinal pigmented 
epithelium (RPE). 
During development of the human retina, the progenitors 
of these two tissues are initially separated. In the 
fourth week of gestation, these come together when the 
optic cup is formed. At this stage, the external, 
presumptive cell layer has no pigment and the retina 
(2) 
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(Adapted from Rhodes 1979) 
(3) 
consists of an outer and an inner marginal layer. In 
the seventh week there is present an inner layer of 
mostly ganglion cells and an outer neuroblastic layer. 
In the ninth week of gestation there are four major 
horizontal layers present. There is a distinctive 
plexiform layer separating the inner ganglion cell layer 
from the outer cell layers. After this the cone cells 
appear, to form part of the outer row of the outer 
neuroblastic layer. Only by mid -term are the nuclei of 
rod cells apparent in the outer nuclear layer, by which 
time the cone axons have elongated and the pedicles 
widened, terminating in a widening outer plexiform layer 
(Rhodes 1979),(Figure 1.2.). In the following weeks, 
the retina widens further, the peripheral retina 
maturing before the macular area. 
In contrast to the human retina, the mouse retina has 
not undergone differentiation by the time of birth. 
Only two weeks after birth, do the developing outer 
segments give the retina an almost mature appearance and 
development is not complete until postnatal day thirty- 
five (Caley et al 1974), (Figure 1.3.). 
1.3. Function of the retina 
The overall function of the retina is to produce 
chemical messages, which are understood by the brain, in 
response to light signals. In addition to producing a 
static picture of the field of vision, the retina is 
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Figure 1.3 Diagram of the development of the neural 
retina of the normal and of-the CBA rod less mouse from 
1 -35 days after birth. 
(Adapted from Caley al 1974) 
(5) 
of light and also of colour. Of the five classes of 
neurones present, three are directly responsible for 
this. 
Light is initially absorbed by the photoreceptor cells 
which synapse with the bipolar cells which in turn 
synapse with the ganglion cells (or in the case of the 
rod stimulated bipolar cells, via the amacrine II cells) 
(Sterling et al 1986). The final message is transported 
to the brain from the ganglion cells, via the optic 
nerve. The horizontal cells and the amacrine cells have 
associated regulatory functions (Kolb et al 1981, 
Sterling 1983). As well as enhancing stimulated bipolar 
cells, the horizontal cells inhibit surrounding bipolar 
cells so producing a greater contrast between stimulated 
and unstimulated cells. The horizontal cells are also 
regulatory and act on classes of ganglion cells 
including those which are direction dependent. 
Amacrine cells contain different neurotransmitter -like 
molecules such as substance P or acetylcholine. These 
cells terminate at one of the sub -sets of ganglion cell 
synapses within the inner plexiform layer (Brecha et al 
1987). Cells containing one type of neurotransmitter do 
not contain any of the other neurotransmitter -like 
molecules found in the other amacrine cells (Osborne 
1982). The amacrine cells are classified on this basis. 
(6) 
1.4. Light absorbtìon by the photoreceptor cells 
The photoreceptor cells are responsible for the primary 
step of the visual cycle. It is in these cells that 
photons are initially absorbed and a chemical response 
produced (Wald 1968; Baylor 1987). The major protein of 
rod outer segments, opsin, binds 11 -cis retinal to 
become rhodopsin. When light is absorbed by rhodopsin, 
it is bleached, that is the 11 -cis retinol is converted, 
via several intermediates to its all -trans form (Hubbard 
and Kropf 1968), which dissociates from the opsin. This 
process leads to the catalysis of a series of reactions 
similar to that of the adenylate cyclase system. In the 
case of the rod photoreceptor cells, the photo- excited 
rhodopsin catalyses the release of GDP and the binding 
of GTP by transducin molecules. The GTP.transducin 
complex releases an inhibitory constraint on the cGMP- 
dependent phosphodiesterase and cGMP hydrolysis is 
initiated. The final result is a reduction in the 
levels of cGMP within the outer segments of light - 
stimulated rods. 
Rods are active when unstimulated in the dark, in that 
ion channels in the plasma membrane of the outer segment 
allow a continuous influx of sodium ions, producing the 
"dark" or photosensitive current, and the photoreceptor 
cells are thereby constantly depolarised. Light causes 
the ion channels to close and the whole cell to 
hyperpolarise with a reduction in transmitter release 




Figure 14.. Diagram of Rod (left) and cone (right) 
photoreceptor cells. 
The light sensitive outer segments (OS) are composed of 
discs (D), the main intrinsic protein being photo - 
pigment. The discs develop as evaginations of the 
plasma membrane of the OS base to form basal discs (BD). 
The rod discs are pinched off from the plasma membrane 
whereas the cone discs are continuous with each other. 
The rod discs have incisions (I) and are attached at 
their margins by disc filaments (DF). The OS and inner 
segments (IS) are linked by connecting cilium (CC). The 
IS contains the nucleus and is composed of an ellipsoid 
(E) rich in mitochondria and a myoid (M) containing 
organelles for the synthesis and transport of macro- 
molecules. Calycal processes (CP) are continuous with 
the IS. The synaptic terminal (ST) may contain multiple 
synaptic ribbons (SR) which are surrounded by synaptic 
vesicles 
(Cdapte. d from Bok 1985) 
(9) 
messenger is necessary for the transduction process and 
recent experiments using isolated patches of rod outer 
segment plasma membrane suggest that the cGIMP is 
responsible for this, acting allosterically to close the 
ion channels (Fesenko et al 1985). 
1.5. Structure of the photoreceptor cells 
There are two types of photoreceptor cells, rods which 
are responsive to dim light of broad wavelength 
specificity, and the cones, which respond to light of 
different wavelengths, that is to coloured light. These 
two cell types are similar in structure in that both 
consist of an outer segment portion, an inner segment 
bridged by a connecting cilium and a cell body 
containing the nucleus. The outer segments show obvious 
morphological differences. They have different shapes, 
the rods are cylindrical whereas the cones are tapered 
towards their tips giving them a conical shape. The 
plasma membrane of the rod outer segments forms 
evaginations from the connecting cilium to produce 
internal stacks of independent plasma membrane discs 
along the entire length of the structure. The cones 
differ in that the plasma membrane of the outer segment, 
although evaginated along its length, is continuous and 
no discs are present (Figure 1.4.). 
It is possible to isolate rod outer segments from the 
retina by loose homogenisation which releases the rod 
outer segment discs. These can be harvested by density 
(9) 
gradient centrifugation. Cone outer segments however 
are not found in any recognisable form. This ability to 
isolate rod but not cone outer segments, as well as the 
high average ratio of rods to cones in the mammalian 
retina (Marc and Sperling 1977), has meant that to date 
less biochemical analysis has been carried out on 
mammalian cones whereas the rods have been more fully 
characterised. Recent recombinant DNA methods have 
allowed some comparisons to be made between the two cell 
types. Genes have been cloned from each which encode 
similar but distinctly different proteins, for example, 
rod and cone cells have specific colour pigment proteins 
(Nathans et al 1986) and transducinU sub -units (Grunwald 
et al 1986; Lerea et al 1986; Lerea et al 1989). 
1.6. Interactions between the photoreceptor cells and 
the Retinal Pigmented Epithelium (RPE) layer 
When studied by electron microscopy it is seen that the 
tips of the photoreceptors are in close proximity to the 
adjacent pigmented epithelium cell layer. These cells 
are continually engulfing the tips of the photoreceptors 
(Young and Bok 1969), which means that the 
photoreceptors must continually synthesise new proteins 
and membrane throughout life in order to maintain their 
on structure. When pulsed with radiolabelled amino 
acids, the subsequent autoradiographs showed the 
movement through time of newly- synthesised 
(radiolabelled) proteins from the inner segments towards 
(10) 
the tips of the rod outer segments where they were 
finally phagocytosed by the pigmented epithelium cells 
(Young and Bok 1969). In contrast, in cones, 
radiolabelled proteins were diffused throughout the 
outer segments before they were phagocytosed at the tips 
(Hagan et al 1974). From this it would appear that 
different mechanisms exist in rods and cones for the 
maintainance of their structure. There must be some 
additional (as yet unknown) mechanism in cones to 
maintain their tapered shape as their tips are removed. 
At present, the recognision signal(s) involved in the 
interaction between the RPE and the photoreceptors are 
unclear although the phagocytosis process is highly 
specific towards the rod outer segments (Mayerson and 
Hall 1986). The rhodopsin present in the rod outer 
segment disc membrane of the plasma membrane has been 
suggested as a possible ligand recognised by the RPE 
cells. Studies so far have shown that neither the 
carbohydrate groups of the rhodopsin (Shirakawa et al 
1987), nor purified rod outer segment disc membranes 
(Laird and Molday 1988) are responsible for this. It 
has been suggested that some component specific to rod 
outer segment plasma membrane may be the ligand 
responsible (Laird and Molday 1988). Rod outer segment 
plasma membrane -specific glycoproteins have been 
identified (Molday and Molday 1987a; 1987b; Polans and 
Burton 1988; Cook et al 1989), although functions have 
been assigned to only some of these. The lipid 
compositions of the disc membranes and the plasma 
membrane are also distinct (Boesze -Battaglia and Albert 
1989). It has also been shown that the process of 
phagocytosis is under periodic control (LaVail 1976) and 
is independent of the visual cycle. 
It would seem reasonable to suggest that the surface 
components of the photoreceptor cells and the contents 
of the space between the retina and the pigmented 
epithelium which surrounds the photoreceptors may have 
some influence. 
1.7. Cell surface molecules of the photoreceptors 
Lectins have been used to study the cell surface 
molecules of the photoreceptor cells. Lectins are 
chemicals, usually plant derived, which bind to specific 
carbohydrate moieties. They therefore distinguish 
between glycoconjugates present on the surface of a cell 
which contain different carbohydrate structures. 
A number of lectins have been used to study the cell 
surface glycoconjugates of the developing and mature 
retina of various species (Bridges 1981; Blanks and 
Johnson 1983; 1984; Uehara et al 1985;). For example, 
in vertebrates the lectin Concnavalin A (ConA - specific 
for glucose and mannose residues) binds to cells in all 
layers of the retina, but is most highly concentrated in 
the outer segments due to the large amount of rhodopsin 
present there (Blanks and Johnson 1983). This compares 
to Wheatgerm Agglutinin (NBA - specific for N- acetyl 
(12) 
glucosamine and sialic acid residues), which binds less 
strongly to the inner retinal layers whilst the outer 
segment reactivity is high (Blanks and Johnson 1983), 
again partly due to the rhodopsin which contains these 
sugar residues. Neuraminidase treatment reduces the 
outer segment binding of the lectin (Uehara et al 1985), 
suggesting that reactivity is due to the sialic acid 
component of the glycoconjugates. Wood et al state that 
in rat (and probably Man), trypsin digestion of the 
retina results in the confinement of binding to trypsin- 
resistant, WGA- binding domains on the distal tips of 
some outer segments at the outer segment /retinal 
pigmented epithelium interface (Wood et al 1986). These 
WGA- binding domains indicate the presence of a distinct 
population of neuraminidase- sensitive sialoglyco- 
conjugates (Wood et al 1986). 
In contrast, Peanut Agglutinin (PNA - specific for D- 
galactose ß -1 ->3 N- acetyl- galactosamine- galactose 
residues) does not bind to rhodopsin and reacts with a 
sub- population of the photoreceptor outer segments, 
postulated to be cone outer segments (Bridges 1981; 
Blanks and Johnson 1983; Uehara 1983; Uehara et al 1985; 
Hageman and Johnson 1986). This is true for many 
species including fish, rabbit, monkey, human, chick, 
turkey, rat and dog (Blanks and Johnson 1984; Hageman 
and Johnson 1986). Improved embedding and fixation 
processes allowed light microscopy at a higher 
resolution to be carried out. This showed the PNA- 
(13) 
binding material to be present in the interphotoreceptor 
matrix, in the form of distinct domains which ensheath 
the vertebrate cone photoreceptors, rather than to be a 
structural part of the cones themselves (Johnson et al 
1985; Johnson et al 1986). Oblique tissue sections show 
this PNA- binding cone extracellular matrix sheath to be 
composed of structural entities which are sensitive to 
trypsin but not to chondroitinase ABC, chondroitinase AC 
or heparinase (Johnson et al 1986), suggesting that 
glycosaminoglycans are not major sheath components. PNA 
also binds to cone cell body and axonal membranes, to 
cone synaptic pedicles located in the outer plexiform 
layer, to regions within the inner plexiform layer, and 
to the inner limiting membrane (Blanks and Johnson 1983; 
1984). It has been suggested that some retinal PNA - 
binding glycoproteins might serve as specific molecular 
markers for cone photoreceptor cells. 
To date much less is known about the molecular 
composition of the cone photoreceptors than about the 
rods. Differences in the chemical reactions and control 
mechanisms within the two cell types have yet to be 
studied. A 33kDalton fucosylated glycoprotein has been 
identified in the cone photoreceptors of fish, which is 
not present in the rods. The PNA- binding properties of 
this molecule have not been determined (Bunt and Saari 
1982). Similarly, there is a preferential uptake of 
radiolabelled galactose in the bovine cones but not in 
rods (Keegan et al 1985). Again the PNA- binding 
(14) 
properties of the final synthesised product have not 
been studied and it is not known if this is the PNA - 
binding material associated with the cones. 
Many attempts have been made to isolate and characterise 
the PNA- binding glycoproteins present in the cone 
sheaths of the interphotoreceptor matrix. The 
literature concerning these glycoproteins is somewhat 
confusing. Some reports indicate the presence of high 
molecular weight PNA -binding glycoproteins (Uehara et al 
1983; 1986b). Western blots of monkey retinal extracts 
were treated with PNA and identified a 160kDalton 
glycoprotein, although PNA- affinity chromatography 
failed to isolate this molecule. Polyclonal antibodies 
raised against this molecule recognise molecules present 
on both the rod and cone cells (Uehara et al 1986a). 
A PNA- binding glycoprotein with a molecular weight 
similar to that of the interstitial retinol binding 
protein (IRBP) has been identified in the human retina 
(Shuster et al 1987). This molecule has a distribution 
pattern distinct from that of IRBP as it is associated 
with both the rods and cones whereas IRBP is associated 
with the rods only. The fact that PNA binding is 
limited to the cones and that this high molecular weight 
PNA- binding glycoprotein is found to be associated with 
both the rod and cone cells may indicate that not all 
forms of the molecule are glycosylated to the same 
extent and that forms which do not bind PNA are 
associated with the rod photoreceptors, whilst the 
(15) 
other(s) is /are seen associated with the cones. Other 
studies have indicated the presence of predominantly 
lower molecular weight PNA- binding glycoproteins 
(Johnson et al 1985; Hageman and Johnson 19B6), with 
varying degrees of glycosylation (Uehara et al 1986b). 
These are largely conserved throughout many species 
including turkey, rat, dog, pig, monkey and human. The 
fact that many of these molecules are susceptible to 
trypsin, and that the PNA- binding sheaths surrounding 
the cone photoreceptors are also susceptible to trypsin 
would suggest that these isolated PNA- binding 
glycoproteins are present within the sheath structures 
in vivo ( Hageman and Johnson 1986). 
1.8. The interphotoreceptor matrix 
The space between the photoreceptor cells and the 
pigmented epithelium cell layer is known as the 
interphotoreceptor matrix (IPM)(Röhlich 1970). In 
contrast to the material in the extracellular matrix of 
connective tissues, studies have indicated that neither 
fibronectin nor collagen are present in the IPM (Adler 
and Klucznik 1982; Kohno et al 1983) and that the 
soluble protein fraction of bovine IPM consists of 
protein and glycoprotein (98% w /w) and glycosamino- 
glycans (2% w /w) (Adler and Klucznik 1982; Adler and 
Severin 1981). The IPM is critical in the transfer of 
nutrients and metabolites to and from the photoreceptors 
since these cells rely predominantly on the choroidal 
(16) 
capillaries behind the RPE rather than the blood vessels 
of the retina itself. Components of the IPM must also 
have structural roles with respect to the maintainance 
of the shapes of the photoreceptor cells. The IPM has 
also been implicated as having a role in retinal 
adhesion, phagocytosis and retinoid transfer (Zimmerman 
and Eastham 1959; LaVail et al 1981; Adler and Klucznik. 
1982; Fong et al 1984; Okajima et al 1989) although the 
functions of many of the individual IPM molecules are 
not known for certain. 
There is also uncertainty as to where most of the 
constituents of the IPM are synthesised. It is most 
likely that the surrounding photoreceptor, Muller or RPE 
cells are responsible for their synthesis and subsequent 
secretion into the IPM (Adler and Severin 1981). 
Initial studies of the constituents of the IPM 
concentrated on the glycosaminoglycans present in it. 
Histological studies were carried out with the use of 
cationic dyes to demonstrate the presence of 
glycosaminoglycans with dyes such as ruthenium red, 
alcian blue, colloidal iron and silver methanamine used 
to identify polysaccharide -rich molecules (Zimmerman and 
Eastham 1959; Röhlich 1970; Feeney 1973). 
Further analysis of the glycosaminoglycans involved the 
chemical fractionation and characterisation of the 
glycosaminoglycan chains (Bach and Berman 1971a; 1971b). 
(17) 
The ability of the neural retina to incorporate 
radiolabelled sulphate and to deposit radiolabelled 
sulphated glycosaminoglycans into the medium indicated 
that cell types within that tissue were responsible for 
their presence in the IPM (Hall et al 1965; Occumpaugh 
and Young 1966; Morris 1984). Similar types of studies 
have also implicated the cells of the RPE as a source of 
glycosaminoglycans in the IPM (Zimmerman and Eastham 
1959; Röhlich 1970; Stramm 1987). It is, of course, 
likely that both sources provide the IPM with a distinct 
set of glycosaminoglycan molecules. 
More recent histological studies of the IPM have used 
the dyes cuprolinic blue (Tawara et al 1988) and 
cupromeronic blue (Tawara et al 1989) which may be used 
at a critical electrolyte concentration to stain 
sulphated polyanions. Such studies have indicated the 
presence of chondroitin sulphate -type molecules in 
distinct areas within the IPM. Large aggregates 
surrounding the photoreceptor cells were identified, as 
well as smaller filaments in the area of the IPM 
adjacent to the RPE. No staining was apparent within 
the photoreceptor cells whereas staining was seen within 
the RPE cells. It is possible that the RPE cells are 
responsible for the synthesis and the subsequent 
secretion of these chondroitin sulphate -type molecules 
in the form of the smaller filaments and that these 
(18) 
filaments then aggregate to form the large mass of 
chondroitin sulphate -type structures surrounding the 
photoreceptor cells. 
Immunocytochemica l analyses of the IPM have also been 
carried out using monoclonal antibodies raised against 
chondroitin sulphate molecules after digestion to remove 
their sulphate groups. It was found that rat IPM 
contains 6- sulphated chondroitin sulphate and also 
unsulphated chondroitin proteoglycans in distinct 
regions of the IPM, and does not appear to contain 4- 
sulphated chondroitin sulphate or dermatan sulphate 
proteoglycan (Porello and LaVail 1986; Porello et al 
1989). In primates it was found that chondroitin 6- 
sulphate glycosaminoglycan is a major constituent of the 
cone photoreceptor matrix sheath (Hageman and Johnson 
1987). From this it would appear that physical 
interactions may occur between certain types of 
glycosaminoglycan structures and specific molecules 
associated with the surfaces of the different 
photoreceptor cell types, for example the PNA- binding 
glycoproteins discussed in 1.7, and primate chondroitin 
6- sulphate proteoglycans would appear to be co- 
localised, in the area surrounding the cone 
photoreceptor cells. 
Studies of the proteins and glycoproteins within the IPM 
are less extensive. Proteins have been identified by 
SDS- polyacrylamide gel electrophoresis and many are 
conserved between a wide variety of species (Adler et al 
(19) 
1988). The functions of these molecules are largely 
unknown althought the most abundant glycoprotein present 
in the IPM, the interstitial retinol binding protein 
(IRBP) has been well characterised. 
1.9. The interstitial retinol binding protein 
The interstitial retinol binding protein (IRBP) is the 
major component of bovine IPM where it is present at a 
concentration of 30 -100uM Adler and Klucznik 1982). Its 
molecular weight on calibrated gel filtration columns 
appears to be 249 000 Daltons while SDS- polyacrylamide 
gel electrophoresis gives an apparent molecular weight 
of 144 000 Daltons suggesting that it may exist as 
dimers (Fong et al 1984a). Bovine IRBP contains 8.4. 
(w /w) carbohydrate, consisting of sialic acid, neutral 
hexoses and glucosamine in a molar ratio of 1:3:2 and it 
has at least four Concanavalin A binding forms with pI 
values ranging from 4.4 to 4.8 (Fong et al 1984a). An 
analogous protein has been isolated from human IPM with 
an apparent molecular weight of 135 000 Daltons. 
Studies with lectins suggest that at least one of its 
oligosaccharide chains is a sialated biantennary complex 
type containing fucose (Fong et al 1984b). Monkey 
neural retinas incubated in vitro in media containing 
[7.H]Fucose (Holleyfield et al 1985), or [ '5H]Leucine 
(Fong et al 1984b) and also bovine retina incubated with 
(20) 
[H)Fucose (Fong et al 1984a), have both been shown to 
synthesise and secrete radiolabelled IRBP into the 
medium. 
Immunocytochemistry using polyclonal antibodies however, 
has shown IRBP to be confined predominantly to the IPM 
(Fong et a1 1984b, Schneider et al 1986). It may be 
that the antigenic determinants are somehow masked, or 
that the protein is in too low a concentration within 
the cells of the retina to be detected by these means. 
The cellular origin of IRBP was found from the 
distribution of a cDNA clone of the IRBP gene. This was 
restricted to rod outer segments and to pineolocytes 
(van Veen et al 1986). 
Bovine IRBP binds two molecules of all -trans retinol 
(Fong et al 1984a) and is the only retinol- binding 
species in the interphotoreceptor matrix (Pfeffer et al 
1983). It also bind exogenous cholesterol, d%- tocopherol 
and all -trans retinoic acid, all of which are completely 
displaced by all -trans retinol (Fong et al 1984a). The 
amount of retinol bound to IRBP depends on the 
proportion of bleached rhodopsin in the retina. Light - 
adapted IPM contains much more bound retinol than does 
dark -adapted IPM (Adler and Martin 1982). It is 
believed that IRBP may be involved in the transfer of 
retinol between the RPE and the retina during the visual 
cycle. It has been suggested that it may also have a 
protective role preventing the oxidation of the retina 
(21) 
by retinol, which itself is a highly toxic molecule, or 
by other exogenous materials such as dk- tocopherol (Fong 
et al 19B4a). 
1.10. Abnormalities of the retina 
There are many genetic diseases involving abnormalities 
of the retina which ultimately lead to blindness. 
Retinitis Pigmentosa is the collective name for many 
such diseases. The disease often becomes apparent in 
the early twenties when the degeneration of the 
photoreceptors is observed leading to a pigmented effect 
on the retina. There is a preferential loss of rod 
photoreceptors, the cones remaining intact for much 
longer periods. Degeneration is gradual and finally 
leads to blindness after many years of a gradual loss of 
sight. 
The disease often becomes apparent later in life and is 
not a fatal condition, and so it is rare to obtain 
affected eyes for research purposes, especially those 
which are at an early stage of the disease. Much 
research has therefore turned to the use of suitable 
animal models. 
The retina of rodents provides a convenient system in 
which to study the development of healthy and diseased 
retina because of its rapid postnatal development 
(1.2.). There are several inherited retinal defects 
such as the retinal degenerate mouse (Sidman and Green 
1965), the rodless CBA mouse (Caley et al 1974) (Figure 
(22) 
1.4.), the Purk.inje cell deficient (pcd) mouse (LaVail 
et al 1982) and the Royal College of Surgeons (RCS) rat 
(Bok and Hall 1971). 
In the case of the RCS rats, the disease is associated 
with a mutation in genes of the cells of the pigmented 
epithelium, which ultimately leads to the degeneration 
of the photoreceptor cells. Here the pigmented 
epithelium is unable to phagocytose the rod outer 
segments when they are shed by the photoreceptors. As a 
result, photoreceptor fragments accumulate in the IPM, 
debris builds up and the photoreceptors begin to 
degenerate. Within one month, only the cone 
photoreceptors remain. If the IPM plays a key role in 
normal photoreceptor physiology it is important to study 
the IPM in those diseased states in which the 
photoreceptors degenerate. Histochemical studies 
using alcian blue, toluidine blue and colloidal iron to 
detect glycosaminoglycans, metachromatic staining 
substances and highly negatively charged substances 
respectively have been used to follow the development of 
the retina of the RCS rat (LaVail et al 1981; Cohen and 
Nir 1984). This showed the normal intense staining of 
the IPM next to the retinal pigmented epithelium to be 
incomplete in RCS rats and that this staining disappears 
as debris builds up. The basal outer segment staining 
however is greater in RCS rats presumably due to the 
abnormal accumulation of IPM in this region. It is 
possible that this IPM distribution alters the normal 
(23) 
diffusional processes, resulting in photoreceptor cell 
death. For example, proteoglycans of the IPM may form 
some physical barrier and may cause either the 
accumulation of metabolites next to the photoreceptors, 
or the exclusion of these metabolites from the debris. 
In order to understand the mechanisms of disease, a 
standard model- of developing tissue is necessary to 
allow comparisons to be made between diseased and 
healthy tissue at specific stages of development. 
Cell lineage pathways have been constructed to establish 
the ancestry of specific cell types and to identify the 
progenitors of these cells (Turner and Cepko 1987; Adler 
and Hatlee 1989). Although these studies show where 
cells originate, they do not show how the differ- 
entiation process is regulated and which environmental 
or genetic factors have any effect. 
1.11. Specific cell markers 
The alternative approach to this problem is to identify 
cell -specific markers within the tissue. One such 
method is to study the carbohydrate structures of the 
glycoconjugates present on the surface of cells, using 
them to provide differentiation markers for use in the 
study of tissue development. Lectins have often been 
used for this purpose, however their uses are limited in 
that they do not bind specifically to single molecular 
structures and lectin affinity chromatography cannot 
distinguish between different molecules containing 
(24) 
similar carbohydrate moieties. For example, PNA -agarose 
affinity chromatography of solubilised retinal tissue 
would not distinguish between the PNA- binding material 
of the inner retina and that associated with the cone 
photoreceptors (1.7.). The use of further standard 
chemical purification steps to fractionate the mixture 
of PNA- binding components would lead to the isolation of 
a molecule of unknown source. Hence a further method of 
detection and identification is often required. 
Two tools have recently become available for 
establishing this, that is, monoclonal antibodies and 
recombinant DNA molecules. These both offer the 
possibility of defining some of the molecules of 
importance in the retina. Both methods rely upon the 
ability to clone pure reagents out of heterogeneous 
starting mixtures. This is very important when the 
complexity of the tissue makes it extremely difficult to 
obtain any single molecule in sufficient quantity and 
purity for more traditional approaches. A major 
difference however between the two techniques is that 
molecules can become localised in different sub -cellular 
components, for example, to the outer segments of the 
photoreceptors or to the dendrites of nerve cells. This 
distinction is not picked up by DNA probes but may be by 
antibodies, that is, the final gene product is detected 
as opposed to the gene itself. 
(25) 
Monoclonal antibodies can be raised against specific 
antigens to link in vivo and in vitro studies by 
allowing unambiguous cell identification and studies in 
cellular heterogeneity, detecting gradients of 
expression and control of development, so leading to an 
understanding of these features in molecular terms. It 
was hoped that monoclonal antibodies would reveal unique 
cell surface antigens in embryogenesis, differentiation 
and oncogenesis. However many were found to be 
carbohydrate structures of glycoproteins and glycolipids 
occuring in many cell types (Siddiqui and Hakamori 1971; 
Slomiany et al 1982), suggesting important roles for the 
diverse carbohydrate structures as receptors involved in 
cell growth and differentiation. It may be that the 
sequential addition (or deletion) of a monosaccharide 
might be a mechanism for the appearance or disappearance 
of antigens during stages of development and 
differentiation (Feizi 1981; Gooi et al 1981). possibly 
due to differences in enzyme activities. There is the 
possibility that saccharides are the cell surface 
markers that distinguish immature from mature cells, and 
tumour cells from their normal counterparts. The 
carbohydrate sequences may have specific roles in normal 
cell growth and differentiation and the disruption of 
this may contribute to the disordered behaviour of 
tumour cells. Roles of the terminal galactose residues 
of asialo -glycoproteins as recognision structures for 
their clearance from serum by uptake into hepatocytes, 
(26) 
and the importance of phosphorylation of mannose 
residues on lysosomal enzymes for their correct routing 
to lysosomes have been well established (Ashwell and 
Hartford 1982). 
Monoclonal antibodies would appear to be very useful 
tools for studies of glycoconjugates of specific cell 
types and to be a very sensitive method of vivalising 
diversity in individual cells. 
1.12. The use of monoclonal antibodies in studies of 
the neural retina 
Monoclonal antibodies have been raised against the major 
cell classes in the retina: rod photoreceptor cells 
(Barnstable 1980; Fekete and Barnstable 1983; Hicks and 
Molday 1986; McKechnie et al 1986; Cook et al 1989); 
bipolar cells (Barnstable et al 1983); amacrine cells 
(Barnstable et al 1985); horizontal cells (Young and 
Dowling 1984); Müller cells (Barnstable 1980; Barnstable 
et al 1983; Lemmon 1985); ganglion cells (Barnstable and 
Drä.iger 1984; Fry et al 1985). Reports have been more 
recently made of monoclonal antibodies against the cone 
outer segments (Lemmon 1986; Szél et al 1986; Johnson 
and Hageman 1988; Lerea et al 1989). 
Monoclonal antibodies have been produced against 
molecular markers of cell position. Such molecules have 
been postulated to play a role in the development of the 
nervous system. Antibodies have been raised against TOP 
molecules (Trisler et al 1986); N -CAM molecules (Noble 
(27) 
et al 1985); JONES molecules (Constantine -Paton et al 
1986). Monoclonal antibodies have also provided 
developmental markers for neural retina tissue (Cole and 
Glaser 1984; Sarthy and Bacon 1985). 
Also available are monoclonal antibodies which have been 
raised against molecules known to be specific to a 
single cell type in various tissues of origin, for 
example intermediate filaments, which have been used to 
identify neural and glial cells (Hyndman and Lemmon 
1975). These however have a limited use, since often 
the intermediate filament specific for a mature cell 
type appears late in development. This is true for 
glial fibrillar acidic protein in glial cells. 
In addition, monoclonal antibodies have been reported 
which are specific to sub -classes of a specific cell 
type. Young and Dowling have reported monoclonal 
antibodies specific to sub -classes of horizontal cells 
(Young and Dowling 1984). Such variation between cells 
presumably has some reflection on the functions of these 
cells. 
1.13. Aims of this thesis 
Little is known about the factors involved in 
maintaining the structure of the photoreceptors as they 
are continually renewed throughout life, or the factors 
involved in controlling the phagocytosis which occurs 
between the cells of the RPE and the tips of the 
photoreceptors. Little is known biochemically about 
(28) 
differences in composition between the rod and cone 
photoreceptors, or about the molecules in the IPM which 
associate with these cells. Such molecules presumably 
have regulatory fuctions with respect to the rod or cone 
cells. 
One approach to identifying surface molecules specific 
to a single cell type, or to molecules associated with 
the cell, is to raise monoclonal antibodies. 
Therefore the initial aim of this thesis was to raise 
mouse monoclonal antibodies against cell -specific 
molecules either within, or associated with, the rod and 
cone photoreceptor cells. 
Once established, the monoclonal antibodies would be 
used to characterise the cell -specific molecules in 
biochemical terms. The distribution of the molecules 
would be established and further work would involve 
finding the distribution of the cell -specific molecules 
during development of the retina. This would be carried 
out with the view to establishing a normal pattern of 
development in the retina, with respect to these cell - 
specific molecules, before comparisons could be made 
with diseased retina. 
Throughout the text, references are made to other 
sections of text both forward and backward. These are 
indicated by the relevent section number in paratheses; 
for example, (1.1.) refers to the text in Section 1.1. 
(29) 
SEE T 10N 2 : H 1. STJLO61 CAL MEl HODS . 
2. Histological methods 
2.1. Preparation of tissue sections 
Bovine eyes were trimmed of excess tissue, cut in half, 
the vitreous humour and the anterior portion removed and 
the posterior portion fixed by immersion in fixative 
solution. 
2.1.1. Fixed tissue sections 
Fixation was carried out in a solution of formol calcium 
containing 4% paraformaldehyde (w /v), i% calcium 
chloride (w /v) and 0.5. glutaraldehyde (v /v) in 0.1M 
sodium phosphate buffer pH7.0. The small percentage of 
glutaraldehyde was found necessary to maintain tissue 
integrity without significantly reducing its 
antigenicity. An overnight incubation at 4 °C was 
sufficient to fix the tissue. The aldehyde groups of 
the fixative were quenched by incubating the fixed 
tissue in a 1M solution of sucrose containing 50mM 
ethanolamine pHS and 50mM Tris HC1 pH7.4, overnight. 
Small blocks (approximately 10mm x 3mm) were cut from 
the eye cup, mounted onto Tissue -Tek OCT (Miles 
Scientific), rapidly frozen in liquid nitrogen and 
stored at -20 °C. Microscope slides were subbed by 
dipping in a 1% (w /v) gelatine solution containing 0.05% 
(w /v) chromic potassium sulphate dodecahydrate 
(KCr(SO4) =.M.H.-20) and then air drying. 10 -15 um tissue 
sections were cut at -10 °C using a cryostat (Slee, 
(30) 
London), melted onto subbed slides, dried with a warm 
air flow and stored in a dry box at room temperature. 
The integrity of the retina was checked by staining with 
toluidine blue (2.2.4.). 
2.1.2. Frozen unfixed tissue sections. 
The tissue was prepared as for fixed tissue sections 
except that fresh blocks of tissue were immediately 
embedded in Tissue -Tek OCT and sections cut. 
2.1.3. "Semi- thin" tissue sections 
Small pieces of fixed retina were progressively 
dehydrated in aqueous dimethyl sulphoxide (DMSO) and 
embedded in Lowycryl K4M, using a variation of the 
method of Altman et al (Altman et al 1984). 
Polymerisation took place overnight at room temperature 
in the presence of 360nm UV light. i um tissue sections 
were cut using an LKB ultramicrotome. 
2.2. Treatment of tissue sections 
2.2.1. Antibody treatment using immunofluorescence 
Each incubation was carried out at room temperature in a 
high humidity chamber with a 100 ul aliquot of the 
incubation solution per tissue section unless otherwise 
stated. 
(31) 
Sections of the neural retina were each incubated 
overnight in antibody -diluting solution containing 20. 
(v /v) antibody -containing culture supernatant. The 
antibody -diluting solution consisted of TBS pH 7.4 
containing 5% normal sheep serum (v /v) and 0.05% sodium 
azide (w /v). The antibody solution was then drained 
from the slide which was rinsed in TBS for 10 minutes 
and then drained of any excess liquid before the next 
incubation step took place. The second incubation was 
for 2 -3 hours in a solution containing a 50 -fold 
dilution of a sheep anti -mouse %globulin- biotin 
conjugate (4.6.3.1.) or in a solution containing a 500 - 
fold dilution each of commercial sheep anti -mouse IgM 
biotin and sheep anti -mouse IgG biotin conjugates. The 
slides were rinsed as above, and this was followed by a 
1 hour incubation in a 50 ug /ml solution of 
streptavidin -FITC (4.6.2.1.). Finally the slides were 
rinsed, coverslipped in glycerol and viewed. 
2.2.2. Immunoperoxidase staining 
The first antibody incubation was carried out as 
described in Section 2.2.1., prior to a two hour 
incubation with a 50 -fold dilution of sheep anti -mouse 
`globulin (Scottish Antibody Production Unit, Carlukes), 
in antibody -diluting solution (2.2.1.). This was 
followed by a further two hour incubation with a 6 -fold 
dilution of the culture medium of a mouse monoclonal 
antibody raised against horseradish peroxidase (HRP) (a 
(32) 
gift from Dr. V. van Heyningen, MRC Human Genetics Unit, 
Western General Hospital, Edinburgh). The final 
incubation was for 1 hour, with a 20 ug /ml solution of 
HRP diluted in TBS /lmg /ml BSA. HRP binding was 
visualised by the development of colour on the addition 
of the substrate 4- chloro -l- naphthol in a 20% (v /v) 
methanol solution containing 200 ug /ml 4- chloro -1- 
naphthol and 0.005. H.(3= (v /v) (final concentration) 
(added immediately before use). The sections were 
rinsed between each incubation step and coverslipped 
(2.2.1.) before being viewed. In experiments using 
sections treated by the immunoperoxidase and the 
immunofluorescence methods (2.2.1.), controls were 
carried out on sections where the first antibody was 
omitted from the initial incubation solution. 
2.2.3. Lectin treatment 
A lectin -biotin conjugate solution (4.6.3.2.) 
(containing approximately lmg /ml of lectin) was diluted 
100 -fold in TBS containing lmg /mi of BSA and this was 
incubated in 100 ul aliquots with retina sections for 1 
hour prior to incubation with streptavidin -FITC, as 
described in Section 2.2.1. The sections were finally 
mounted in DPX mountant and viewed. Alternatively the 
sections were incubated for 1 hour in a 200 -fold 
dilution of lectin -FITC (4.6.2.2.) in antibody diluting 
solution for one hour, prior to rinsing and viewing as 
above. 
(33) 
Control sections were run simultaneously where the 
lectin- biotin conjugate solution was omitted, or where 
the lectin solution was preincubated and incubated in a 
solution of TBS containing img /ml of BSA and 200mM 
hapten sugar. 
2.2.4. Toluidine blue staining 
Sections were incubated in stain (0.25 %, w /v) for 5 
minutes, washed in distilled water and dehydrated in 
increasing concentrations of alcohol and finally cleared 
in xylene before being coverslipped in DPX mountant. 
2.3. Treatment of "semi- thin" tissue sections 
2.3.1. Antibody treatment using colloidal gold- silver 
enhancement 
All incubations were done by placing the sections onto 
drops (approximately 0.2m1) of the incubation solution, 
placed on top of a sheet of wax proof paper. Transfer 
between solutions was by means of fine forceps. The 
sections were finally dried onto microscope slides and 
viewed. 
Sections were treated with antibody as before (2.2.1.) 
except that the streptavidin -FITC conjugate solution was 
replaced by a 50 ug /ml solution of streptavidin 
conjugated to 50nm diameter colloidal gold particles. 
The colloidal gold treatment was followed by silver 
enhancement in order to visualise antibody binding. The 
(34) 
sections were washed for 2 -3 minutes in 60mM citric acid 
pH7.0 and incubated in the dark in developing solution 
for 5 -6 minutes. The developing solution was prepared 
in dark bottles and used immediately. 15ml of solution 
A (0.6M hydroquinone in 0.1M citric acid pH7.0) was 
added to 15ml of solution B (50mM silver lactate in 
citric acid pH7.0). The sections were then fixed using 
photographic fixing solution and finally rinsed in 
distilled water. 
2.3.2. Lectin treatment using colloidal gold- silver 
enhancement. 
This was carried out as for treatment with lectin 
(2.2.3.), except that the streptavidin -FITC solution was 
replaced by a solution of streptavidin- colloidal gold, 
which was used as described in Section 2.3.1. 
(35) 
SECTION 3: 1 MONOLOG CAL. ME-1 HODS 
3. Immunological methods. 
3.1. Preparation of Monoclonal antibodies 
3.1.1. Immunisation 
Ten week. -old female Balb \c mice were injected 
subcutaneously at two sites on the flanks with a total 
of 100 ul of immunogen containing approximately 100 ug 
of protein, mixed with Freund's Complete Adjuvent. This 
was repeated four weeks later but with Freund's 
Incomplete Adjuvant replacing the Freund's Complete 
Adjuvant. After a further two weeks, the mice were 
injected intravenously via the tail -vein with 100 ul of 
the immunogen and the cell fusion was carried out four 
days later. 
3.1.2. Medium 
Serum -free medium consisted of RPMI1640 with 0.1% (w;v) 
sodium bicarbonate, 20mM HEPES and 10 -4M ß- mercapto- 
ethanol. This is Dutch modification, especially 
suitable for lymphocytes and resistant to fluctuations 
in CO- concentrations which occur during prolonged 
viewing or manipulation of the cells. 
HAT selection medium consisted of serum -free medium with 
the addition of heat inactivated foetal calf serum to 
give a final 10. (v \v) concentration and also of 
hypoxanthine (13.61mg /l), aminopterin (0.176mg/1) and 
thymidine (3.876mg/1). 
(36) 
In the maintenance medium, the aminopterin was omitted. 
All media used contained the antibiotics penicillin 
(200IU /ml), and streptomycin (0.2mg /m1) and also the 
fungicide, Fungizone (0.25 ug /ml). 
3.1.3. Cell counting 
The cells were counted by applying a drop of the cell 
suspension to a haemocytometer and examining this either 
under phase contrast or by the following acridine 
orange /ethidium bromide method. A volume of the cell 
suspension was added to an equal volume of ethidium 
bromide and acridine orange solution (1 part per million 
of each). Viable cells appear green due to the 
accumulation of acridine orange in acidic compartments 
(lysosomes). Dead cells do not maintain any pH gradient 
and have permeable plasma membranes so allow the entry 
and intercalation of the ethidium bromide into the DNA 
and therefore appear orange (Parkes et al 1979). 
3.1.4. Cell fusion 
This was carried out using a variation of the method of 
Galfré and Milstein (Gaifré and Milstein 1981). 
B- Lymphocytes were obtained from the spleen of an 
immunised Balb /c mouse, and feeder cells (thymocytes) 
from the thymus of a six week -old female c57 /B1 mouse. 
Stock myeloma cells were of the NSO line which do not 
secrete antibody or antibody chains and are also 
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HGPRT Hypoxanthine guanine phosphoribosyl transferase 
tk thymidine kinase 
Figure 3.1 Diagram of the pathways relevant to hybrid 
selection in HAT medium. If the main synthetic pathways 
are blocked with aminopterin, cells depend on the 
"salvage" enzymes HGPRT and tk. HGPRT- cells may be 
selected by growth in medium containing the toxic base 
analogue 8- azoguanine. HGPRT- cells cannot grow in HAT 
medium unless they are fused with HGPRT cells. 
tran sferase (HGPRT). To ensure no revertants 
(insensitive to HAT) were present prior to fusion, the 
NSO cells were cultured in maintenance medium (3.1.2.) 
containing 8- azoguanine (0.13mM), for 24 hours (Figure 
3.1). This selection medium was replaced by fresh 
maintenance medium and the cells were grown to log phase 
before the fusion took place. 
3.1.4.1. Day 0. 
The spleen cells were teased apart by passage through a 
25mm piece of nylon gauze into serum -free medium 
(3.1.2.). The lymphocytes were pelleted from the 10m1 
suspension by centrifuging at 1000g for 10 minutes. 
They were then resuspended in 10m1 of serum -free medium 
(3.1.2) and the cell yield determined (3.1.3.). The NSO 
cells, in log growth phase, were dislodged from their 
flask, pelleted by centrifugation at 1000g for 10 
minutes and resuspended in 5m1 of serum -free medium for 
counting. 
B- lymphocytes were fused with NSO cells at a ratio of 
between 10 and 20 to 1. The correct ratio of the cell 
types were mixed and pelleted together by centrifugation 
at 1000g for 10 minutes. The pellet was kept as near to 
37 °C as possible while 0.8ml of warm polyethyleneglycol 
1540 was added dropwise over a period of 30 seconds. 
After a further 30 seconds of gentle mixing, 2m1 of warm 
serum -free medium was added dropwise over a period of 2 
minutes and the pelleted cells resuspended. A further 
(39) 
bml of warm serum -free medium was added over 3 minutes. 
The cells were then pelleted by centrifugation at 1000g 
for 10 minutes and then gently resupended in a suitable 
volume of HAT selection medium (3.1.2.) containing 
approximately 8x107 thymocytes. The thymocytes were 
prepared 24 hours earlier and had been incubated at 37 °C 
in 5. CO-,). The total volume of HAT selection medium 
used to dilute the fused cells allowed approximately 
1x104 potentially fused NSO cells to be dispensed in 
100 ul aliquots into all the wells of five or six 9b- 
well culture plates. Plates were incubated at 37 °C in 
an atmosphere of humid 5. CO -. 
3.1.4.2. Day 5 
Half the medium was removed from each well by aspiration 
and replaced by 100 ul of fresh HAT selection medium 
(3.1.2.). 
Small colonies of growing hybridomas were usually 
observed around Day 8 by inverted stage microscopy. 
3.1.4.3. Day 10 
The cells were re -fed with maintainance medium 
(3.1.2.), (as by this stage all NSO cells were dead). 
1 -2 days after feeding, the wells were screened for 
anti -retinal antibody secretion (3.1.7.). 
(40) 
When antibody- secreting cell colonies had been 
identified and grown almost to confluence, they were 
transferred to 24 -well culture plates, into a volume of 
500 ul of maintainance medium. 
When the cell colonies became established in the 24 -well 
plates, they were transferred to 25cm12 flasks containing 
5m1 of maintainance medium (repeated testing of antibody 
secretion was necessary at each expansion step). 
Antibody- secreting cells present in flasks were then 
cloned by limiting dilution (3.1.5). 
3.1.5. Cloning cell lines 
Aliquots of resuspended cells were counted (3.1.3.) and 
aliquots of the cells diluted into three different 
volumes of maintenance medium (3.1.2.), so that when 
dispensed in 100 ul aliquots into 96 -well plates, each 
individual well would contain an average of 1,5, or 10 
cells. The growing -up and screening procedures were 
repeated as for the initial growing stages after fusing 
except that maintenance medium was used throughout. 
(3.1.4.). 
If a colony of antibody- secreting cells is produced from 
a single original cell then this is considered cloned 
and to be a true monoclonal antibody. The greatest 
problem is to avoid the presence of non -secreting cell 
lines which may have a tendency to outgrow their 
secreting neighbours. At each stage of expansion, it is 
(41) 
important to check that the cells are still secreting 
antibody as it is not uncommon for cells to stop 
secreting, especially in the initial expansion steps. 
3.1.6. Freezing cells 
Aliquots of established colonies of cells were frozen 
and stored for security. 
Approximately 1x10 cells were pelleted by 
centrifugation at 1000g for 10 minutes and quickly 
resuspended in 500 ul of ice cold 10. DMSO (v /v) in 
foetal calf serum. The cells were initially stored at 
-70°C and then moved into liquid nitrogen for long term 
storage. 
3.1.7. Screening cells 
Initial screening of antibody -secreting cells was 
carried out on fixed tissue sections of bovine neural 
retina, unless otherwise stated (2.1.1.). 
From the 96 -well plates, 20 ul aliquots of culture 
medium from each of six adjacent wells were pooled and 
incubated on a single tissue section. The tissue 
sections were then subjected to treatment as described 
in Section 2.2.1. The six members of each group which 
showed anti -retinal antibody activity were then tested 
individually in order to identify which of the group of 
six contained the antibody- secreting cells. 
(42) 
3.2. Characterisation of antibody secreted by cell 
lines. 
This was carried out by dot blotting, Western blotting 
and immune precipitation. 
3.2.1. Dot blotting 
2 ul of the antigen -containing solution was dotted 
directly onto nitrocellulose membranes and allowed to 
dry. This dotting procedure was repeated several times 
in order to increase the concentration of each dot. The 
membranes were then quenched in TBS containing 0.2. 
(v /v) Tween 20. Antibody culture supernatant to be 
tested was diluted 1:5 in antibody -diluting solution 
(2.2.1.) and incubated with the nitrocellulose membrane 
overnight at room temperature. The nitrocellulose 
membrane was then washed in TBS containing 0.05 % (v /v) 
Tween 20 for 10 minutes and then in TBS for 5 minutes. 
This procedure was carried out between all subsequent 
incubation steps. The next step consisted of an 
incubation in antibody -diluting solution containing a 
200 -fold dilution each of sheep anti -mouse -IgG biotin 
conjugate and sheep anti -mouse -IgM biotin conjugate for 
3 hours at room temperature. This was folllowed by a 1 
hour incubation at room temperature with a streptavidin- 
HRP solution (Amersham International Plc), diluted 1000 - 
fold in TBS containing 1mg /m1 BSA. Peroxidase binding 
was visualised using the substrate 4- chloro -l- naphthol 
(2.2.2.). 
(43) 
3.2.2. Western blotting 
The quenched nitrocellulose membrane from the Western 
blot (4.3.1.) was incubated overnight at room 
temperature with a 1:5 dilution of antibody culture 
medium in antibody -diluting solution (2.2.1.) and was 
then treated as for peroxidase staining of immunodots. 
(3.2.1.). 
3.2.3. Enzyme -linked immunosorbent assay ( ELISA) 
The antigen was diluted in coating buffer (50mM sodium 
bicarbonate pH9.6) and 100 ul aliquots dispensed into 
the wells of a 96 -well microtitre plate and incubated 
for 3 -4 hours at room temperature. The wells were 
emptied and unnoccupied binding sites quenched by the 
addition of 200 ul aliquots of coating buffer containing 
0.5% (w /v) egg albumen. This was incubated at 4 °C' 
overnight before the wells were emptied. At this stage, 
the plates were either covered and stored at -20 °C, or 
used immediately. If being used, the wells were washed 
three times with washing buffer (TBS containing 0.05. 
(v /v) Tween 20), each for 10 minutes. To each well was 
added either 100 ul of undiluted culture medium, culture 
medium diluted in antibody -diluting solution (2.2.1.), 
or partially -purified ascitic fluid (3.3.2.) diluted in 
antibody -diluting solution. The plate was incubated 
overnight at 4 °C, the wells were washed as before and 
100 ul of second antibody solution added and incubated, 
also overnight at 4 °C. The second antibody solution was 
(44) 
antibody -diluting solution containing a 1000 -fold 
dilution of either sheep anti -mouse -IgG alkaline 
phosphatase conjugate solution, or sheep anti -mouse -IgM 
alkaline phosphatase conjugate solution, depending on 
the antibody class of the monoclonal antibody. The 
wells were washed as before and then incubated with 
100 ul of substrate solution for 1 hour or until-colour 
developed. The substrate was p- nitrophenyl phosphate 
disodium (1mg /ml) in 0.1M glycine pH10.4 containing 1mM 
magnesium chloride and 1mM zinc chloride. The reaction 
was stopped by the addition of IN sodium hydroxide and 
the absorbance of the wells read at 405nm. Internal 
controls were carried out on each 96 -well plate by the 
omission of all or one of the following:- antigen coat, 
monoclonal antibody solution or second antibody 
solution. 
Absorbance readings were obtained for four replicate 
wells (treated identically) and the average taken. The 
average values obtained for the control wells were 
subtracted from the average values obtained for the 
experimental wells to allow for non -specific binding and 
substrate colouring. 
3.2.4. Immune precipitations 
This was carried out with the antigen used in its native 
form, or labelled with either biotin (4.6.3.1.), or 
"'"5I-iodine (4.6.1.). 
(45) 
3.2.4.1. Immune precipitations using unlabelled antigen 
This method was initially tested using a mouse 
monoclonal antibody against horseradish peroxidase. 
The solid -state second antibody used was either sheep 
anti -mouse Ó globulin coupled to Sepharose 48 (4.7.), or 
commercial goat anti -mouse IgM (r chain- specific) 
conjugated to agarose beads. 
1m1 of the solid -state sheep anti -mouse Iglobulin was 
incubated with 1.5ml of the monoclonal antibody culture 
medium for 3 -4 hours. This was done in Eppendorf pots 
and spin- washing was done by pelleting the solid state 
antibody in washing buffer (TBS containing 0.05% (v /v) 
Tween 20) and resuspending the pelleted gel in fresh 
buffer. This was done four times before pelleting the 
gel and removing the buffer. To the pelleted gel was 
added 100 ul of a 50 ug /ml solution of horseradish 
peroxidase in TBS containing img /ml of BSA. This was 
incubated at room temperature for 2 hours before spin 
washing as above. The binding of peroxidase to the gel 
was indicated by a colour change on the addition of the 
substrate 4- chloro -1- naphthol (2.2.2.) and the 
subsequent pelleting of the gel in this solution. The 
control gel, treated identically except that the 
monoclonal antibody had been omitted, remained 
colourless. 
(46) 
3.2.4.2. Immune precipitations using labelled antigen 
Antigen was labelled by means of - I (4.6.1.), or by 
biotin (4.6.3.) and the same procedure carried out as 
above. 
The pelleted gel containing the monoclonal antibody and 
the antigen mixture was incubated with sample incubation 
buffer (60 °C) (4.1.1.) for 2.0 minutes and this was 
subjected to polyacrylamide gel electrophoresis 
(4.1.1.). In the case of the 1P5I- labelled antigen, 
autoradiography was carried out (4.2.4.) and in the case 
of the biotin labelled antigen, the gel was Western 
blotted (4.3.1.) and stained to visualise biotinylated 
proteins by incubating the nitrocellulose with 
streptavidin -HRP (4.3.3). 
3.3. Ascitic fluid 
Monoclonal antibody culture media generally contain 
antibody concentrations of 1 -10 ug /ml. In order to 
produce larger quantities of antibody, ascitic fluid may 
be produced containing up to 10mg /m1 of antibody. 
3.3.1. Production of ascitic fluid 
Ten week -old female Balb /c mice were injected 
intraperitoneally with 100 ul aliquots of Pristane 
(2, 6,10,14- tetramethylpentadecane) and one month later 
with i x 106 antibody- secreting cells which had been 
(47) 
pelleted and resuspended in 500 ul of physiological 
saline. Tumours were allowed to form over the next four 
weeks before the ascitic fluid was drained. 
The ascitic fluid was allowed to settle on standing for 
2 hours before the upper layer was removed from the 
lower layer of cells. The upper layer was aliquoted and 
stored at -20 °C. 
7.3.2. Purification of ascitic fluid 
The ascitic fluid was tested for antibody content using 
fixed tissue sections of bovine neural retina (2.1.1.), 
using the immunofluorescence method (2.2.1.). 
Purification steps were tested by the same method. 
3.3.2.1. Purification of ascitic fluid using DEAE 
cellulose ion exchange chromatography (4.8.3.) 
5m1 of swollen gel (DE52, Whatman Ltd, Maidstone, Kent) 
was equilibrated in 50mM Tris HC1 pH 8.4. 1.5ml of 
ascitic fluid (dialysed against the same buffer) was 
added to the column. More of the same buffer was added 
and 0.5ml fractions collected. The optical density at 
280nm was measured to determine protein content and 
antibody content tested (3.3.2.). 
Those fractions with both a high optical density and 
specific- antibody content were retained and stored in 
aliquots at -20 °C. 
(48) 
SECTION 4: GENERAL METHODS AND MATERIALS. 
4.1. Electrophoretic methods. 
4.1.1. SDS -Polyacrylamide gel electrophoresis 
Unless otherwise stated SDS -PAGE was carried out using a 
discontinuous buffer system (Laemmli and Favre 1973) 
with a 10/ acrylamide separating gel and a 5% acrylamide 
stacking gel. 
The sample was prepared by adding it to half its volume 
of sample incubation buffer, consisting of 0.2M Tris HC1 
pH 6.5 containing 8% SDS (w /v), 8mM EDTA and 40/. 
glycerol (v /v). The mixture was heated to 60 °C and 
incubated for 15 -20 minutes before a small drop of 
bromophenol blue tracker dye was added (approx lmg /ml) 
and the mixture loaded onto the gel. 
The gel was run until the tracker dye was approximately 
lcm from the foot of the gel. This was done either 
overnight with a constant voltage (40 volts), or quickly 
during the day with a constant current (40 milliamps). 
SDS- polyacrylamide gel electrophoresis separates 
proteins on the basis of their molecular weights 
(Shapiro et al 1967). In general over a wide range of 
molecular weights there is a linear relationship between 
log molecular weight of the protein and its RT value 
(Shapiro et al 1967; Weber and Osborn 1969). This 
relationship can be used to estimate the molecular 
(49) 
weight of proteins of unknown mass by using a number of 
well characterised marker proteins of known molecular 
weight to calibrate each gel. 
4.1.2. 2- Dimensional gel electrophoresis 
This was carried out according to the method of 
O'Farrell (O'Farrell 1975). 
In the first dimension a pH gradient was established on 
running the gel after loading the sample. The gel was 
run under denaturing and reducing conditions. To the 
sample was added a quarter of its volume of sample 
buffer containing 9.5M urea, 5% Triton X100 (v /v), 7% 
ampholytes (v /v) and 7% 5- mercaptoethanol (v /v). 
The sample was loaded onto the top of the gel, in 
contact with the top gel buffer (0.4% ethanolamine 
(v /v)) and a current was established between this and 
the bottom buffer (0.2% ortho -phosphoric acid (v /v)). 
The pH gradient formed across the gel was measured by 
incubating slices of the gel after electrophoresis in 
boiling water for 10 minutes, and measuring the pH of 
the solution using pH indicator paper. 
In the second dimension a 6-15% exponential acrylamide 
gradient separating gel and 5% acrylamide stacking gel 
were used. 
This was run as described in Section 4.1.1. 
(50) 
4.2. Staining_ of electrophoresis gels 
4.2.1. Coomassie Blue staining of protein. 
Slab gels were fixed for ihr at room temperature in a 
20% methanol (v /v), 10/ acetic acid (v /v) solution. 
Staining was then done in Coomassie Brilliant Blue R 
stain solution (0.25% (w /v) Coommassie Brilliant Blue R- 
250 in 25% (v /v) methanol, 10% acetic acid, (v /v)) for 20 
minutes at room temperature before destaining in destain 
solution (10% methanol, 7% acetic acid (v /v)) containing 
small squares of white polyurethane foam to absorb free 
dye in the solution. 
4.2.2. Silver staining of protein. 
This is a much more sensitive protein stain than the 
Coomassie blue stain and can detect protein at the ing 
level. This was carried out according to the method of 
Wray et al (Wray et al 1981). The slab gel was fixed for 
lhr in a 40. methanol (v /v), 10% acetic acid (v /v) 
solution. It was then soaked in 50% methanol (v /v) for 
ihr, followed by 10 minutes in distilled water. This 
methanol /water routine was repeated twice. Solution A, 
containing 0.6g of silver nitrate in 4m1 of distilled 
water was added dropwise to a continuously stirred 
solution B. Solution B contained 21m1 of 0.36% sodium 
hydroxide (w /v) and 1.4ml of 14.BM ammonium hydroxide. 
This mixture when made up to 100m1 with distilled water, 
constituted the stain solution. The washed gel was 
incubated in fresh stain solution for 20 minutes at room 
(51) w ` 
temperature. The gel was then washed in distilled water 
for 20 minutes with changes every 5 minutes. The 
developing solution was prepared by mixing 2.5ml of 1% 
(w /v) citric acid and 250 ul of 38. (v /v) formaldehyde 
followed by the addition of 500m1 of distilled water. 
The developing solution was used immediately to develop 
the protein stains. This process was halted by 
replacing the developing solution with a 10. (v /v) 
acetic acid solution and the stained gel was stored in 
50% (v /v) methanol. 
4.2.3. Periodic acid -Schiffs staining of carbohydrate. 
This is a general carbohydrate stain of relatively low 
sensitivity used in polyacrylamide gels. It was carried 
out according to the method of Zacharius (Zacharius et 
al 1969). 
The gel was initially soaked in 12.5. (w /v) 
trichloroacetic acid for 30 minutes, rinsed in distilled 
water and soaked in a fuschin sulphite solution in the 
dark for 50 minutes and then washed three times, each 
for 10 minutes, in a 0.5. (w /v) potassium metabisulphite 
solution. Finally the gel was washed in distilled water 
until it became colourless, when it was transferred 
into, and stored in 5% (v /v) acetic acid. 
(52) 
4.2.4. Autoradiography of polyacrylamide gels. 
The polyacrylamide gel was fixed, stained and destained 
(4.2.1.) and then dried down under vacuum onto blotting 
paper. This was then exposed to a FUJI X -ray film and 
stored in an X -ray cassette at -70 °C prior to the film 
being developed. 
4.3.1. Western blotting. 
Proteins were transferred from slab gels according to 
the method of Towbin (Towbin 1979). A 0.5A current was 
used for two hours. Amido black stain was used to test 
for the transfer of protein from the gel to the 
nitrocellulose. (4.3.2.) After transfer, quenching of 
the unoccupied binding sites of the nitrocellulose 
membranes was carried out by a 1 hour incubation in TBS 
containing 0.2% TWEEN 20 (v /v). The membrane was then 
treated with antibody (3.2.2.), or lectin (4.3.3.). 
4.3.2. Amido black staining of protein 
This is a general protein stain of low sensitivity used 
to stain nitrocellulose. It was carried out according 
to the method of Davies (Davies 1964). 
The nitrocellulose from 4.3.1. was stained for 2 -3 
minutes in amido black before quenching and 
then destained in destain solution (90% methanol (v /v), 
27. acetic acid (v /v). 
(53) 
4.3.3. Lectin treatment of Western blots 
The quenched nitrocellulose was incubated for 2 hours at 
room temperature in a 100 -fold dilution of stock lectin- 
biotin conjugate (4.6.3.2.), in TBS containing BSA 
(1mg /ml,w /v). The nitrocellulose was then rinsed for 10 
minutes in TBS /0.05% TWEEN 20 (y/y) followed by 5 
minutes in TBS, before the addition of Streptavidin -HRP 
conjugate diluted 1000 -fold in TBS containing BSA 
(1mg /ml,w /v). This was incubated at room temperature 
for 1 hour before visualising HRP binding by the 
addition of the substrate 4- chloro -l- naphthol (2.2.2). 
The alternative method was to incubate the 
nitrocellulose for 1 hour at room temperature in a 
fifty -fold dilution of peroxidase -lectin conjugate prior 
to chloronaphthol staining. 
4.3.4. Lectin treatment of dot blots 
This was carried out as for lectin treatment of Western 
blots (4.3.3.) except that the sample being tested was 
dotted directly onto the nitrocellulose before 
quenching (4.3.1). 
4.4. Bradford protein assay. 
This was carried out according to the method of Bradford 
(Bradford 1976). 
(54) 
Aliquots of the protein solutions were each added to 
0.5ml aliquots of Bradford reagent containing 0.01% 
Serva blue dye (w /v), 4.7% ethanol (v /v) and 8.5% 
phosphoric acid (v /v). The mixtures were allowed to 
stand for 10 -15 minutes before the absorbance at 595nm 
was read and interpreted by means of a set of standard 
-(0 - 100 ug /0.5m1) BSA solutions. 
4.5. Immunoglobulin isolation from serum 
A 5m1 aliquot of sheep serum containing anti -mouse 
immunoglobulin was added to 10m1 of 50mM sodium acetate 
pH4.0. 370 ul of octanoic acid was added drop -wise to 
the mixture which was stirred continuously. This was 
left to stand for 30 minutes at room temperature before 
the precipitate was pelleted by centrifuging the mixture 
at 100 000g for 30 minutes. The resulting soluble 
globulin fraction was dialysed against the appropriate 
buffer overnight and used as required. 
4.6. Labelling of protein 
4.6.1. Labelling with 172°I using the Chloramine T 
method. 
This was carried out according to the method of 
Greenwood et al 1963,. 200 ul of sample containing 
0.2mg of soluble protein was dialysed against 50mM 
phosphate buffer pH7.2 containing 0.15M sodium chloride. 
This was mixed with 10 ul (0.5mCi) of sodium 
E"--~I]iodide and 50 ul of a fresh 16mg /m1 chloramine T 
(55) 
solution. This was left for 2 minutes at 0 °C before 
50 ul of 19mg /ml sodium thiosulphate and 25 ul of 
30mg /m1 sodium iodide solutions were added. The mixture 
was then desalted to remove free iodide using a P6DG 
desalting gel (4.8.2.). A 10 ul sample of the labelled 
fraction was counted in a gamma counter to check the 
efficiency of - I incorporation. 
4.6.2. Protein labelling with FITC. 
4.6.2.1. Streptavidin 
0.5mg of lyophilised streptavidin was dissolved in 
100 ul of distilled water and added to 400 ul of 50mM 
sodium bicarbonate buffer pH 9.5. To this was added 
20 ul of a 10mg /m1 (w /v) solution of FITC (isomer II) in 
dimethyl suiphoxide (DMSO). This mixture was stirred in 
the dark for 4 -5 hours. A volume of ethanolamine pH8 
was added to give a final 50mM solution. This was 
incubated for 30 minutes and then dialysed overnight at 
4 °C against TBS. 
4.6.2.2. Lectins 
This was carried out as for streptavidin, using a 1mg /m1 
(w /v) lectin solution containing the hapten sugar at a 
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Figure 4.1. The reaction mechanism involved in 
coupling biotin to protein using NHS -biotin. The 
nucleophilic, unprotonated E -amino groups of the 
lysine residues of the protein molecules attack 
the activated ester of NHS -biotin resulting in an 
amide bond and the release of N- hydroxy- 
succinimide. See text for experimental detail. 
is7i 
4.6.3.1. Protein Labelling with N- Hydroxy- 
succinimidobiotin (NHS- Biotin). 
A 1mg /m1 solution of protein was dialysed overnight 
against 50mM sodium bicarbonate buffer pH9.5. To 1ml of 
this was added 20 ul of a 33mg /m1 NHS -biotin in dimethyl 
formamide (DMF) solution. The mixture was stirred for 1 
hour at room temperature before dialysis against TBS 
overnight (Figure 4.1.). 
4.6.3.2. Lectins 
This was carried out as above using a 1mg /m1 solution of 
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Figure 4.2 The reaction mechanisms involved in: A. activation of Sepharose 4B by cyanogen bromide in the presence of triethylamine. B. coupling of the activated Sepharose 4B to protein. 
(59) 
4.7.1. Cyanogen bromide activation of Sepharose 4B (Kohn 
and Wilchek 1982) (Figure 4.2.). 
15g of Sepharose 4B was sequentially washed in distilled 
water, 30. acetone, 60% acetone solutions and then 
resuspended in a 60% acetone solution. This was cooled 
to -15 °C on a salt /ice mixture and all subsequent steps 
and reagents were maintained at this low temperature. 
375mg of cyanogen bromide dissolved in 375 ul of acetone 
and 375 ul of 1.5M triethylamine in acetone were added 
with constant stirring. The activated gel was quickly 
added to 150m1 of a 1:1 mixture (v /v) of acetone and 
0.1M HC1. The gel is in a stable form at this low pH. 
Rehydration was carried out by rapid sequential washes 
in 60/ acetone, 30% acetone and 50mM sodium bicarbonate 
buffer pH 9.5 before the gel was resuspended in 15ml of 
the buffer solution. 
4.7.2. Coupling of protein to cyanogen bromide - 
activated Sepharose 4B 
The protein to be coupled to the activated gel was 
dialysed against 50mM sodium bicarbonate buffer pH9.5. 
To each ml of activated gel mixture was added one of the 
following:- 1m1 of sheep anti -mouse /globulin (4.5.), or 
1m1 of a 1mg /m1 lectin solution containing the hapten 
sugar at a concentration of 200mM. 
The mixture was incubated overnight on an end -over -end 
mixer at 4 °C. The gel was washed in TBS, or column 
buffer in the case of the lectin- conjugated gel 
(60) 
(4.8.1.). The protein content of the samples before and 
after addition to the activated gel were compared using 
the Bradford assay (4.4.) to check the efficiency of 
coupling. 
4.8. Chromatography methods 
4.8.1. Lectin affinity chromatography 
This was carried using either a Sepharose 4B gel coupled 
to lectin (4.7.2.) or commercial lectin- conjugated 
agarose. The sample to be chromatographed was dialysed 
against column buffer and all further steps were done in 
the presence of either column buffer or eluting buffer. 
The column buffer was 0.1M HEPES /sodium hydroxide pH7.2 
containing 0.15M sodium chloride, 0.05% sodium azide 
(w /v), 1mM calcium chloride, 1mM magnesium chloride and 
1mM manganese chloride. The eluting buffer had the 
addition of the hapten sugar at a concentration of 200mM 
for the appropriate lectin conjugate being used. 1ml of 
sample (1mg /m1 of protein) was run into, but not 
through, the lectin- agarose (3m1 bed volume) and 
incubated for 2 hours at room temperature. The gel was 
washed through with column buffer to remove all unbound 
material. The eluting buffer was then run into the gel 
and incubated for 2 hours at room temperature. Eluted 
material was collected when subsequent additions of one 
bed volume of eluting buffer were made. When elution 
(61) 
was complete the column was stored in eluting buffer at 
4 °C. The Bradford protein assay was used to check the 
washing and eluting steps were complete. 
In some cases it was found easier to carry out this 
procedure in batch form where the sample was mixed end - 
over -end with a suspension of the gel. Washing and 
eluting steps were carried out by a series of spin 
washes of the gel mixture and the appropriate buffer 
(2500 rpm for 10 minutes). 
4.8.2. P6DG gel filtration (desalting) chromatography 
This method was used as a quick alternative to an 
overnight dialysis step. 
1m1 aliquots of swollen gel (P6DG BioRad Laboratories, 
Richmond, California) were washed in TBS prior to 200 ul 
of sample being loaded and run into the gel. In some 
cases an unreactive, coloured dye (phenol red) was added 
to the sample prior to loading, to indicate the position 
of the low molecular weight material within the gel. 
Fractions were collected up to the point where the dye 
was eluted, and tested for protein content by the 
Bradford method (4.4.). Those containing protein were 
pooled and stored to be used as required. 
The alternative method used was to add 0.5ml aliquots of 
swollen gel to Eppendorf pots into which small holes had 
been previously pin -pricked at the top and bottom, and 
with small amounts of glass wool placed inside the 
bottom. After spin -washing with TBS (by centrifuging at 
(62) 
1000g for 10 minutes and replacing the supernatant with 
fresh TBS), the gel was finally spun dry. To this was 
added 0.5ml of sample which was then centrifuged as 
above and the eluted material collected from the 
Eppendorf pot -holder. 
4.8.3. DE cellulose ion exchange chromatography 
Swollen gel (DEAE 52 cellulose, Whatman Ltd, Maidstone, 
Kent) was equilibrated in 25mM Tris HC1 buffer pH7.2 and 
packed into a column (3ml bed volume). Samples were 
dialysed against the same buffer before application to 
the column. 0.5ml of sample (1mg /m1) was added to the 
gel and unbound material was removed by the further 
addition of the same buffer. Elution of bound material 
was by the addition of aliquots of sodium chloride in 
the Tris buffer, each aliquot increasing in 
concentration in increments of 50mM. Care was taken to 
ensure that the elution of material by a particular salt 
concentration was complete before the salt 
concentration was increased. The protein content of the 
fractions was checked by the use of the Bradford assay 
(4.4.). The alternative batch method was used at times 
as for the affinity chromatography (4.8.1.). 
(63) 
4.8.4. Fast protein liquid chromatography using the 
Superose 12 HR 10/30 gel filtration FPLC Column. 
The Superose 12 column (24ml bed volume), was 
equilibrated with TBS before 500 ul of sample (1mg /m1 of 
protein) was loaded. A flow rate of 0.3m1 /minute was 
maintained and 0.5ml fractions collected. Protein in 
the eluate was detected by the absorbance at 280nm and 
information recorded on a chart recorder. The molecular 
weights of the proteins eluted from the column were 
calculated by comparison with the retention times of 
proteins, of known mass. 
(64) 
4.9. Enzymatic Treatments 
4.9.1. Trypsin treatment of protein 
The sample containing protein was incubated in TBS 
containing 10U /m1 of bovine pancreatic trypsin. The 
reaction was stopped by the addition of phenyl - 
methylsulphonyl fluoride (PMSF) to a final concentration 
of 0.1mM. 
Fixed tissue sections to be treated with the enzyme were 
rinsed for ten minutes in TBS before being incubated for 
ten minutes at room temperature in 100u1 of the same 
buffer containing 1U of the enzyme. The tissue section 
was then well rinsed with TBS and treated with antibody 
as required. 
Control incubations were carried out without the enzyme. 
4.9.2. Neuraminidase treatment of glycoconjugates. 
Fixed tissue sections were rinsed for ten minutes in 
100mM MES pH5.0 before being incubated for thirty 
minutes in 100u1 of the same buffer containing 0.1U of 
neuraminidase (type V from Clostridium perfringens). 
The tissue section was then rinsed in TBS and treated 
with antibody or lectin as required. 
(65) 
4.9.3. Heparinase treatment of proteoglycan 
The sample containing proteoglycan was incubated with 
heparinase II (from Flavobacterium heparinum) (0.2U /ml 
final concentration) in 50mM sodium acetate pH 5.0 
containing 1mM calcium chloride, overnight at room 
temperature. 
Fixed tissue sections were rinsed for ten minutes in 
100mM sodium acetate pH5.0, containing 1mM calcium 
chloride and were then incubated for five hours at room 
temperature in the same buffer containing 0.25U of the 
enzyme. The sections were then rinsed with TBS and 
treated with antibody as required. 
Control incubations were carried out without the enzyme. 
4.9.4. Chondroitinase ABC treatment of proteoglycan. 
50 ul of the sample containing proteoglycan was added to 
an equal volume of chondroitinase ABC (from Proteus 
vulgaris) (in distilled water) to give a final 
concentration of 0.5U /ml. The mixture was incubated for 
2 hours at 37 °C. 
Fixed tissue sections were rinsed for ten minutes in TBS 
before being incubated for five hours at room temp- 
erature in 100u1 of the same buffer containing 0.1U of 
the enzyme. The sections were then rinsed in TBS and 
treated with antibody as required. 
Control incubations were carried out without the enzyme. 
(66) 
4.9.5. Nitrous acid treatment of glycosaminoglycan 
The sample containing glycosaminoglycan was incubated in 
1.BM acetic acid containing 0.25M sodium nitrite (final 
concentration) for 2 hours at 37 °C. This was then 
dialysed against TBS. 
4.9.6. Chondroitinase AC treatment of proteoglycan 
Fixed tissue sections were rinsed for ten minutes in TBS 
before being incubated for five hours at room 
temperature with 500u1 of the same buffer containing 
0.5U of the enzyme. The tissue sections were then 
rinsed in TBS before being treated with antibody as 
required. 
4.9.7. Hyaluronidase (testicular) treatment of 
proteoglycan 
The sample containing proteoglycan was incubated with 
50mM sodium acetate pH5.0 containing 3000/m1 type 1 -S 
bovine testes hyaluronidase, for 2 hours at 37 °C. 
Fixed tissue sections were rinsed for ten minutes in 
100mM sodium acetate pH5.0 before being incubated for 
five hours at room temperature with 500u1 of the same 
buffer containing 150U of the enzyme. The section was 
then rinsed in TBS before being treated with antibody as 
required. 
Control incubations were carried out without the enzyme. 
(67) 
4.9.8. Hyaluronidase (Streptomyces) treatment of 
proteodlycan. 
Fixed tissue sections were rinsed for ten minutes in 
100mM sodium acetate pH5.0 before being incubated for 
five hours at room temperature with 100u1 of the same 
buffer containing 500U of hyaluronidase (from 
Streptomyces hyalurolyicus). The section was then 




All chemicals were obtained from BDH Chemicals Ltd and 
were of AnalaR grade, or from Sigma, London, unless 
otherwise idicated in the text. 
All enzymes, commercial antibody solutions, lectin 
solutions and tissue culture media and supplements were 
obtained from Sigma, London. 
Tissue culture plastic was obtained from Flow 
Laboratories Ltd, Irvine and ELISA plates from Falcon 
Laboratory, Oxford. 
Cattle eyes were obtained from the local slaughterhouse 
and mice from animal house stock. 
The FPLC columns and amphylytes were obtained from 
Pharmacia Ltd, Milton Keynes. 
Nitrocellulose membranes ( 0.45 um, 400 x 200mm) were 
obtained from Schleicher and Schuell, Dassel, W Germany. 
1 =I- Sodium Iodide was supplied by the Radioimmunoassay 
Department, University of Edinburgh. 
Tissue Tek OCT was obtained from Lab -Tek Products, 
Division Miles Laboratories Inc. 
(69) 
SECT ION 5: TISSUE PREPARAT TON. 
Section 5 Tissue preparation 
5.1. Preparation of Interphotoreceptor Matrix (IPM) 
Bovine eyes were collected from the slaughterhouse and 
transported on ice. The eyes were used immediately and 
all solutions and tissue were maintained at 4 °C. 
The eyes were trimmed free of excess fatty tissue, cut 
in half, the lens and vitreous humour removed and the 
anterior portion discarded. 
The retina was floated in 1 -2 ml of TBS (containing 
0.1mM PMSF) in order to separate it from the adjacent 
layer of retinal pigmented epithelium (RPE) cells. The 
retina was detached by cutting it from the optic nerve 
and was rinsed in a small volume of the TBS. This 
process was repeated with each eye, using the same TBS 
rinsing solution to produce a highly concentrated 
solution of IPM in a minimum volume. The rinsing 
solution was centrifuged at 100 000g for 30 minutes, the 
soluble fraction was removed, aliquoted into smaller 
volumes and stored at -20 °C. 
The protein content of the IPM was estimated by the 
Bradford method (4.4.) and was usually 1- 2mg /ml, 
depending on the number of retinae available and the 
volume of TBS used. 
(70) 
5.2. Preparation of interstitial retinol binding 
protein (IRBP) 
IRBP was purified from IPM by ConA -affinity 
chromatography (4.8.1.) using either a commercial ConA - 
Adarose gel, or ConA coupled to Sepharose 4B gel by the 
cyanogen bromide activation method (4.7.1 and 4.7.2.). 
The Sepharose 4B -ConA gel was estimated to contain 
approximately 1mg of lectin per ml of swollen gel, 
therefore a ratio of 1 volume of gel to 2 volumes of a 
1mg /m1 solution of IPM was used to remove all the IRBP 
from a volume of IPM. This assumes that at least two of 
the four mannose binding sites on each of the ConA 
molecules are still active after coupling to the gel and 
that ConA and IRBP have approximately the same molecular 
weight. 
The commercial gel contains (according to the suppliers) 
10 -20mg of lectin /ml of gel. Small volumes of the gel 
were mixed with ten times its volume of Sepharose 4B to 
make handling easier. 
2m1 of the ConA -agarose gel or the ConA - 
agarose/Sepharose 4B mixture was equilibrated in column 
buffer (4.8.1). The gel was centrifuged at 1000g for 10 
minutes, the supernatant replaced with fresh column 
buffer and the process repeated twice. The gel was 
finally pelleted before the addition of 4m1 of IPM 
(1mg /m1), previously dialysed against column buffer 
overnight. This was mixed end -over -end for 3 -4 hours 
before spin washing the gel as above. The first 
(71) 
supernatant was collected and called "IPM -IRBP" (in some 
cases this fraction was subjected to the above treatment 
for a second time in order to deplete the IPM of IRBP 
completely). To the pelleted gel was then added 2m1 of 
column buffer containing 200mM a- methyl mannoside. The 
mixing and spin washing procedures were repeated. This 
time, the first two supernatants, containing the 
majority of the eluted IRBP, were collected. The 
fractions were tested for protein content by the 
Bradford assay (4.4.) and for purity by SDS- 
polyacrylamide gel electrophoresis (4.1.1.) followed by 
treating subsequent Western blots with ConA (Figures 
5.1. and 5.2.). 
(72) 
Figure 5.1 10% polyacrylamide gel stained with 
Coomassie blue showing the purification of 
IRBP from IPM by ConA affinity chromatography. 
See text for experimental detail. 
1. IPM (100ug) (Starting material). 
2. IPM depleted of IRBP (1st pass- through 
fraction) . 
3. IRBP (1st purified fraction). 
4. IRBP (2nd purified fraction). 
1 Z 3 4 ó 
Figure 5.2. Western blot of a 10% polyacrylamide gel 
treated with ConA -bio, followed by Streptavidin -HRP 
and stained with chloronaphthol, showing the 
purification of IRBP from IPM by ConA affinity 
chromatography See text for experimental detail. 
1. IRBP (2nd purified fraction). 
2. IRBP (1st purified fraction). 
3. IPM depleted of IRBP. 
4. IPM (100ug) (Starting material). 
5. Bovine serum albumin. 
(14) 
5 3. Preparation of crude photoreceptor outer segments 
(PROS) 
The eyecup was treated as for IPM, the retina in this 
case being separated from the RPE layer in 50mM Tris HCI 
pH7.4 containing 0.32M sucrose and 0.1mM PMSF. The 
retina was added to more of the same solution when 
detached from the eyecup. Approximately 1 -2ml of 
solution was allowed for each eye. The retinae were 
lightly homogenised in a loose -fitting teflon -glass 
homogeniser and then centrifuged at 1000g for 10 
minutes. The supernatant was removed and the top layer 
of the pellet was collected. (This was pinkish in 
colour indicating the presence of the pigment proteins 
from the outer segments of the photoreceptors). The 
pellet was resuspended in the sucrose buffer containing 
one tenth of its volume of stock 10% Triton X100 
detergent solution (final i% solution)(v /v). The 
solution was stood on ice for 30 minutes before being 
centrifuged at 100 000g for 30 minutes. The soluble 
fraction was removed, aliquoted into smaller volumes and 
stored at -20 °C. (Figure 5.3.). 
(75) 
Figure 5.3. 1.0% polyacrylamide gel stained with 
Coomassie blue. See text for experimental detail. 
1. crude photoreceptor outer segments (80ug). 
2. molecular weight markers. 
(7 b) 
SECTION 6: RESULTS. 
6.1. Introduction 
The aim of this project was to produce monoclonal 
antibodies which would react specifically with cell 
surface molecules of the photoreceptor cells, or with 
molecules present in the interphotoreceptor matrix (IPM) 
which are associated with the surfaces of the 
photoreceptors. 
This would enable such cell surface or cell surface 
associated molecules to be identified and characterised 
biochemically. Comparisons could then be made between 
normal adult tissue, developing tissue and diseased 
tissue. 
A monoclonal antibody raised against a molecule specific 
to a single cell type may also be used to identify other 
constituents of the same cell type, which may co- purify 
with the antigen. Therefore monoclonal antibodies 
raised against cell- specific molecules may be very 
powerful tools in the elucidation of molecular 
constituents of a specific cell. 
Of particular value in a study of the photoreceptor 
cells and the IPM would be monoclonal antibodies which 
differentiate between the disc membrane and the plasma 
membrane of the rod photoreceptor cells. Much work has 
been done biochemically on the discs of the rod 
photoreceptor cells but less is known about the plasma 
membrane of these cells. This is largely because the 
plasma membrane of the rod photoreceptors comprises only 
2% of the total membrane content of the cells, the 
(77) 
majority being present in the disc membranes. 
Monoclonal antibodies may be used to identify molecules 
common to both types of membranes, or molecules specific 
for the plasma membrane. 
Monoclonal antibodies which specifically recognise the 
cone photoreceptors would also be very useful. To date 
there is no method of isolating the cone outer segments 
from the retina. The production of monoclonal 
antibodies which have immunoreactivity against these 
cells would seem a reasonable approach to identifying 
some of their cellular components. 
Such monoclonal antibodies may allow the identification 
of constituents of the rod and cone cells which are 
specific to a single cell type, or which are common to 
rods and cones, and would also allow the two cell types 
to be distinguished unequivocally. Further biochemical 
analysis of these molecules would then be possible, and 
their appearance through development and in diseased 
tissue may be monitored. 
Three methods of approaching the problem of producing 
monoclonal antibodies specific for cell surface, or cell 
surface associated molecules of the photoreceptor cells 
were taken. 
1.To immunise mice repeatedly with unpurified 
preparations of antigen mixtures for example crude 
photoreceptor outer segments (5.3.1, or IPM (5.1.), and 
to carry out many cell fusions-, selecting hybridoma cell 
lines which secrete antibodies that react specifically 
(78) 
with the IPM or the photoreceptor cells. This approach 
relies heavily on luck and there is no guarantee of 
producing antibodies which are specific to any 
particular cell type. 
2.To purify, or at least partially purify some of the 
constituents known to be present either within, or 
associated with, the surfaces of the photoreceptor 
cells, for example, the PNA- binding material associated 
with the cone photoreceptors (Blanks and Johnson 1984). 
Such relatively pure fractions can be used to immunise 
mice. There should be a higher probability of any 
monoclonal antibodies produced from subsequent fusions 
being immunoreactive with either the rod or cone 
surfaces, compared to any antibodies produced by method 
1. above. This more selective immunisation process 
should increase the chances of producing the required 
cell -specific monoclonal antibodies. 
3.To synthesise a protein, or a peptide fragment of a 
protein, which is known to be unique to a single retinal 
cell type (for example a cone -specific protein) and to 
use this as the immunogen in mice prior to cell fusion. 
Monoclonal antibodies produced by this method should be 
reactive with a single protein and therefore with the 
single cell type in which the protein is found. The 
monoclonal antibody may then be used to identify the 
cell type and also possibly to isolate further 
constituents of the same cell type for further analyses. 
(79) 
The above three methods were used in attempts to raise 
monoclonal antibodies specific for the surfaces of the 
rod and cone photoreceptor cells, or against material in 
the IPM which is associated with the photoreceptor 
cells. 
This was carried out using bovine tissue (available in 
abundance) as the antigen source, with a. view to 
transferring to human and /or mouse tissue systems (less 
readily available in large quantities) for further 
studies using the antibodies produced against the bovine 
retina. 
(80) 
6.2. Repeated immunisation of mice with unpurified 
antigen mixtures 
This was the first approach taken to solve the problem 
of obtaining cell specific monoclonal antibodies. 
Mice were immunised (3.1.1.) with 1mg /m1 solutions of 
either IPM (5.1.) or crude photoreceptor outer segments 
(5.3.). The subsequent cell fusions were carried out by 
Dr J Haywood (3.1.4.) and antibody- secreting cell lines 
were identified, using fixed tissue sections of bovine 
neural retina (3.1.7.) which were treated to visualise 
antibody binding by the immunofluorescence method 
(2.2.1.). Those cell colonies identified as secreting 
anti -retinal antibodies were expanded (3.1.4.) and 
finally cloned (3.1.5.) to produce true monoclonal 
antibody- secreting cell lines. 
Two different cell lines secreting monoclonal antibodies 
were established. These were coded 1001.A1 and 1001.A3. 
The use of class -specific sheep anti -mouse 1,globulin 
biotin conjugates in the staining procedure showed that 
both of these antibodies belong to the IgM class. 
6.2.1. Analysis of the 1001.A1 antigen 
6.2.1.1. Light microscopy 
The 1001.A1 cell line was tested for the presence of 
retina -specific antibodies using fixed tissue sections 
of bovine neural retina. Immunoreactivity was detected 
by the immunofluorescence and peroxidase staining 
(2.2.2.) methods and was found to be specific to the 
(81) 

Figure 6.2.1. Photomicrographs of the bovine neural 
retina treated with 1001.A1 antibody followed by a 
biotinylated second antibody and Streptavidin -FITC as 
indicated in the text. 
All photomicrographs were generated using a Biorad 
confocal laser microscope and image analyser. 
a. Transverse tissue section of the bovine neural retina 
indicating staining in the outer segments (OS) of the 
photoreceptor cells and in the Interphotoreceptor Matrix 
(IPM). (Magnification X 150) 
b. Oblique tissue section of the bovine neural retina 
indicating staining associated with the photoreceptor 
cells. (magnification X 600) 
(82) 
outer segments of the photoreceptors and to the IPM 
where there was intense staining of the tissue. Faint 
staining was also visualised in the photoreceptor cell 
bodies, indicating a le.s. ,6er degree of immunoreactivity 
in this region, perhaps due to a lower concentration of 
the antigen (Figure 6.2.1.). 
6.2.1.2. High resolution light microscopy 
Higher magnifications of the stained tissue sections 
would give a higher resolution of the antibody 
localisation, and may distinguish whether the 
immunoreactivity is membrane -associated, cytosolic or 
specific to some cellular organelle. For this to be 
possible, it is necessary to produce much thinner 
sections of tissue (lum), which requires embedding the 
tissue in hard plastic rather than in OCT. Higher 
resolution light microscopy and also electron microscopy 
may then be used. 
lum tissue sections were cut of the bovine neural retina 
and treated to visualise 1001.A1 binding using the 
colloidal gold -silver enhancement method (2.3.1.). No 
staining was observed. Sections were also treated to 
visualise lectin binding (ConA and PNA) using the 
colloidal gold -silver enhancement method (2.3.2.). In 
both cases the pattern and intensity of staining 
appeared similar to that seen on the 15um sections. 
This confirmed that the colloidal gold -silver 
enhancement staining method was viable and that the lack 
(83) 
of antibody staining was for some other reason. It 
appeared likely either that the antigenicity of the 
tissue was lost during the embedding process or that the 
penetration of the antibody molecules into the tissue 
was hindered by the Lowicryl in which it was embedded. 
Higher magnifications providing a higher resolution to 
visualise 1001.A1 binding could not be obtained. 
Further characterisation of the 1001.A1 antigen was 
therefore continued by biochemical rather than 
histochemical methods. 
6.2.1.3. Immunodottinq of 1001.A1 
Immunodotting was carried out (3.2.1.), using IPM as the 
antigen mixture, and 1001.A1 culture medium in the first 
incubation solution. 
In the process of immunodotting, the antigen maintains 
its native state, minimising any losses in its 
antigenicity, and so maximising the probability of 
detecting antibody binding. 
1001.A1 showed immunoreactivity with the IPM and so the 
antigen would appear to be present in the IPM (no 
reactivity was detected in control dots treated 
identically except that 1001.A1 was omitted from the 
first incubation). 
(84) 
Figure 6.2.2. A strip cut from a Western blot of a 
5 -15% gradient polyacrylamide gel loaded with 
500ug of IPM. The blot was treated with 1001.A1 
followed by biotinylated second antibody, 
streptavidin -HRP and stained with chloronaphthol. 
See text for experimental detail. 
(85) 
6.2.1.4. Western blotting of 1001.A1 
In order to identify the molecular weight of the 1001.A1 
antigen, Western blotting was carried out. 
IPM was subjected to SDS polyacrylamide gel electro- 
phoresis (4.1.1.), the gel blotted (4.3.1.) and the 
nitrocellulose stained to visualise antibody binding 
(3.2.2.). 
Immunoreactivity was seen as a single stained band on an 
area of the nitrocellulose, corresponding to a high 
molecular weight substance (Figure 6.2.2.). 
Amido black staining of another strip of nitrocellulose 
from the same blot showed IRBP to be present on a 
similar area of the nitrocellulose to this antibody - 
binding component of the IPM. 
Bovine IRBP has a molecular weight of 140 KDaltons in 
its monomeric state (Fong et al 1984a) and is a major 
component of the IPM (Adler and Kluckznik. 1982). 
Further experiments were carried out to find whether 
this high molecular weight material which binds to 
1001.A1 was in fact IRBP. 
Strips of nitrocellulose were cut from a Western blot of 
IPM and these were then treated with ConA, WGA (using 
the lectin -HRP method), (4.2.3.3.) or 1001.A1. The 
strips originated from the same Western blot and so it 
was possible to compare staining patterns between the 
different nitrocellulose strips. Those strips treated 
with Con A, WGA or 1001.A1, all stained in exactly 
the 
same area of the nitrocellulose (Figures 6.2.2.,6.2.3.), 
(86) 
Figure 6.2.3. Strips cut from a Western blot of a 
10% polyacrylamide gel loaded with 600ug of IPM. 
The blots were treated with lectins conjugated to 
HRP or with Conn followed by HRP, and stained with 





indicating that the ConA, W6A and 1001.A1 all bind to 
components of the IPM with the same molecular weight. 
This area of the nitrocellulose remained unstained on 
the strip treated to visualise PNA- binding components of 
the IPM. 
IRBP is known to bind ConA and WGA but not PNA (Fong et 
al 1984a), and so the fact that ConA, WGA and 1001.A1 
all bind to this high molecular weight component of the 
IPM, while PNA does not, suggests that 1001.A1 does in 
fact bind IRBP. 
To confirm this possibility, further dot blotting 
experiments were carried out this time, using a purified 
fraction of IRBP (lmg /m1) (5.2.) as the antigen. 
1001.A1 immunoreactivity was confined to the IRBP 
purified fraction of the IPM (Table 6.2.1.). 
Table 6.2.1. Dot blotting experiments using 
different antigen solutions and the 









( -) (-) ( -) 
( +) ( +) ( -) 
( +) ( -) ( +) 
( -) no immunoreactivity 
( +) immunoreactivity 
IPM -IRBP IPM depleted of IRBP 
(88) 
6.2.1.5. 1001.Á1 binding to other tissue types 
The monoclonal antibody was tested for immunoreactivity 
on fixed sections of other tissue types by Mr A Stewart, 
(an Honours student of the Department of Biochemistry), 
using the immunofluorescence method. No fluorescence 
was visualised on fixed tissue sections of bovine brain 
stem, cerebellum, hypothalamus or adrenal medulla and 
cortex, in agreement with the lack of IRBP in these 
tissues. 
6.2.1.6. Summary of the 1001.Ái antigen analysis 
In conclusion, 1001.Á1 shows immunoreactivity with the 




Figure 6.2.4. Photomicrographs of the bovine neural 
retina treated with i001.Á3 antibody followed by a 
biotinylated second antibody and Streptavidin --FITC as 
indicated in the text. 
a. Transverse tissue section of the bovine neural retina 
indicating staining in the outer segments (OS) of the 
photoreceptor cells and in the Interphotoreceptor Matrix 
(IPM). (magnification: X 150) 
b. Oblique tissue section of the bovine neural retina 
indicating staining around the photoreceptor cells. 
(magnification: X 900) 
(90) 
6.2.2. Analysis of the 1001.A3 antigen 
6.2.2.1. Light microscopy 
The distribution of 1001.A3 binding was visualised on 
fixed tissue sections of bovine neural retina by the 
immunofluorescence method. Immunoreactivity was 
localised to the outer segments of the photoreceptor 
cells and to the IPM (Figure 6.2.4.). No staining was 
apparent in the cell bodies of the photoreceptor cells. 
When tissue sections cut tangentially with respect to 
the photoreceptor cells were studied (Figure 6.2.4.), 
immunoreactivity was seen to be restricted to an area of 
the IPM surrounding the rod photoreceptor cells. The 
antigen appeared to form a distinct sheath -like 
structure around both the inner and outer segments of 
the photoreceptors. Binding of 1001.A3 was different to 
that of 1001.A1 which appeared to bind within a much 
less rigidly defined area. Although both antibodies 
show immunoreactivity within the same region of the 
retina, the localisation of their binding would appear 
to differ slightly. 
It was not possible to determine the presence of 1001.A3 
immunoreactivity within the photoreceptor cells, or 
within the cells of the pigmented epithelium at this 
resolution of microscopy. Unfortunately, as with 
1001.A1, the antigenicity of the tissue was lost when it 
was embedded in Lowicryl K4M and so higher 
magnifications could not be used to further study the 
(91) 
binding pattern of 1001.Á3. Biochemical techniques were 
therefore used to characterise and distinguish the 
1001.Á3 and 1001.Á1 antigens. 
6.2.2.2. Immunodotting of 1001.Á3 
Immunodotting was carried out (3.2.1.) using IPM (1mg /m1 
protein) as the antigen solution and a first incubation 
solution containing 1001.Á3 culture medium. Very strong 
immunoreactivity was found in the IPM indicating that 
1001.Á3 binds to a component present in the IPM. This 
was repeated using either purified IRBP, or IPM in which 
the IRBP had been removed. 1001.3 was seen to bind 
strongly to the fraction of IPM from which IRBP had been 
removed and not with the purified IRBP fraction (Table 
6.2.1). 
This confirmed that 1001.Á3 shows a different binding 
specificity to that of 1001.Á1, and does not bind to 
IRBP, but to some other component of the IPM. 
6.2.2.3. Western blotting of 1001.Á3 
Western blotting was then carried out to identify this 
component of the IPM. A 6 -15% exponential acrylamide 
gradient SDS polyacrylamide gel was used. This was made 
by using a multi -channel pump to transfer, at equal flow 
rates (approximately 2m1 /min) gel mixture containing 6% 
acrylamide into a 15% acrylamide gel mixture, and the 
mixed acrylamide solution into the gel cassette. The 
stacking gel consisted of a 5% acrylamide solution. The 
(92) 
nitrocellulose was treated to visualise 1001.Á3 binding 
to IPM. Very faint chloronaphthol staining ocurred on 
an area of the nitrocellulose corresponding to the 
stacking gel and to the top of the separating gel (the 
staining was too weak to be photographed and is not 
shown). This indicated that the antigen has a very high 
molecular weight, that it fails to penetrate the 
separating gel and that it is present in small amounts 
in the stacking gel or does not transfer efficiently to 
the nitrocellulose in Western blotting. A 
polyacrylamide gel loaded with IPM and stained for 
protein by the silver stain method (4.2.2.) showed this 
area of the gel to be apparently devoid of protein. 
Western blotting of 1001.Á3 was repeated using a 2- 
dimensional gel system (4.1.2.). 70 ul of IPM was 
loaded onto the 1st dimension IEF gel and the 2nd 
dimension consisted of a 6 -15% acrylamide gradient SDS- 
polyacrylamide gel with a 5% acrylamide stacking gel. 
Following Western blotting, the nitrocellulose was 
treated to visualise 1001.A3 binding. Very weak 
staining occurred on an area of the nitrocellulose 
corresponding to the top of the SDS- polyacrylamide gel 
and near the basic end of the IEF gel (Figure 6.2.5.). 
A pH gradient was not fully established across the first 
dimension of this gel, probably due to too short a time 
being allowed for its electrophoresis. For this reason, 
little confidence can be given to the pI value obtained 
for the 1001.A3 antigen although its position at the top 
(93) 
a1001 
Figure 6.2.5. Chloronaphthol staining of a Western 
blot of a two -dimensional polyacrylamide gel 
loaded with 70ug of IPM. The blot was treated 
with 1001.A3 followed by biotinylated second 
antibody and Streptavidin -HRP. See text for 
experimental detail. 
(94) 
E- basic / 
alool A'3 
acid is -t 
Figure 6.2.6. A two -dimensional polyacrylamide gel 
loaded with 70ug of IPM, silver stained for 
protein. See text for experimental detail. 
19S) 
of the gel suggests that it may be basic. However this 
method provided a means of concentrating the antigen in 
such a way as to allow it to be visualised by antibody 
treatment. The very high molecular weight of the 
antigen means it may have been impeded in the ist 
dimension gel and may have been unable to move away from 
the basic end of the gel towards the more acidic end. 
Another gel treated identically and stained for protein 
by the silver stain method again showed the area 
associated with the antigen to be apparently devoid of 
protein (Figure 6.2.6.). 
In conclusion the antigen is only detected on the basis 
of its immunoreactivity. It is not detected by protein 
staining, either because it stains poorly using 
conventional protein staining techniques, or because it 
is present in too low a concentration to be detected by 
these techniques. The very strong immunoreactivity (on 
the basis of dot blotting) would argue against the 
latter and would suggest that this high molecular weight 
antigen does in fact stain poorly and /or has difficulty 
in entering the SDS polyacrylamide gel systems used. It 
may also blot poorly, perhaps having difficulty in 
penetrating out from the polyacrylamide gel onto the 
nitrocellulose. This would lead to a reduction in the 
amount of antigen available for detection by the methods 
used above. 
(96) 
6.2.2.4. Immune precipitations of antigens using 
monoclonal antibodies 
Attempts were made to immune precipitate the 1001.A3 and 
1001.A1 antigens from IPM. 
If successful this might allow the isolation of enough 
1001.A3 antigen to make it possible to detect it by 
conventional staining methods and provide a method of 
purifying the antigen from the IPM for further 
biochemical analysis. 
An enzyme -linked immunosorbent assay ( ELISA) system was 
used to establish the conditions which would allow a 
fixed volume of monoclonal antibody solution to bind a 
maximum possible amount of antigen. 
6.2.2.4.1. Enzyme -linked immunosorbent assay ( ELISA) 
This method is described in Section 3.2.3. Individual 
wells of 96 -well microtitre plates were each coated with 
different amounts of IPM (0.5 ug -10 ug of protein /well) 
and the plates were incubated with first antibody 
solution containing 1001.A1, 1001.A3 culture medium, 
223.C3 ascitic fluid (6.2.2.4.11.) or antibody -diluting 
solution. 
In the case of 1001.A1 culture medium a maximal 
absorbance value was obtained with those wells coated 
with 2 ug of protein (the equivalent of 2 ul of IPM) 
when incubated with 100 ul of 1001.A1 culture medium. 
(97) 
Table 6.2.2. The ratio of monoclonal antibody 
to antigen (v /v), which allows maximal binding 










223.C3 (Asc) 1:2 
(Asc) = Ascitic fluid 
(98) 
This indicated a ratio of 50:1 1001.A1 culture 
medium:IPM (v /v) is necessary for maximal antigen 
binding to monoclonal antibody (Figure 6.2.7a.). 
Wells were then coated with 2 ug of protein and 
incubated with different volumes of 223.C3 ascitic 
fluid. Figure 6.2.7b. shows the absorbance values 
obtained and indicates that monoclonal antibody binding 
is not saturated with this volume of antigen and so for 
this monoclonal antibody the values obtained from Figure 
6.2.7a. are valid. The equivalent absorbance values are 
not shown for 1001.A1 or 1001.A3, but it was obvious 
that the same was also true for these, as the absorbance 
values increased when larger volumes of monoclonal 
antibody solution were incubated in wells coated with 
equal amounts of antigen. The ratios for optimal 
binding of the other monoclonal antibodies used are 
shown in Table 6.2.2. 
These ratios of antigen to antibody were used in the 
incubation steps of immune precipitations. 
It seemed sensible initially to try the immune - 
precipitation of IRBP from IPM using 1001.A1, since IRBP 
can be easily detected and recognised. This would allow 
the technique to be perfected before being adapted to 
the immune precipitation of a molecule of unknown 
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Figure 6.2.7.t The absorbance values from ELISA 
plates coated with 2pg of protein and treated 
with varying of 223.C3 ascitic fluid. 
See text for experimental detail. 
6.2.2.4.2. Immune precipitation of IRBP from IPM using 
1001.A1 
This was carried out essentially by the method described 
for the immune precipitation of horseradish peroxidase 
(3.2.4.1.) except that 1.5ml of 1001.A1 culture medium 
was incubated with 1ml of sheep anti -mouse 'globulin - 
Sepharose 4B conjugate, 30 ul of IPM was added as the 
antigen solution and Tween 20 was added to a final 
concentration of 0.05. (v /v) in all solutions used. The 
final pelleted gel containing the antigen /antibody 
mixture was treated for SDS polyacrylamide gel 
electrophoresis by the addition of 50 ul of sample 
incubation buffer (60 °C) (4.1.1.). The mixture was 
incubated for 20 minutes before the liquid was loaded 
onto an SDS polyacrylamide gel. The electrophoresed gel 
was fixed and stained for protein by the silver stain 
method. The track of the gel containing the immune 
precipitate was compared to the adjacent tracks 
containing the control precipitates in which either the 
culture medium or the antigen mixture (IPM) had been 
omitted. IRBP was not present at a higher concentration 
in the experimental fraction than in the control 
fractions and so appeared not to have been precipitated 
by this procedure. 
It was not clear why this procedure did not produce a 
successful precipitation. One mg of sheep anti -mouse 
)globulin was available on the Sepharose 4B gel for 
binding the monoclonal antibody present in the culture 
(102) 
medium (estimated to contain 1.5 µg -15 ug of monoclonal 
antibody in 1.5ml of culture medium) and enough antigen 
was used to be detected after SUS polyacrylamide gel 
electrophoresis even allowing for losses of up to 60% 
(leaving 12 ug of protein, easily detected by the silver 
staining method). One possible explanation was that the 
monoclonal antibody was unable to bind to the solid 
state second antibody due to the limited number of sheep 
anti -mouse IgM antibodies present. The method used to 
prepare the l globulin fraction for coupling to the 
Sepharose 4B involves the precipitation of a sheep anti - 
mouse )jglobulin fraction. Normal mouse serum contains 
on average 1- 10mg /ml of globulin, the majority being 
IgG molecules and only 5% of which may be IgM molecules 
(Goding 1983) and therefore a sheep anti -mouse Iglobulin 
fraction may contain predominantly anti -mouse IgG 
antibodies rather than-anti-mouse IgM antibodies. The 
availability of anti -IgM antibodies for coupling to 
Sepharose 4B would therefore be much lower than that of 
anti -IgG antibodies. For this reason it is likely that 
the majority of the antibody molecules coupled to the 
Sepharose 48 are of the anti -mouse IgG type rather than 
anti -mouse IgM molecules. 
An insufficient number of second antibody molecules with 
the ability to bind 1001.A1, an IgM class antibody 
would lead to a reduction in the amount of IRBP which 
could be precipitated. The same sheep anti -mouse 
globulin fraction is used to prepare the sheep anti- 
(103) 
mouse globulin- biotin conjugate, used in the initial 
screening of the monoclonal antibodies by the 
immunofluorescence method. This fraction does therefore 
contain some anti -mouse IgM molecules. The 
immunofluorescence method does, however, deal with very 
small quantities of antigen and antibody (not easily 
quantified) presumably at low enough levels for the 
anti -IgM molecules present in the sheep anti -mouse 
globulin- biotin conjugate solution to be in sufficient 
quantity to bind to the small concentration of 
monoclonal antibody bound to the tissue section. 
To increase the number of anti -mouse IgM antibody 
molecules available for binding the 1001.A1 IgM 
monoclonal antibody, the solid state Iglobulin was 
replaced by commercial goat anti -mouse IgM (r chain - 
specific) antibody conjugated to agarose beads. 
6.2.2.4.3. Immune precipitation of IRBP using solid 
state goat anti -mouse IgM antibodies 
The above process was repeated except that the solid 
state anti -mouse Iglobulin was replaced by 50 ul of the 
goat anti -mouse IgM molecules conjugated to agarose 
beads. This volume of gel is stated by the suppliers to 
be capable of binding 20 ug of mouse IgM antibodies, 
more than is present in 1.5ml of culture medium 
(assuming 1 -10 ug /ml of IgM /ml of culture medium). 
(104) 
IRBP- 
1 2 3 4 5 6 
Figure 6.2.8. Attempted immune precipitations of 
IRBP from IPM using 1001.A1, visualised on a 10% 
polyacrylamide gel, silver stained for protein. 
See text for experimental detail. 
1. molecular weight markers. 
2. IPM (80ug). 
3. aIgM + IPM (no 1001.A1) (70u1 fraction). 
4. aIgM + 1001.A1 + IPM (70u1 fraction). 
5. aIgM + 1001.A1 (noIPM) (70u1 fraction). 
6. molecular weight markers. 
(105) 
Again the silver stained SDS polyacrylamide gels of the 
presumptive immune precipitate failed to show any 
immune -precipitated IRBP (Figure 6.2.8.). 
It seemed, that the detection methods being used to 
visualise the precipitated antigen were too insensitive 
and the background levels of non -specific binding too 
high. One method of raising the sensitivity levels is 
to label the antigen in such a way that lower 
concentrations of the antigen may be detected by means 
of its label, whereas unlabelled molecules would not be 
detected. 
Two labelling methods were used; the proteins in the IPM 
were covalently labelled with either 1 5I- iodine or with 
NHS -biotin. 
6.2.2.4.4. of IPM proteins 
The proteins in the IPM were labelled with 1T-'5I -iodine 
by the Chloramine T method (4.6.1.). A 10 ul sample of 
the labelled IPM was taken for radioactive counting. 
This contained 2.56x106 counts per minute (cpm). With 
an efficiency of counting "T-5I of 80% this corresponds 
to approximately 3x106 disintegrations per minute (dpm), 
that is, 5x104 disintegrations per second (dps). Thus 
10 ul of 1 -'5I -IPM contains approximately 
5x104/37x106mCi, that is, 1.3 uCi (since 1mCi = 37x106 
Bequerel (Bq) = 37x106dps). 
(106) 
Figure 6.2.9. Autoradiograph of the immune 
led antigen by 1001.A1 
IaM-agarose (aM-IgM) 
of 50u1). See text for 
precipitation of 126I-lab-_-1 
or 1001.A3 using anti-mouse 
(samples 1n a final volume 
experimental detail. 
I. (10iy1). . 123I-IF'M (5u1). 
3. 1001.A1 + 25u1 aM-IgM + 1zsl-IBM. 
4. 100i.A1 + 50u1 aM-IgM + izsT_IF'M. 
5. 1001.A1 + 75u1 aM-igM + 123I-IF'M. 
b. 1001.A3 + 25u1 aM-IgM + 12I-iF'M. 
7. 1("í01.A-? + 50u1 aM-IgM + isl-IF'M. 
8. 1001.A3 + 75u1 aM-IgM + 
9. 50u1 aM-IqM + 12sI-IF'ti. 
(107) 
To check that 1 °5I label was present on IRBP, 10 ul of 
the treated IPM was subjected to SDS -polyacrylamide gel 
electrophoresis and autoradiography. This showed that 
IRBP did appear to be labelled (Figure 6.2.9.). 
6.2.2.4.5. Immune precipitation of IRBP from "1'51- 
labelled IPM 
The immune precipitation of "E'5I -IRBP from the 1 :I -IPM 
was carried out as described in Section 6.2.2.4.2., 
except that 10 ul of IPM containing approximately 
1.3 uCi of 1 <SI- iodine covalently bound to protein 
(6.2.2.4.4.) was added to the IPM before being used. 
The immune precipitate was treated by SDS polyacrylamide 
gel electrophoresis and X-ray film was exposed to the 
radioactive overnight before being developed. The 
IRBP was detected at equal levels in the controls and in 
the immune precipitates (Figure 6.2.9.). indicating that 
either no IRBP was precipitated or that the 1001.A1 
monoclonal antibody is selectively binding the 
unlabelled IRBP which cannot be detected by this method. 
It is possible that this method of labelling the IRBP 
may alter the structure of the antigenic determinant so 
that it is no longer recognised by the antibody. 
6.2.2.4.6. NHS -Biotin labelling of IPM proteins 
NHS -biotin was used to label the proteins in IPM by the 
method described in Section 4.6.3.1. Labelling was 
confirmed by Western blotting an SDS polyacrylamide gel 
(108) 
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IRBP 
Figure 6.2.10. Western blot of the immune 
precipitation of a biotinylated antigen by 1001.A1 
using anti -mouse IgM -agarose (aM -IgM). Samples had 
for experimental a final 
detail. 
volume of 50u1, see text 
1. 20u1 IPM -bio + 500u1 1001.A1 
2. 40u1 IPM -bio + 500u1 1001.A1 
3. 20u1 IPM -bio + 500u1 1001.A1 
4. 40u1 IPM -bio + 500u1 1001.A1 
5. 20u1 IPM -bio + 2.5ml 1001.A1 
6. 40u1 IPM -bio + 2.5ml 1001.A1 
7. 20u1 IPM -bio + 2.5ml 1001.A1 
S. 40u1 IPM -bio + 2.5ml 1001.A1 
9. 20u1 IPM -bio + 5.0m1 1001.A1 
10.40u1 IPM -bio + 5.0m1 1001.A1 
11.20u1 IPM -bio + 5.0m1 1001.A1 
12.40u1 IPM -bio + 5.0m1 1001.A1 
13.20u1 IPM -bio + 40u1 aM -IgM. 
14.40u1 IPM -bio + 40u1 aM -IgM. 
15.IPM -bio (70u1). 
+ 20u1 aM -IgM. 
+ 20u1 aM -IgM. 
+ 40u1 aM -IgM. 
+ 40u1 aM -IgM. 
+ 20u1 aM -IgM. 
+ 20u1 aM -IgM. 
+ 40u1 aM -IgM. 
+ 40u1 aM -IgM. 
+ 20u1 aM -IgM. 
+ 20u1 aM -IgM. 
+ 40u1 aM -IgM. 
+ 40u1 aM -IgM. 
(109) 
containing the biotinylated fraction, followed by 
staining the nitrocellulose to visualise the 
biotinylated material as for treatment with lectin. 
IRBP did appear to be labelled (Figure 6.2.10.). 
6.2.2.4.7. Immune precipitation of IRBP from 
biotinylated -IPM 
The immune precipitation was carried out essentially as 
before, replacing the IPM with biotinylated -IPM. As it 
was not certain that the biotinylated IRBP would bind to 
1001.A1 to the same extent as does unlabelled IRBP, 
various ratios of IRBP:1001.A1 were used in the immune 
precipitations. The immune precipitate was subjected to 
SDS polyacrylamide gel electrophoresis as above and then 
to Western blotting. The nitrocellulose was treated to 
visualise the presence of biotinylated- protein 
(6.2.2.4.6.). Chloronaphthol staining of the 
nitrocellulose occurred as a single band (Figure 
6.2.10.). This was present in all the precipitation 
fractions, including those in which either the 
monoclonal antibody or the second antibody had been 
omitted. This protein was therefore not specifically 
immune precipitated, and the staining of the 
nitrocellulose indicated some non -specific binding 
occurring, probably in the staining procedure between 
the streptavidin -HRP conjugate and the antibody 
molecules in the precipitation mixture. 
(110) 
6.2.2.4.8. Other anti -IRBP monoclonal antibodies 
The monoclonal antibodies 1001.B4, 1001.C4 and 223.03 
(raised in a similar manner to 1001.A1 as described in 
Section 6.2.) have been shown to react with IRBP. They 
have the ability to bind to purified IRBP (seen by 
immunodotting experiments using purified IRBP as the 
antigen solution). Epitope analysis has not yet been 
carried out, so these monoclonal antibodies may or may 
not share common antigenic determinants on the IRBP 
molecules. 
6.2.2.4.9. Immune precipitations using other anti -IRBP 
monoclonal antibodies 
Attempts were made to immune precipitate IRBP from the 
IPM using each of the monoclonal antibodies 1001.B4, 
1001.04 and 223.03. IPM and biotinylated -IPM were used 
as described above. 
None of these monoclonal antibodies immune precipitated 
the IRBP. 
The availability of several different monoclonal 
antibodies directed towards the same molecule led to the 
possibility of producing a synthetic "multi- clonal" 
antibody against the IRBP (assuming the antigenic 
determinant for each monoclonal antibody is not the 
same). It was thought that such a "multi- clonal" 
antibody would bind to antigen molecules more tightly 
than single monoclonal antibodies, increasing the 
possibility of cross -linking occuring between the 
antigen and different antibody molecules. For this 
reason, immune precipitations were attempted using such 
a "multi- clonal" antibody. 
6.2.2.4.10. Immune precipitation of IRBP from IPM using 
"multi- clonal" antibodies 
The immune precipitation of IRBP from IPM was attempted 
using a synthetic "multi- clonal" antibody solution 
containing equal volumes of. each anti -IRBP monoclonal 
antibody culture medium available, in a total volume of 
1.5ml (to replace the 1.5ml of 1001.A1 culture medium 
used previously). 
Again, the IRBP was not immune precipitated. 
There was still the possibility that not enough 
monoclonal antibody was binding to the solid state 
second antibody to allow enough antigen to bind and to 
be detected. To increase the concentration of 
monoclonal antibody in solution available for binding 
both the solid state second antibody and antigen, 
ascitic fluid was used. 
6.2.2.4.11. 223.C3 Ascitic fluid 
Ascitic fluid containing 223.C3 monoclonal antibody was 
produced (3.3.1.) and partially purified by DEAE- 
cellulose ion exchange chromatography (3.3.2.). 
When used in the ELISA system, it was found that 223.C3 
ascitic fluid could bind much more IRBP than could an 
equal volume of 1001.A1 culture media (Table 6.2.2.). 
(112) 
Figure 6.2.11. Autoradiograph of the immune 
precipitation of i2 °I- labelled antigen by 223.C3 
ascites using anti -mouse IgM -agarose (aM -IgM). 
Samples in a final volume of 50u1, see text for 
experimental detail. 
1. 126I -IPM (10u1). 
2. 50u1 aM -IgM + 123I -IPM 
3. 75u1 aM -IgM 
4. 50u1 aM -IgM 
5. 25u1 aM -IgM 
6. (10u1). 
+ 223.C3 ascites + 12I -IPM. 
+ 223.C3 ascites + 125I -IPM. 
+ 223.C3 ascites + 
(U3) 
6.2.2.4.12. Immune precipitation of IRBP from IPM using 
223.C3 ascitic fluid 
Attempts were made to immune precipitate IRBP from the 
IPM using 223.C3 ascitic fluid to replace the 1001.A1 
culture medium used previously. A 50 ul aliquot of 
purified 223.C3 ascitic fluid was used to replace the 
1001.Á1 culture medium and 100 ul of IPM (or 
biotinylated -IPM), was used instead of 30 ul of IPM. 
This achieved optimal conditions for the 
antibody:antigen binding as found by the ELISA method 
(6.2.2.4.1.)(Table 6.2.2.). 
Again the monoclonal antibody apparently failed to 
immune precipitate the IRBP (Figure 6.2.11.). 
It was unlikely in this case that there was too little 
monoclonal antibody present to allow enough IRBP to be 
immune precipitated and detected. 
The increased sensitivity gained by the use of 
biotinylated -IPM may counteract its usefulness by 
reducing the binding capacity of the monoclonal antibody 
to the antigen. It is possible that the biotinylation 
of the antigen may alter its structure so that it is no 
longer recognised or is poorly recognised by the 
antibody molecules. 
Another reason for the lack of success in this immune 
precipitation method would be explained by the inability 
of the monoclonal antibody to bind to both the solid 
state second antibody and to the antigen at the same 
time, perhaps due to steric hindrance. 
(114) 
6.2.2.4.13. Immune precipitation of the 1001.A3 antigen 
from the IPM using 1001.A3 
A final attempt using IPM, 1 = °I -IPM or biotinylated -IPM 
with 1001.A3 culture medium, to immune precipitate the 
1001.A3 antigen was carried out. 
The same conditions as for 1001.A1 were used 
except that 1.5 ml of 1001.A1 culture medium was 
replaced by 1.5ml of 1001.A3 culture medium; and either 
75 ul of IPM, 75 ul of biotinylated IPM, or 75 ul of IPM 
containing 10 ul of 1 =RI -IPM (containing 1.3 uCi of 
1 =5I) was used, according to the ratio of antibody to 
antigen required for optimal binding, as determined by 
the ELISA method (Table 6.2.2.). The presumptive immune 
precipitate was subjected to SDS -polyacrylamide gel 
electrophoresis, Western blotting or autoradiography, 
depending on the label. Silver stained gels failed to 
visualise any precipitate, stained nitrocellulose failed 
to visualise a biotinylated- precipitate and the 
autoradiographs failed to visualise a radio -labelled 
precipitate (Figure 6.2.9.). 
It is possible in this case that it is not the immune 
precipitation procedure but the ability of the antigen 
to enter SDS -polyacrylamide gel systems that is the 
limiting factor in detecting precipitated antigen. 
Tests were carried out to find which step in the immune 
precipitations may have been responsible for the 
failures. A 50 ul aliquot of solid state anti -mouse 
IgM- agarose conjugate was mixed with 1.5ml of 1001.A3 
(115) 
culture medium, incubated for 2 hours and then spin 
washed as before. To the pelleted gel was added 1.5ml 
of a 1000 -fold dilution of a stock sheep anti -mouse -HRP 
conjugate solution in TBS /BSA(1mg /ml), and this was 
incubated for a. further 2 hours. The gel was spin 
washed again before the addition of 4- chloro -l- naphthol 
stain (2.2.2.) to visualise the presence of HRP. The 
pelleted gel became purple whereas the control gel 
treated identically (except that the 1001.A3 monoclonal 
antibody was omitted) remained white. This indicated 
that the 1001.A3 monoclonal antibody had bound to the 
gel and that the sheep anti -mouse -HRP conjugate had in 
turn, bound to the 1001.A3 antibody. This suggests that 
the failure to immune precipitate the 1001.A3 antigen 
was due either to a failure in antigen:monoclonal 
antibody binding, or in the detection system used to 
visualise the precipitated antigen. 
6.2.2.4.14. Summary of the immune precipitation 
experiments 
It is unclear as to why these immune precipitations were 
not successful. There may be different reasons for the 
failures using the different antibodies. 
It is possible that in all cases the labelled antigen is 
no longer recognised by the monoclonal antibody or that 
the monoclonal antibody favours binding to the 
unlabelled antigen. This is unlikely to have occurred 
(116) 
for every antibody used as the 17--RI label is directed 
towards tyrosine residues whereas the biotin is towards 
the amino groups of lysine residues. 
A second possibility is that the monoclonal antibodies 
are incapable of binding to both the solid state second 
antibody and to the antigen at the same time. This may 
be sterically unfavourable due to the large size of the 
IgM antibody molecules which, when in close proximity to 
the gel or to each other, may hinder antigen binding 
(especially if the antigen molecule is also large). 
The monoclonal antibodies may have low affinities for 
their antigen and may not be able to precipitate the 
antigen. This is especially true for the 1001.Á1 
antibody. IRBP is the major glycoprotein constituent of 
IPM whereas proteoglycans and glycosaminoglycans are 
said to comprise only 2. (w /w) of the IPM (1.8.) and yet 
the intensity of chloronaphthol staining in dot blotting 
experiments indicates a lesser degree of binding of 
1001.Á1 to IRBP than of 1001.Á3 to the 1001.Á3 antigen. 
The difference in binding capacities of the two 
antibodies may be due to the presence of a higher number 
of antibody binding sites per individual molecule in the 
case of the 1001.Á3 antigen as compared to IRBP. 
Proteoglycan molecules are composed of identical 
repeated units of carbohydrate and so an antigenic 
determinant may be present many times in a single 
proteoglycan molecule. In comparison, it is possible 
that the peptide structure of the IRBP molecule which is 
(117) 
recognised by 1001.A1 is present only once in each IRBP 
sub -unit. It seems likely that the affinity of 1001.A1 
to IRBP is the limiting factor in the immune 
precipitation procedures and that the antibody is 
incapable of immune precipitating the IRBP. 
A third possibility (in the case of 1001.A3) is that the 
immune precipitation procedure does in fact work but the 
detection methods are not suitable for the antigen. 
It would appear that the use of immune precipitation 
procedures as a method of isolating the 1001.A3 antigen 
in order to characterise it biochemically is not 
feasible and that some other method is required for its 
isolation. The inappropriateness of these detection 
methods became apparent when further analyses of the 
1001.A3 antigen molecule was carried out (6.2.2.15). 
The next step taken was to make use of standard 
biochemical protein separation methods to fractionate 
the IPM with the purpose of testing each fraction for 
its ability to bind the monoclonal antibody. The 
components of the fractions with the ability to bind the 
monoclonal antibody would then be characterised 
biochemically. 
The IPM was initially fractionated according to 
molecular weight by gel filtration (size exclusion) 
chromatography. 
(118) 
6.2.2.5. Gel filtration chromatography of IPM 
500 ul aliquots of IPM (1mg /m1 of protein) was subjected 
to gel filtration chromatography using a Superose 12 
10/30 HR FPLC column (4.8.4.)(Figure 6.2.12). Thirty - 
two 1m1 fractions were collected and the constituents of 
each tested by immunodotting for their ability to bind 
1001.A3, (3.2.1.), using the fractions collected as the 
antigen solutions (Table 6.2.3.). 
Three successive fractions were found to contain 
components to which 1001.A3 could bind, the second of 
the three containing the highest concentration of these 
(corresponding to the immunodot which was the most 
highly stained with chloronaphthol). The retention time 
of this fraction indicated that the material collected 
had been excluded from the pores of the gel. According 
to the suppliers, the Superose 12 10/30 HR gel has an 
exclusion limit of 2x106 Daltons for globular proteins, 
indicating that the material to which 1001.A3 binds has 
a molecular weight, or is part of a mixture of 
components with an overall molecular weight of greater 
than 2x106 Daltons. The fraction which stained the most 
intensely in the dot blotting experiments was subjected 
to SDS polyacrylamide gel electrophoresis and the gel 
was silver stained for protein or stained for 
carbohydrate by the PAS method (4.2.3.). No protein or 
carbohydrate was visualised after staining. The very 
high molecular weight of the substance led to the 
suggestion that it may not be able to enter a 10/ SDS 
(119) 
polyacrylamide gel and therefore a 5% SDS polyacrylamide 
gel was used and again silver staining of the gel failed 
to show any protein present. The process was repeated 
using a 3% SDS polyacrylamide gel but due to the flimsy 
nature of such a low percentage acrylamide gel, it 
proved impossible to carry out the silver staining 
procedure. Instead, the less sensitive but simpler 
Coomassie blue staining method was used. No protein was 
visualised after staining, indicating that either there 
was no protein present, that it was present in too low a 
concentration to be detected by the Coomassie blue 
stain, or that it failed to stain by this method. 
(120) 
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Figure 6.2.12. The 280nm absorbance profile of IPM 
subjected to a Superose 12 10/30 HR FPLC gel 
filtration column under native conditions. See 
text for experimental detail. 
A 1001.A3 antigen 
B IRBP 
C PNA- binding material 
1 Blue dextran (2000kDalton) 
2 /3- amylase (200kDalton) 
3 Bovine serum albumin (66kDalton) 
4 Cytochrome C (12.4kDalton) 
(Ill) 
Tables 6.2.3_ The results of dot blot? inq_ 
experiments where the fractions obtained from a 
Superase 12 HR 10/30 gel filtration chromatography 
run were dotted onto nitrocellulose and treated 
with monoclonal antibody or lectin, as described 
in the text. 
`f=raction 
number no 
Monaclonal. ar;tibcrcry (Mab) /)ectin 
Mah 1001.A1 1001.A3 PNA (:;onA 
IPM ( -) ( +) ( +) ( +) (-`) 
1. ( -) (- -) ( +) ( +-- -) (+-) 
2. ( -) C -) ( +) ( + -) (+_.) 
3. ( -) ( --) ( -) ( -) ( -) 
4. ( -) ( -) ( --) ( -) ( -) 
5. ( --) ( +) ( -) ( -) (±) 
6. ( -) (+) ( -) ( -) (i -) 
7. ( -) ( -) ( -) ( +) ( --) 
8. ( -) ( --) ( -) (F) ( -) 
9 -37- ( -) ( -) ( -) ( -) ( -) 
( -) no immunoreactivity /reactivity 
( + --) little immunoreactivity /reactivity 
(+) immunoreactivity /reactivity 
6.2.2.6. Gel filtration of IPM in the presence of 
quanidinium HC1 
It was thought possible that the isolated 1001.A3 
antigen, shown to have a very high molecular weight by 
gel filtration under non -denaturing conditions, could be 
part of a large molecular aggregate of some sort, 
containing among other things the 1001.A3 antigen, 
rather than the antigen being a single molecular entity. 
To test this possibility, IPM was treated with 
guanidinium HC1 and fractionated by gel filtration 
chromatography in the presence of guanidinium HC1. This 
is a denaturing agent used to dissociate non -covalently 
bound material. Molecular aggregates in the presence of 
guanidinium HC1 should dissociate into their primary 
constituents which would then separate according to 
their individual sizes by gel filtration chromatography. 
A 400 ul aliquot of IPM was added to 200 ul of 8M 
guanidinium HC1. 500 ul of this mixture was subjected 
to gel filtration chromatography as described in Section 
6.2.2.5. except that the system was run in 4M 
guanidinium HC1 instead of TBS (Figure 6.2.13.). 
Fractions were collected and dot blotted as before to 
identify which fractions the 1001.A3 monoclonal antibody 
bound (Table 6.2.4.). The absorbance profiles at 280nm 
of the gel filtration runs under the denaturing and 
native conditions were found to be similar (Figures 
6.2.12.,6.2.13.). There was no obvious reduction in the 
amount of the high molecular weight material excluded 
(123) 
from the the gel, in the presence of guanidinium HC1, 
and there was no obvious increase in material with 
smaller molecular weights. The results of the dot 
blotting experiments indicated that the high molecular 
weight material maintained its ability to bind 1001.A3, 
although the immunoreactivity was spread over a larger 
number of fractions. No other fractions corresponding 
to lower molecular weight material showed an ability to 
bind 1O01.A3 and therefore it was concluded that the 
high molecular weight material must be a single entity 
with a molecular weight of at least 2x10 Daltons, 
rather than being a molecular aggregate of smaller 
components. 
Those fractions with the ability to bind 1001.A3 were 
subjected to SDS polyacrylamide gel electrophoresis. 
The gel was then silver stained for protein but again no 
protein was visualised. 
(124) 
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Figure 6.2.13 The 2B0rnm absorbance profile of IPM sub- - 
jected to a Superose 12 10/30 HR FPLC gel filtration 
column under denaturing conditions. See text for 
experimental detail. 
A 1001..A3 antigen 
1. Blue dextran (2000 KDalton). 
2 (3-- amylase (200 KDalton). 
3 Bovine serum albumin (66 KDalton). 
4 Cytochrome C (12.4 KDalton). 
(15) 
Table 6.2.4 The results of dot blotting 
experiments where the fractions obtained from a 
Superose 12 HR 10/30 gel filtration chromatography 
run under denaturing conditions were dotted onto 
nitrocellulose and treated with 1001.A3, as 
described in the text. 
traction 
number 1001 , A3 no Mab 
1PM ( + +) (-) 
1. ( +) ( --) 
2. ( +;) ( - ) 
3. ( + +) ( -) 
4. ( + +) (-) 
..?. ( +) ( --) 
6. (+-) ( -) 
7. (+- -) ( -) 
8. ( + -) (-) 
9 -48. (- -) ( --) 
(-) no immunoreactivity 
( 
---) little immunoreactivity 
(4) immunoreactivity 
( + +) strong immunoreactivity 
Mab monoclonal. antibody 
06) 
6.2.2.7. Trypsin treatment of IPM 
Trypsin is a serine protease which cleaves peptide bonds 
on the carboxyl side of arginine and lysine residues 
(Brown and Wold 1973). 
50 ul aliquots of IPM (1mg /m1 of protein) were incubated 
with trypsin at various concentrations (1U /m1- 1000/ml, 
final concentration) for 10 minutes at room temperature. 
PMSF was then added to a final concentration of 0.1mM, 
to prevent any further protease activity. Immunodotting 
was carried out using the digested IPM as the antigen 
solutions. The dots were treated to visualise the 
binding of either 1001.A1 or 1001.A3 to the digested 
IPM. Neither monoclonal antibody appeared to bind to 
the IPM which had been treated with trypsin at a 
concentration of greater than 10U /m1 (Table 6.2.5.). 
Table 6.2.5 The effects of trypsin treatment 
of IPM, with respect to its ability to bind 
the monoclonal antibodies 1001.A1 and 1001.A3 
I / Monoclonal Concentration of trypsin 
antibody (U /ml) 
(Mab) (100) (50) (10) (5) (1) 
1001.A1 ( -) ( -) ( + -) ( +) ( +) 
1001.A3 ( -) ( -) ( + -) ( +) ( +) 
no MAb ( -) ( -) ( -) ( -) ( -) 
( +) immunoreactivity 
( -) no immunoreactivity 
( + -) little immunoreactivity 
(127) 
The IPM treated with the highest concentration of 
trypsin which had no effect on the immunoreactivity of 
1001.Á3 antibody (5U /ml), and IPM treated with the 
lowest concentration of trypsin which abolished the 
immunoreactivity of the 1001.Á3 monoclonal antibody 
(10U /ml) were subjected to SDS- Polyacrylamide gel 
electrophoresis (6 -15% exponential acrylamide gradient) 
and Western blotting. The nitrocellulose treated with 
1001.Á3 showed the high molecular weight material which 
binds 1001.Á3, to have been present in the stacking gel 
of the gel -track loaded with IPM treated with the low 
concentration of trypsin whereas it was absent from the 
gel- track loaded with IPM treated with the high 
concentration of trypsin. No lower molecular weight 
degradation products with antibody immunoreactivity were 
visualised on the nitrocellulose. The procedure was 
repeated with the high molecular weight material, 
(isolated by gel filtration) (6.2.2.5.), which binds 
1001.A3. The silver stained gel of the trypsin treated 
fractions failed to visualise the presence of any 
protein and a similar gel stained by the PAS method 
failed to detect any carbohydrate present. 
In conclusion, the IRBP (1001.Á1 antigen) and the 
1001.Á3 antigen present in the IPM both have a protein 
component which when enzymatically digested causes the 
structure of the antigenic determinant to change so that 
it is no longer recognised by, and so no longer binds to 
the antibody. 
(128) 
It was thought that treatment of the IPM with trypsin 
would digest the high molecular- weight substance which 
binds 1001.A3, producing degradation products of lower 
molecular weights with the ability to enter the 
separating gel in SDS polyacrylamide gel 
electrophoresis. It was hoped that these could then be 
detected by staining the gel (for example for protein or 
carbohydrate). This was not the case and so the 
substance in the IPM which binds to 1001.A3 remains 
elusive to detection by any staining procedure other 
than that based on its antibody binding capacity. 
It is possible that this substance contains only a very 
small proportion of protein and that this protein may 
itself (especially after treatment with trypsin) have a 
very small molecular weight and therefore may not be 
detected by this gel electrophoresis system. On the 
other hand it is possible that the protein may be very 
large and be effectively unable to enter into the gel 
systems used. 
Further characterisation of this substance would rely on 
finding its susceptibility to other enzymatic treatments 
and the use of this information to determine its 
chemical composition. 
The protein content of the 1001.A3 antigen fraction 
obtained by gel filtration was assayed by the Bradford 
method and was found to be less than i ug /ml. IPM is 
known to contain a small proportion of glycosaminoglycan 
and proteoglycan (2% w /w), (Adler and Kluckznif 1982), 
(129) 
some of which are localised to different regions of the 
IPM (Feeney 1973). For this reason, IPM was treated 
with enzymes which react with different types of 
proteoglycan structures to establish whether the 
substance in the IPM which reacts with 1001.A3 is in 
fact a proteoglycan. IPM was treated with 
chondroitinase ABC, hyaluronidase, heparinase or nitrous 
acid before being tested for immunoreactivity with 
1001.A3. 
6.2.2.8. Chondroitinase ABC digestion of IPM 
Chondroitinase ABC catalyses the release of chondroitin 
sulphate and dermatan sulphate side chains from 
proteoglycans giving protein enriched core molecules 
still containing core side chains (Dike et al 1980, Oike 
et al 1982). The enzyme has high specificity for 
galactosamine glycan chains and has no activity on the 
core proteins, keratan sulphate chains, heparin or 
heparan sulphate chains. A reduction in antibody 
immunoreactivity as a result of chondroitinase ABC 
action on IPM would suggest the presence of chondroitin 
sulphate or dermatan sulphate groups within the 
structure of the antigen. 
A 50 ul aliquot of IPM was treated with chondroitinase 
ABC (4.8.4.) and the mixture was tested for its ability 
to bind the antibodies 1001.A1 and 1001.A3 by the dot 
(130) 
blotting method. 1001.A1 showed immunoreactivity with 
the chondroitinase ABC -treated IPM whereas 1001.43 did 
not (Table 6.2.6.). 
Table 6.2.6 The effects of various enzyme treat- 
ments of IPM with respect to its ability to bind 
the monoclonal antibodies 1001.A1 and 1001.A3. 
Monoclonal Enzymatic treatment of IPM 
antibody 
(Mab) Chon Hyal N/A Hep 
1001.A1 ( +) ( +) ( -) ( +) 
1001.A3 ( -) ( +) ( -) ( +) 
no Mab ( -) ( +) ( -) ( -) 
( -) no immunoreactivity 
( + -) little immunoreactivity 
( +) immunoreactivity 
Chon Chondroitinase ABC 
Hyal Hyaluronidase 
N/A Nitrous acid 
Hep Heparinase 
Western blotting of the chondroitinase ABC -treated IPM 
was carried out and the nitrocellulose was treated to 
visualise antibody binding. 1001.43 failed to bind as 
no staining was seen on the nitrocellulose corresponding 
to the high molecular weight antigen or to any lower 
molecular weight degradation products. The IPM 
incubated under the same conditions without the addition 
of the chondroitinase ABC maintained its immuno- 
(131) 
reactivity with both antibodies, indicating that this 
loss of immunoreactivity was due to the enzymatic action 
of the chondroitinase ABC. 
These results suggest the presence of chondroitin 
sulphate or dermatan sulphate groups within the antigen 
structure. The fact that IRBP was unaffected by the 
chondroitinase ABC treatment suggests that protease 
activity in the incubation mixture is not responsible 
for the loss of antigenicity of the IPM and that this is 
due to the specific activity of the chondroitinase ABC. 
The inability of 1001.A3 to bind its antigen after the 
sulphate groups have been removed from this structure 
indicates that these sulphate groups may form part of 
the antigenic determinant. 
6.2.2.9. Nitrous acid deamination of IPM 
Nitrous acid treatment of the glycosaminoglycan chains 
of a proteoglycan may result in the cleavage of 
carbohydrate units at those glycosidic linkages 
involving hexosamine residues in which the amino groups 
are either N- sulphated or unsubstituted (Borders and 
Raftery 1968). 
A 50 ul aliquot of IPM was treated with nitrous acid 
(4.9.5.) and then processed as for the chondroitinase 
ABC -treated IPM (6.2.2.8.). 
The ability of the IPM to bind 1001.A1 or 1001.A3 was 
abolished by the nitrous acid treatment (Table 6.2.6.). 
1001.A1 would appear to bind the protein structure of 
(132) 
IRBP (since binding is abolished by the action of 
trypsin) and therefore binding of 1001.Á1 to IRBP should 
not be affected by the nitrous acid treatment, since 
this should only alter the carbohydrate part of IRBP. 
It must be assumed therefore that the antigen 
determinant of IRBP for 1001.Á1 was lost due to the 
harsh acidic conditions imposed on it rather than due to 
the specific chemical reaction taking place. The same 
conclusion may be drawn from the loss of 1001.Á3 
antigenicity of the IPM and therefore no information is 
gained. 
6.2.2.10. Hyaluronidase (testicular) treatment of IPM 
Hyaluronidase catalyses the hydrolysis of ß(1 -->4) 
linkages between N- acetylglucosamine and D- glucuronate 
in hyaluronic acid (Dorfman 1955). 
50 ul of IPM was treated with hyaluronidase(testicular) 
(4.9.6.) and then as for the chondroitinase ABC treated 
IPM (6.2.2.8.). 
Both antibodies appeared to -maintain immunoreactivity 
with the hyaluronidase treated IPM as seen by the dot 
blotting method. The control dots which were treated 
under identical conditions (except that the monoclonal 
antibody solution was omitted), also stained (Table 
6.2.6.). From this it was concluded that the 
hyaluronidase was binding non -specifically to either the 
second antibody (anti mouse -biotin conjugate) or to the 
streptavidin -HRP conjugate during the staining 
(133) 
procedure. This meant that it was impossible to 
conclude anything with respect to the structure of the 
1001.A3 antigen by this method. 
Western blotting was then carried out and the 
nitrocellulose blotted with the hyaluronidase- treated 
IPM failed to stain in the region corresponding to the 
1001.Á3 antigen in the IPM, or in any other area 
previously unstained, whereas the control strip of 
nitrocellulose containing untreated IPM, did stain. 
From this it was concluded that the 1001.Á3 antigen is 
susceptible to hyaluronidase and that the antigenic 
determinant may be part of a hyaluronic acid molecule. 
6.2.2.11. Heparinase treatment of IPM 
Heparinase catalyses the hydrolysis of 0- Sulphate and 
sulphamide groups to produce AB- unsaturated uronides 
(Linker and Hovingh 1972). 
A 50 ul aliquot of IPM was treated with heparinase 
(4.9.3.) and then as for the chondroitinase ABC treated 
IPM (6.2.2.8.). 
The heparinase had no effect on the binding of either 
1001.Á1 or 1001.Á3 to IPM (Table 6.2.6.). It was 
concluded from this that either the 1001.A3 antigen is 
not a heparan sulphate or heparin molecule, or that the 
antigenic determinant within such a molecule type is not 
itself altered by the heparinase treatment. 
(134) 
6.2.2.12. Enzymatic treatment of tissue sections of 
bovine neural retina 
In order to further characterise the nature of the 
1001.A3 antigen, the experiments described in Sections 
6.2.2.7.- 6..2.11. were repeated and expanded upon, 
using fixed tissue sections of the bovine neural retina 
in place of IPM, and a larger selection of enzymes. 
Sections were treated with either chondroitinase ABC, 
chondroitinase AC, hyaluronidase (testicular), 
hyaluronidase (Streptomyces), heparinase, neuraminidase 
or trypsin, before being treated to visualise 1O01.Á3 
binding. 
Binding of the antibody was unaffected by treating the 
sections with heparinase or neuraminidase and was 
completely abolished by treating the sections with 
either trypsin, chondroitinase ABC, chondroitinase AC or 
hyaluronidase (testicular). Treatment with 
hyaluronidase (Streptomyces) had no effect on the 
ability of the antibody to bind, although the 
distribution of binding was altered. The sheath 
structures surrounding the photoreceptors appeared to 
collapse, giving the immunofluorescente staining a 
"fuzzy" appearance (Figure 6.2.14.). 
(135) 
Figure 6.2.14. Photomicrographs of the bovine neural 
retina treated with enzyme followed by treatment with 
1001.A3 antibody, a biotinylated second antibody and 
Streptavidin -FITC as indicated in the text. 
a. Transverse tissue section of the bovine neural retina 
treated with chondroitinase AC. Staining of the 1001.A3 
antibody is abolished from the photoreceptor cells and 
the Interphotoreceptor Matrix. (magnification X 150) 
b. Transverse tissue section of the bovine neural retina 
treated only with biotinylated second antibody and 
Streptavidin -FITC, indicating background staining in the 
absence of 1001.A3, similar to that in the 
chondroitinase AC treated retina. (magnification X 150) 
c. Transverse tissue section of the bovine neural retina 
treated with Streptomyces hyaluronidase. Staining does 
not appear to be reduced although the binding pattern is 
altered. (magnification X 150) 
d. Transverse tissue section of the bovine neural retina 
treated as in c. The staining pattern of 1001.A3 remains 
associated with the photoreceptor cells and with the 
Interphotoreceptor Matrix but is no longer present as 
an ordered structure and staining adopts a "fuzzy" 
appearance. (magnification X 900) 
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6.2..13. Conclusions from the enzymatic treatments of 
IPM 
The fact that the 1001.A3 antigen is sensitive to 
chondroitinase ABC and chondroitinase AC would suggest 
it to be a chondroitin A sulphate and /or a chondroitin C 
sulphate- containing molecule and not a dermatan sulphate 
molecule, which would not have been affected by the 
chondroitinase AC enzyme. 
The 1001.A3 antigen is sensitive to trypsin, indicating 
the presence of a core protein and /or link protein, and 
that it is not a hyaluronic acid molecule (Laurent and 
Fraser 1986). The sensitivity of the antigen to 
hyaluronidase (testicular) and not to hyaluronidase 
(Streptomyces) would appear to verify this. 
Hyaluronidase (testicular) as well as using hyaluronic 
acid as a substrate is capable of using chondroitin 
sulphate groups A and C as substrates (Borders and 
Raftery 1968) whereas hyaluronidase (Streptomyces) 
reacts specifically with hyaluronic acid molecules. The 
ability of the hyaluronidase (Streptomyces) to alter the 
binding pattern of 1001.Á3 suggests that the antigen is 
associated with hyaluronic acid molecules and that the 
chondroitin sulphate- containing molecules, recognised by 
1001.Á3, are held in a rigid sheath -like structure by 
the hyaluronic acid molecules. 
Evidence exists for the presence of chondroitin sulphate 
molecules and the absence of dermatan sulphate molecules 
in the inner segment /outer segment region of the IPM 
(136) 
(Porrello and Lavail 1486). This appears to confirm the 
conclusions obtained from the analyses of the 1001.A3 
antigen structure. 
6.2.2.14. 1001.Á3 binding to other tissue types 
l001.Á3 was tested for its ability to bind ovine 
cartilage and mast cells (which contain and secrete 
large amounts of proteoglycan) by Dr. H Miller, Moredun 
Research Unit, Edinburgh. There was no antibody 
binding, indicating the absence of the 1001.A3 antigen 
in these cell types. 
6.2.2.15. Summary of the 1001.Á3 antigen analysis 
1001.Á3 binds to a component of the IPM which is part of 
a sheath -like structure, surrounding the inner and outer 
segments of the photoreceptor cells. 
The antigen has an apparent molecular weight of at least 
2x106 Da and is a chondroitin sulphate- containing 
molecule, which may be unique to the IPM of the retina. 
These chondroitin sulphate- containing molecules are 
associated with hyaluronic acid molecules which are 
necessary for the maintainance of the sheath structure. 
The fact that the antibody binding relies on the 
presence of sulphate groups on the side chains of the 
presumptive glycosaminoglycans suggests that it is the 
extent or the positioning of these sulphate groups which 
makes this molecule unique to the IPM. 
(137) 
6.2.3. Discussion 
In retrospect, the methods used to identify the antigens 
of the 1001.Á1 and 1001.Á3 monoclonal antibodies were 
not the most suitable for the task, especially in the 
case of the 1001.Á3 antigen. 
Immune precipitations, SDS- polyacrylamide gel 
electrophoresis and Western blotting techniques are most 
suitable for the analysis of protein molecules. Such 
molecules tend to be globular in shape and have a 
molecular weight of under 20 000 Daltons. These 
techniques are not as well suited to the analysis of 
very large molecules or highly glycosylated proteins. 
The progress of large molecules is hindered through 
polyacrylamide gels and glycoproteins or proteoglycans 
are not well detected using conventional protein stains. 
Such molecules also fail to transfer well onto 
nitrocellulose from polyacrylamide gels. In order to 
precipitate the antigen using a monoclonal antibody, 
there must be high affinity binding between the two 
molecule types. This is especially true for very large 
antigen molecules. Higher affinity antibodies may be 
produced by lengthening the period of time in which mice 
were immunised, and by subjecting the animals to a 
greater number of immunisations. Both monoclonal 
antibodies produced were of the IgM class which tend to 
have a lower affinity than IgG molecules and do not 
mature through time (Gearhart et al 1981). The 
(13B) 
production of IgG antibodies may be more useful since 
higher affinity antibodies may be used more successfully 
in immune precipitations. 
Standard biochemical separation techniques such as gel 
filtration and ion exchange chromatography are also not 
always suitable, due to the highly charged nature and 
large size of proteoglycan molecules. Other techniques 
such as density centrifugation and chemical analyses are 
often used to characterise such molecules. 
The alternative approach to identifying the 1001.A3 
antigen and of discovering more about its properties 
would be to study its biosynthetic pathway. This would 
be possible using radio- labelled sulphate, amino acid 
and /or sugar molecule precursors, combined with the use 
of pathway inhibitors such as ß- xylosides (which block 
the addition of chondroitin sulphate chains to the core 
glycoprotein by acting as acceptors for the synthesis of 
sulphated glycosaminglycan chains) (Schwartz et al 
1974a, Schwartz et al 1974b); or tunicamycin (which 
inhibits the addition of asparagine- linked carbohydrate 
groups to the protein) (Schwartz et al 1982, Schwartz 
and Datema 1988). Analysis of the production of the 
proteoglycan antigen could then be acheived by a 
combination of immunohistochemistry and sub -cellular 
fractionation techniques. This it should be stressed is 
a long -term approach and would not be acheived in a 
short period of time. An initial problem is that it is 
not known for sure where the 1001.A3 antigen is 
(139) 
synthesised (the photoreceptor cells, glial cells or 
pigmented epithelium cells are all possible candidates) 
and so this would have to be established -first. 
In conclusion, two monoclonal antibody- secreting cell 
lines were produced by immunising mice with unpurified 
mixtures from the retina. 
In an attempt to produce more photoreceptor, or IPM - 
specific monoclonal antibodies, the second strategy (as 







Figure 6.3.1. Fixed tissue section of the bovine 
neural retina treated with PNA-FITC. 
6.3. Immunisation of mice with purified antigen 
6.3.1 Introduction 
As discussed in Section 6.1., a second approach to the 
production of cell -specific monoclonal antibodies is to 
purify, or at least partially purify, a cell -specific 
antigen with the intention of using this to immunise 
mice. This would also reduce the probability of 
producing monoclonal antibodies with similar binding 
characteristics to those already produced and which are 
discussed in Section 6.2. 
It would be unwise to isolate a substance, for example, 
a protein, and to assume this to be specific to a 
particular cell type (in vivo), unless it can be 
identified both in the in vivo and in vitro situations. 
The cone photoreceptor cells in the retina are not as 
well defined biochemically as the rods (discussed in 
Section 1.6), however the Peanut Agglutinin (PNA) - 
binding material which is associated with the outer 
segments of the cones is a candidate suitable for 
isolation as a cone -specific antigen. This is easily 
identifiable, since no other substance present in the 
outer retina binds PNA (as determined by treating tissue 
sections of neural retina with PNA (2.2.3.)(Figure 
6.3.1.). PNA binds to the inner plexiform layer of the 
retina as well as to the outer segments of the cone 
photoreceptors and the cone pedicles. Other lectins 
such as ConA and WGA also bind the outer segments of the 
(142) 
photoreceptor cells but none specifically to the cones. 
Treatment of a section of the retina with neuraminidase 
(which removes terminal sialic acid molecules from the 
carbohydrate groups of glycoconjugates), followed by 
treatment of the tissue with PNA, results in the 
staining of both the rod and the cone photoreceptors. 
It is not clear if this post -neuraminidase staining is 
due to the lectin binding to the same molecule, present 
on both rod and cone cells but normally sialylated when 
associated with the rods, or whether the PNA is binding 
to quite different molecules in each case. 
Substances isolated from the outer retina which bind PNA 
before neuraminidase treatment must therefore originate 
from molecules associated with the cone photoreceptors. 
'6.3.2. Isolating the PNA -binding material 
The PNA- binding material is extracellular and forms a 
domain around the cone photoreceptors, distinct from the 
remainder of the IPM (Johnson et al 1986). It was 
neccessary to establish whether this material is removed 
from the retina during the preparation of IPM (5.1.), or 
whether it remains associated with the retina. To test 
this, after the removal of IPM, the retina was cut into 
squares (approximately 25mm= and then embedded, 
sectioned (2.1.1.) and treated with PNA. 
The intensity of fluorescence due to the lectin binding 
appeared the same as in tissue sections of control 
retina in which IPM had not been removed. 
(143) 
In conclusion therefore, the PNA- binding material 
associated with the cone photoreceptors (or with the 
inner retina) was not removed from the retina by the 
normal method of preparing IPM, or at least not to any 
great extent (it was impossible to tell if a small 
proportion of the PNA- binding material had been 
removed). 
The IPM therefore may contain a small amount of the PNA - 
binding material originally associated with the cone 
photoreceptor cells, but the majority of it remains 
associated with the retina after IPM is removed. 
The first step in the purification of this PNA- binding 
substance would appear to be the removal of IPM from the 
retina. 
6.3.3. Liberating PNA -binding material from the retina 
using high salt concentrations 
The next step in purifying the PNA- binding material 
associated with the cone photoreceptor cells was to 
liberate the material from the surface of the retina. 
It was important to keep separate any PNA -binding 
material released from the inner retina from that 
released from the outer retina. The two are distinct in 
tissue sections treated to visualise PNA binding (Figure 
6.3.1.), but it would be impossible to distinguish them 
in solution as the characteristics of these molecules 
(144) 
are not known. This meant that the outer surface of the 
retina had to be treated independently of the inner 
surface when liberating the PNA- binding material. 
Attempts were made to isolate the material by subjecting 
the outer surface of the retina to various high salt 
concentrations, in order to release it from the cone 
plasma membrane with which it is associated. 
IPM was removed and the retina was placed face down in a 
Petri dish (with the photoreceptors facing downwards), 
so that it was floating on the incubation solution. 
Incubation solutions containing high salt concentrations 
were used in an attempt to remove the PNA- binding 
material associated with the cone photoreceptors, as 
such conditions have been used to liberate other 
membrane -associated, or extrinsic membrane proteins from 
membranes (Howell and Palade 1982, Higgins 1984). 
The retina was floated in 1 -2ml of either 50mM Tris HC1 
pH 7.4 containing 500mM sodium chloride, or 100mM sodium 
carbonate /sodium hydroxide pH 11, on ice for periods of 
up to 30 minutes. The retina was then rinsed in a large 
volume of TBS before being embedded and sectioned 
(2.1.2.). The sections were treated with PNA. 
Fluorescence was as intense as for the control retina 
sections (obtained from retinae treated identically 
except that the incubation solution was TBS). In 
conclusion, the high salt concentration treatment of the 
retina did not remove the PNA- binding material 
associated with the cone photoreceptors. Incubations of 
(145) 
the retinae for longer periods of time resulted in the 
tissue becoming very gel -like in appearance and 
difficult to handle, so an alternative treatment was 
required. 
6.3.4. Treatment of the surface of the retina with 
trypsin 
The outer surface of the retina was treated 
enzymatically with trypsin, by the method described 
above for high salt concentration treatment, except that 
the retina was incubated in lml of TBS, containing 
0.001. (w /v) trypsin (10U/m1) for 10 minutes at room 
temperature. Care was taken not to expose the inner 
surface of the retina to this solution. The retina was 
then drained of excess liquid and rinsed in a large 
volume of TBS containing 0.1mM PMSF to prevent further 
protease activity (Provty and Goldberg 1972). PMSF was 
also added for the same reason to a final concentration 
of 0.1mM to the remaining incubation solution. The 
retina was then embedded and sectioned and the sections 
treated with PNA. No fluorescence was visible in the 
outer retina. The PNA- binding material associated with 
the cone photoreceptors had most probably been liberated 
from the retina into the remaining incubation solution. 
This solution was retained for analysis to determine 
whether PNA- binding material was indeed present. 
(146) 
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Figure 6.3.2. Strips from a Western blot of a 10% 
polyacrylamide gel loaded on one half with 300ug 
IPM and on the second half with 300ug trypsin 
digest. The strips were treated with biotinylated 
lectins followed by Streptavidin-HRP' See text 
for experimental detail. 
1. IPM treated with PNA' 
2' IPM treated with ConA. 
3' IPM treated with Streptavidin only. 
4. Trypsin-digest treated with PNA' 
5' Trypsin-digest treated with ConA. 
It was assumed that the incubation solution would 
contain some membrane -associated material originating 
from damaged outer segments and so detergent was used to 
solubilise protein from the membrane fragments. Triton - 
X100 detergent was added to the incubation solution (1% 
(v /v), final concentration), and the mixture allowed to 
stand on ice for 30 minutes before being centrifuged at 
100 000g for 30 minutes. The supernatant was removed, 
aliquoted into smaller volumes and stored at -20 °C. 
6.3.5. Analysis of the trypsin -digest solution 
containing PNA- binding material 
The solubilised fraction, named "trypsin- digest ", was 
assayed for protein by the Bradford assay (4.4.) and was 
found to contain approximately img /ml of protein. This 
was dotted onto nitrocellulose and treated with PNA 
(4.3.4.). The chloronaphthol- stained nitrocellulose was 
compared to similar dot blots of IPM. The 
nitrocellulose dotted with trypsin- digest stained the 
more intensely of the two. This indicated that both 
solutions contained PNA- binding material and that this 
was at a higher concentration in the trypsin- digest 
solution than in the IPM. Western blotting was then 
carried out using trypsin- digest (4.3.1.) and strips of 
the nitrocellulose were treated with PNA or ConA 
(4.3.3.). The chloronaphthol staining pattern on the 
nitrocellulose indicated the presence of several PNA- 
binding glycoproteins (Figure 6.3.2.). The 
(148) 
nitrocellulose treated with ConA was devoid of staining, 
indicating there was no IRBP or digested fragments of 
IRBP (containing mannose residues) present in the 
trypsin- digest and this was taken to indicate the 
absence of other proteins from the IPM or of rod outer 
segment material which may bind ConA. Western blots of 
IPM were treated with PNA or ConA (Figure 6.3.2.) and 
these were compared to those of the trypsin- digest. 
Those strips of nitrocellulose containing IPM or 
trypsin -digest which were treated with PNA had similar 
staining patterns whereas those strips treated with ConA 
were different. 
This suggests that the two solutions have common 
components, some of which bind PNA, but that they are 
not identical in composition. It seems that the IPM 
prepared as described in Section 5.1., contains 
contaminating proteins from the surface of the retina, 
which do not constitute part of the interphotoreceptor 
matrix proper, or which are normally shed into the IPM 
by the photoreceptor cells. The alternative 
possibility, that the trypsin- digest contains 
contaminants from the IPM was ruled out by the lack. of 
IRBP, the major glycoprotein of the IPM, in the trypsin- 
digest. 
This finding explains the source of PNA- binding 
glycoproteins in IPM and indicates that these are 
probably the same as the PNA -binding glycoproteins 
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Figure 6.3.3. A silver stained 1!'Et% polyarr:,lamid=- 
gel showing the results of F'NA-affinity 
chromatography of T rypsin-digest. See text for 
experimental detail. 
1. Molecular weight markers (151.g) _ 
2. PNA- binding fraction (40u1) . 
3. Trypsin- digest (starting material) (4010). 
4. as 1. 
(ISO) 
glycoproteins which are present in the trypsin- digest 
have been shown to originate from the cone photo- 
receptors, those PNA- binding proteins present in IPM 
must also originate from the cone photoreceptors. 
A polyacrylamide gel (4.1.1.), loaded with aliquots of 
the trypsin- digest was stained for protein by the silver 
stain method (4.2.2.)(Figure 6.3.3.). Many proteins 
with a wide range of molecular weights were visualised. 
No IRBP was present, confirming the absence of ConA 
binding in the Western blot. 
Attempts were therefore made to isolate the PNA- binding 
glycoproteins from the trypsin- digest. 
(151) 
6.3.6. Affinity chromatography of trypsin -diqest 
Affinity chromatography of trypsin- digest was carried 
out using the batch method, essentially as described in 
Section 4.8.1. 
A 1m1 aliquot of Sepharose -4B conjugate, containing 
approximately 1mg of lectin, was incubated with 1m1 of 
trypsin- digest (previously dialysed against column 
buffer). Material which had bound to the gel was eluted 
in 1ml of column buffer containing 200mM galactose. 
This fraction was subjected to SDS- polyacrylamide gel 
electrophoresis which was subsequently silver stained. 
No protein was apparent in the eluate indicating that 
none of the PNA- binding material had been affinity 
purified from the trypsin digest. 
In order to reduce the steric hindrance on the PNA 
molecules caused by the conjugation process and also to 
increase the concentration of PNA molecules present on 
the gel, the affinity chromatography was repeated using 
a commercial agarose gel conjugated to biotin (agarose- 
bio). A 100u1 aliquot of the agarose -bio gel (capable 
of binding 1.1mg of avidin per ml of gel, according to 
the suppliers) was added to approximately 1m1 of 
Sepharose 4B and spin washed. To the pelleted gel was 
added 500u1 of avidin (1mg /m1 in TBS) and this was mixed 
end -over -end, overnight at 4 °C. After spin washing, 
200u1 of PNA conjugated to biotin (PNA- bio)(4.6.3.2.) 
was added to the pelleted gel and the mixture incubated 
end -over -end for 8 hours at 4 °C. The gel was spin 
(152) 
washed and 3ml of dialysed trypsin- digest was added to 
the pelleted gel. After spin washing, 500u1 of column 
buffer containing 200mM galactose was added to the 
pelleted gel and the mixture incubated for B hours end - 
over -end at 4 °C. The gel was spin washed for a final 
time and stored in excess column buffer containing 200mM 
galactose and 0.05% (w /v) sodium azide. 
Aliquots of the original trypsin- digest and of the sugar 
eluted fraction were subjected to SDS- polyacrylamide gel 
electrophoresis and Western blotting. These were silver 
stained for protein and treated with PNA respectively. 
In the lane of the gel which contained the sugar -eluted 
fraction, a small amount of very low molecular weight 
material was apparent, very close to the dye front. The 
nitrocellulose treated with PNA failed to stain. The 
PNA affinity chromatography procedure was repeated and 
the PNA -bio solution tested for its lectin content after 
it was incubated with the gel mixture. Sections of 
neural retina were treated with PNA using the PNA -bio 
solution and the fluorescence method. No fluorescence 
was seen indicating the the PNA -bio had been removed 
from the solution and was present in the gel mixture. 
The same results were obtained for the affinity 
chromatography, none of the PNA- binding glycoproteins 
being affinity purified from the trypsin- digest. 
Final attempts to do this were carried out using a 
commercial PNA -agarose gel (containing 2 -4mg of 
lectin /ml of gel, according to the suppliers). This was 
(153) 
a much higher concentration of PNA than was present in 
the Sepharose 4B -PNA conjugate. 2m1 of trypsin- digest 
was added to 100u1 of the PNA- aga.rose conjugate and the 
chromatography was carried out by the batch method. The 
material which passed through the gel without binding 
and the material eluted from the gel by the addition of 
200mM galactose were each collected in 100u1 batches and 
50u1 aliquots of each were subjected to SDS- 
polyacrylamide gel electrophoresis and the gel stained 
for protein by the silver stain method. Those lanes of 
the polyacrylamide gel containing either the pass - 
through material which failed bind to the column, or the 
original trypsin- digest, had similar polypeptide 
staining patterns. This indicated that both fractions 
had the same constituents and that nothing in the 
trypsin- digest appeared to have been removed completely 
by the affinity chromatography procedure. The lane 
containing the material eluted with the sugar solution 
again showed very little staining. The staining 
corresponded to the same very low molecular weight 
material as described above which was not obviously 
apparent in the original trypsin- digest (Figure 6.3.3.). 
The procedure was repeated and the same result was 
obtained. 
It is possible that this very low molecular weight 
material does have a carbohydrate group containing 
terminal galactose residues as part of its structure, 
and to which PNA binds. The affinity chromatography 
(154) 
procedure may have acted to concentrate it more than it 
is in the original trypsin -digest. The material was 
apparent in an area of the gel very close to the dye 
front indicating that it may be a glycolipid rather than 
a glycoprotein. The fact that this material when 
visualised by the silver stain method, appeared very 
yellow in colour (rather than dark brown or grey as most 
proteins and glycoproteins appear) would support this 
idea. This would explain why this material was not 
detected in Western blots, since it would tend to 
dissolve in the transfer process due to the high 
methanol content of the blotting buffer. None of the 
PNA- binding glycoproteins visualised by staining Western 
blots of the trypsin- digest (as described in Section 
6.3.5.) were apparent in this eluted fraction from the 
trypsin- digest. A higher concentration of other 
molecules which bind more strongly to PNA would 
effectively compete out the binding of the PNA- binding 
glycoproteins to the immobilised PNA. 
In conclusion the affinity chromatography procedure was 
not successful in isolating the PNA- binding 
glycoproteins from the trypsin- digest. One explanation 
for the failure is the possibility of steric hindrance 
on the PNA molecules after conjugation to the agarose 
and that the galactose residues of the glycoproteins may 
be unable to bind to the lectin. This would be 
(155) 
especially true for carbohydrate groups which are part 
of a large molecule, or those which are hindered by 
other bulky groups. 
It is possible that the PNA- binding glycoproteins found 
in trypsin- digest by SDS -PAGE, are present in vitro in 
the form of a large, high molecular weight complex of 
macromolecules which may not dissociate in the 
conditions used in the PNA- affinity chromatography. 
Such a complex would tend not to bind to the lectin 
under these conditions whereas the individual 
glycoproteins may bind readily, when dissociated. 
Denaturing conditions may have been required for the 
dissociation of the complex to allow binding of the 
glycoproteins to the lectin. In contrast the results 
from the gel filtration chromatography of IPM in non - 
denaturing conditions (6.2.2.5.) in which all the PNA - 
binding material was found to have an apparent molecular 
weight of 30- 70KDa.ltons, would appear to contradict the 
idea of a large aggregate of PNA- binding material. One 
could however argue that the PNA- binding glycoproteins 
are at some point in time, shed individually into the 
IPM from a large complex of PNA- binding molecules found 
only associated with the cone photoreceptor cells. 
These would therefore be detected in the IPM only in the 
form of the lower molecular weight glycoproteins. No 
low molecular weight PNA- binding glycolipids are 
detected in the IPM (6.2.2.5.) and so those detected in 
trypsin- digest by the PNA -affinity chromatography may be 
(156) 
tightly associated within the complex in vivo, 
dissociation only occurring in the presence of trypsin 
in vitro. 
To verify the presence of such a high molecular weight 
complex of molecules trypsin- digest was treated by 
Superose 12 HR 10/30 gel filtration chromatography under 
native conditions in the same manner as was IPM 
(6.2.2.5.). The high molecular weight material excluded 
from the gel was tested by dot blotting for its ability 
to bind PNA. Chloronaphthol staining was found to be 
very high indicating a large amount of PNA- binding 
material present. The argument for the presence of a 
large complex of PNA -binding material would therefore 
appear feasible. 
(157) 
6.3.7. Immunisation of mice with trypsin -diqest 
Since the PNA- binding glycoproteins could not be easily 
isolated from trypsin -digest, mice were immunised 
(3.1.1.) with trypsin- digest and cell fusions carried 
out as described in Section 3.1.4. in an attempt to 
produce monoclonal antibodies against the PNA- binding 
glycoproteins present in the solution. Two such fusions 
were carried out. The first was abandoned after 6 days 
when it became obvious that no colonies of hybridoma 
cells were present. The second fusion produced colonies 
of cells in 261 of the 480 wells observed. On Day 10 
all the wells were screened using unfixed sections of 
the neural retina (the cone photoreceptor cells maintain 
their ability to bind PNA in unfixed tissue sections and 
so these were used to prevent losses in antigenicity 
within the tissue due to fixation), but no 
immunoreactivity was detected in the retina and so this 
fusion was also abandoned. 
(158) 
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Figure 6'3.4' Western blot of a 10% polyacrylamide 
gel loaded with fractions obtained from a Superose 
12 gel filtration column loaded with 500ug IPM' 
The blot was treated with biotinylated PNA 
followed by Streptavidin-HRP and stained with 
chloronaphthol. See text for experimental detail. 
1. IPM' (70ug). 
2- 60ul fraction 
3' 60ul fraction 
7 (Figure 6'2'12.). 
8 (Figure 6'2'12')' 
6.3.9. Isolating PNA- binding glycoproteins from IPM 
From dot blotting experiments, IPM appeared to have a 
lower concentration of PNA -binding constituents than the 
trypsin -digest, however IPM is more readily available, 
being much easier to prepare in large volumes than is 
trypsin- digest. For this reason, attempts were made to 
isolate the PNA- binding glycoproteins from IPM. 
6.3.9. Gel filtration chromatography of IPM 
An FPLC Superose 12 10/30 HR gel filtration column was 
used to fractionate the IPM as described in Section 
4.8.4. 1m1 fractions were collected, dotted onto 
nitrocellulose and treated with PNA (4.3.4.). Two 
fractions were obtained which contained material to 
which PNA binds with an apparent molecular weight of 30- 
70Kdaltons (Figure 6.2.12 and Table 6.2.3.). This was 
distinct from the fractions containing IRBP (identified 
by the ability to bind ConA and 1001.A1). The PNA - 
binding material in this fraction was subjected to SDS- 
polyacrylamide gel elctrophoresis followed by Western 
blotting, or protein staining. The nitrocellulose was 
treated with PNA and the gel stained for protein by the 
Coommassie blue method. The stained nitrocellulose 
indicated the presence of several glycoproteins which 
are capable of binding PNA (Figure 6.3.4.) When 
compared to a Western blot of IPM and of trypsin- digest 
which had been treated with PNA (Figure 6.3.2.), the 
staining patterns of the PNA- binding were similar, 
(160) 
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Figure 6.3.5. Coomassie stained 10/ polyacrylamide 
gel visualising fractions obtained from a Superose 
12 10/30 HR FPLC column, loaded with 500ug IPM. 
50u1 fractions were loaded onto the polyacrylamide 
gel, see text for experimental details. 
1. IPM (60ug). 
2. fractions 1 -14 (Figure 6.2.12.). 
3. as 1. 
(161) 
indicating that PNA- binding glycoproteins present in IPM 
and in the trypsin- digest solution were contained in 
this gel filtration fraction. On the other hand, the 
staining patterns were very different when compared for 
polypeptide bands (Figures 6.2.8., 6.3.3. and 6.3.5.). 
According to the Coomassie stained gel, the two 
fractions (obtained by the gel filtration of IPM) 
containing the PNA -binding material, contained few of 
the proteins found in IPM and did not appear to contain 
unique polypeptides (with respect to the other fractions 
collected from IPM) as may have been expected from the 
dot blotting experiment. It is possible that the PNA - 
binding glycoproteins identified by Western blotting, 
are not visualised by the protein staining method used. 
glycoproteins often do not stain well for protein. 
In conclusion, the PNA- binding glycoproteins present in 
the IPM were isolated into two gel filtration fractions 
which were free of the majority of the other proteins 
present in IPM. 
6.3.10. Immunisation of mice with partially purified 
glycoproteins from IPM 
The gel filtration fraction containing PNA- binding 
constituents (6.3.9.) was used to immunise mice and cell 
fusions were carried out in an attempt to produce 
monoclonal antibodies against the PNA- binding 
glycoproteins found in IPM. Four such fusions were 
carried out. In the first fusion, of the 576 wells 
(162) 
observed less than 80 wells contained colonies of cells. 
Those wells which contained cell colonies were screened 
individually on Day 12 for the presence of anti -retinal 
antibodies. No fluorescence was apparent on the tissue 
sections treated with the culture media, indicating the 
absence of any anti -retina antibodies and so the fusion 
was abandoned on Day 15. The second fusion was 
abandoned on Day 5 due to the absence of colonies in the 
wells and the third fusion was abandoned on Day 6 due to 
the appearance of fungal contamination in the wells. In 
the fourth fusion, colonies were observed in most of 
the wells of the six 96 -well plates used and all were 
screened on Day 10. The majority of the sections 
treated with culture media had fluorescence across the 
entire retina at a higher level than present in the 
control sections. It was impossible to distinguish 
whether the antibodies detected were all capable of 
binding to cells across the entire retina or whether 
antibodies were present which were specific for cell 
layers within the retina. Such antibodies may have been 
present and their specificity obscured by the more 
general binding of any one of the other antibodies in 
the group of six taken together for the initial 
screening. It was not practicable to screen each of the 
576 wells individually, nor was it practicable to expand 
each well which may have contained antibody secreting 
cells. For this reason, 96 of those wells containing 
the largest colonies were expanded into four 24 -well 
(163) 
plates. When screened individually, 7 of these produced 
a high level of fluorescence throughout the retina and 
these were expanded into flasks. Further screening 
revealed no antibody secretion in 2 of the 7, the 
remaining 5 containing antibody which showed 
immunoreactivity with all the layers of the retina and 
so these were finally abandoned on Day 23. 
From this it would appear that the PNA- binding 
glycoproteins associated with the cone photoreceptors 
are not very immunogenic or that the PNA- reactive 
material contains antigenic epitopes common to most 
cells of the retina. The isolation of these 
glycoproteins from those other molecules in IPM which 
are present in abundance e.g. IRBP, did not appear to 
improve the antigenic response to this material in the 
mice immunised with it. 
(164) 
6.3.11. in vitro immunisations 
One method of producing an immune response against non - 
immunogenic material is to allow in vitro priming of the 
spleen cells before carrying out the cell fusion 
(Reading 1982). 
This was done using the gel filtration fraction 
(6.3.9.) containing the PNA- binding material isolated 
from IPM as the in vitro immunogen. 
The spleen from a ten week old female Balb /c mouse was 
asceptically removed. The cells were teased apart and 
suspended in 15ml of serum -containing medium (3.1.2.). 
5m1 aliquots of the cell suspension were added to three 
25cm flasks. The antigen mixture was sterilised by 
filtration through a 0.22um filter before being added to 
the spleen cells. Different quantities of antigen were 
added to the three flasks (10, 50 or 100ug), in the hope 
that the optimum ratio of spleen cells to antigen 
molecules would be present in at least one of the flasks 
in order to produce a strong immune response. The spleen 
cell /antigen mixtures were incubated in an atmosphere 
containing 5% COT, at 37 °C for 4 days before the fusion 
was carried out. 
The spleen cells were pooled, pelleted by centrifugation 
at 1000g for 10 minutes, and resuspended in 10m1 of 
serum -free medium. The cells were then counted before 
fusion with the myeloma cells (3.1.4.). Two such 
(165) 
fusions were carried out, the first by Dr J Haywood. In 
both cases, few colonies were produced in the wells and 
so both fusions were abandoned. 
6.3.12. Discussion 
The use of partially -purified cone -specific antigen 
failed to result in the production of any cone -specific 
monoclonal antibodies. 
The failure to produce antibodies may be explained if 
the immunisation mixtures were not particularily 
antigenic. It is often the case that molecules which 
are highly conserved between species do not elicit an 
immune response in the injected animal (coding 1983) and 
so no antibodies of any use to the research worker are 
produced. 
Another possibility is that the mice did respond to the 
immunisations and became hyperimmune to the antigens, 
but that the hybridoma cells produced in the fusion 
failed to secrete antibody. Cell fusions which produce 
colonies of hybridoma cells do not necessarily produce 
colonies of antibody- secreting cells. There is no 
safeguard against this possibility and a certain amount 
of luck is involved. 
The outer segment of the retina is highly fluorescent 
after tissue sections are treated with PNA (Figure 
6.3.1.). In comparison, the Western blots of the 
trypsin- digest treated with PNA (Figure 6.3.2), stain 
less intensely than might be expected. Although direct 
(166) 
comparisons cannot be made between the intensity of 
staining in the two different systems, one would expect 
the PNA- binding glycoproteins to be present in abundance 
in the trypsin- digest (since the PNA- binding material 
which is present on the retina is removed completely in 
the procedure used to prepare the trypsin- digest), and 
the Western blots should therefore stain strongly. 
It is possible that the glycoproteins which have been 
isolated form only a minor part of the PNA- binding 
material on the outer retina. The use of trypsin to 
liberate this material may cause the glycoproteins to be 
liberated from a larger complex, itself released from 
its attachment to the membrane by trypsin. This complex 
may be comprised of high molecular weight material, or 
of aggregates of lower molecular weight molecules such 
as glycolipids. The results of the PNA -affinity 
chromatography procedure indicated the possibility of 
the presence of galactose- containing glycolipid in the 
trypsin- digest. The fact that a material binds PNA 
indicates that it contains carbohydrate groups with 
terminal galactose sugar groups. These are usually 
associated with 0- linked carbohydrate groups (rather 
than N- linked carbohydrate groups). In general, 0- 
linked are less common than N- linked carbohydrates in 
glycoproteins, but are often found in proteoglycans and 
glycolipids (Wagh and Bahl 1981). 
(167) 
The trypsin- digest was subjected to gel filtration in 
native conditions in a similar way to IPM (4.8.4.). 
This produced a fraction containing very high molecular 
weight material which was excluded from the gel beads 
and which stained intensely when dot blotted and treated 
with PNA. This indicated the presence of high molecular 
weight, PNA- binding material in the trypsin- digest. 
Should the trypsin- digest contain a high concentration 
of PNA- binding material other than the glycoproteins 
identified in the trypsin- digest and IPM, then these 
PNA -binding glycoproteins may only constitute a minor 
proportion of the PNA- binding material associated with 
the cone photoreceptors. If this is true, then these 
glycoproteins may be present in the retina in very small 
quantities, or in very few cells, which would make the 
detection of antibodies raised against this material 
very difficult. 
In conclusion, the second method discussed in Section 
6.1., of immunising mice with purified antigen, for the 
production of cone -specific monoclonal antibodies was 
not successful. 
PNA- binding material was only partially purified. If 
antigen free from contaminants is used to immunise mice, 
in theory all the monoclonal antibodies produced from 
the subsequent cell fusions will bind the antigen. In 
practice it is very difficult to be sure of the degree 
of purity of isolated substances. The immune response 
to contaminants present in an immunisation mixture even 
(168) 
in very small amounts, is often much higher than the 
immune response to the substance against which 
antibodies are desired (coding 1983), especially if the 
contaminant is immunogenic. A method of avoiding this 
is to isolate the immunogen to the extent that it is 
possible to determine or partially determine its amino 
acid sequence (this information may be obtained more 
easily by obtaining the gene sequence). Using this 
information it would then be possible to construct a 
synthetic antigen, free from the contaminants which tend 
to co- purify with the natural antigen. 
This use of a synthetic antigen (as discussed in Section 
6.1.) was the final approach taken to raise cone - 
specific monoclonal antibodies. 
(169) 
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Figure 6.4.1 Localisation of nonconserved (black) amino 
acids in all four human visual pigments and bovine 
rhodopsin. If 4 of the 5 sequences have conserved 
substitutions and the fifth is nonconserved, the 
position is considered nonconserved. 
Amino acids are considered conserved if they belong to 
the same class (1 -5). 






(Adapted from Nathans et ál 1986) 
6.4. Immunising mice with pure antigen 
6.4.1. Introduction 
The production of cone -specific monoclonal antibodies 
should be possible by immunising mice with a pure 
protein, or a peptide fragment of a pure protein, unique 
to these cells and by taking the spleen of the immunised 
mouse to carry out a cell fusion to produce the cell - 
specific monoclonal antibodies. 
The sequence of the bovine rhodopsin gene has been 
determined (Nathans and Hogness 1984) and this has been 
used to construct oligonucleotide probes in order to 
find homologous sequences in the human genome (Nathans 
et al 19B6). The human rhodopsin gene was found to have 
very high homology with its bovine counterpart, (96% 
amino acid identity) and three other genes were found 
which have lower homology (43% amino acid identity). 
These were identified as the genes encoding the three 
cone pigment proteins present in the red, blue or green 
cones. Hydropathy plots suggest the four gene products 
have similar structures in the membrane and vary most at 
their amino terminus, present in the lumen of the disc. 
(Nathans et al 1986)(Figure 6.4.1). 
Those cDNA clones constructed for the blue pigment 
protein had a frequency one hundred and fifty times 
lower than that of the rhodopsin cDNA clones (Nathans et 
al 1986), which corresponds approximately to the ratio 
of blue cones to rods in the human retina (compared to 
(171) 
the red /green cones and rods which have an approximate 
ratio of one to thirty) (Marc and Sperling 1977, McCrane 
et al 1983). 
The eleven N- terminal amino acids of the red and green 
pigment proteins are identical, but differ from the 
corresponding amino acid sequence of the blue pigment 
protein and of rhodopsin (Nathans et al 1986). The 
higher proportions of red /green cones to blue cones 
means that there would be a greater probability of 
detecting red /green cone -specific antibodies than blue 
cone -specific antibodies. It was hoped that monoclonal 
antibodies raised against a synthetic peptide, 
corresponding to the N- terminus of the red /green pigment 
proteins would also show immunoreactivity against the 
native protein in vivo, associated with cone 
photoreceptor cells. The N- terminus of the rhodopsin 
molecule is different to that of the red /green pigment 
proteins and therefore monoclonal antibodies with 
immunoreactivity against the former should distinguish 
between these and the rod -specific protein. 
This was the approach taken attempt to raise cone - 
specific monoclonal antibodies. 
(172) 
6.4.2. Synthesis of the antigen 
An undecapeptide corresponding to the N- terminus of the 
red and green pigment proteins (N- ALA -GLN- GLN- TRP -SER- 
LEU- GLN- ARG -LEU- ALA -GLY), was synthesised using the t- 
BOC method on an LKB automatic petide synthesiser, and 
was deprotected and removed from the resin using 
trifluoroacetic acid. The resulting peptide mixture was 
subjected to HPLC using a C14 reverse phase column and 
the major peak was collected. This was carried out by Dr 
R. Kelly of the MRC Reproductive Biology Unit, 
Edinburgh. 
The purified peptide was subjected to amino acid 
analysis and was sequenced, to check that the correct 
structure had been synthesised and purified. 
(173) 
l ahl e 6.4.1 Amino acid analysis of the 
syrIthetic peptide corresponding to the N- termini 
of_ Lhe red and green cone pigment proteins. 
The reLention Limes of the peptide amino acids are 
compared with those of the standard amino acids 
and the relative amounts of each amino acid used to 
-_al cnlate the empirical ratio cf each within the 
_err dc. 
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Peptide amino acids 
retention % area empirical 
time under ratio 
(minutes) peak 
( -) (-) (--) 
( -) (-) (--) 
15.19 2.045 1. 
17.44 6.900 3 
( -) (-) (-) 
23.64 2.105 1 
25.06 4.720 2 
( -) (-) (-) 
(-) (-) (-) 
(--) (-) (-) 
( - -- ) (-) (-) 
35.19 4.867 2 
36.43 10.000 (-) 
(-) (-) (-) 
(- ) (-) (-) 
( -) (-) (-) 
(_) (-) (-) 
( -) (-) (--) 
52.02 2.671 1 
(174) 
6.4.3. Amino acid analysis 
Ten nmoles of the peptide was added to an acid -washed 
test tube containing a solution of 0.7ml of concentrated 
HC1, 0.5ml of gelatine (0.4mg /ml,w /v) and 0.2ml of 
Norleucine (100nmoles). This was frozen to -88 °C in a 
dry ice /ethanol mixture and then thawed. The tube was 
evacuated and sealed and the sample hydrolysed for 
forty -eight hours at 110 °C. It was then dessicated and 
reconstituted in equal volumes of 0.1M sodium borate 
pH10.0 and 0.2M citrate pH2.2. The sample was finally 
filtered through a 0.22um filter and loaded onto the 
amino acid analyser by Mr A Cronshaw of the Department 
of Biochemistry, Edinburgh University. 
The sample analysis was compared to that of a mixture of 
standard amino acids which had been treated identically. 
From the retention times obtained for each standard 
amino acid and that of the internal Norleucine standard, 
it was possible to determine which amino acids were 
present within the peptide, and the ratios of each. No 
tryptophan was detected as this amino acid is hydrolysed 
under the conditions used for this method (Penko et al 
1974). 
Table 6.4.1. shows the retention time for each standard 
amino acid; the retention time for each amino acid 
within the peptide; the relative concentration of each 
peptide amino acid and the empirical ratio of the 
peptide amino acids. 
(175) 
The amino acids detected in the peptide were in the 
expected ratios for the sequence which was synthesised, 
(except for tryptophan which was not detected). 
In order to be certain that the correct sequence had 
been synthesised and purified, the peptide was 
sequenced. 
6.4.4. Sequencing the synthetic peptide 
Ten U1 of the peptide mixture (0.1mg /m1) in 10% ethanol 
(approximately 1nmol) was applied to an Applied 
Biosystems Ltd automatic gas phase micro -sequencer by Dr 
L Gilmore, of the Department of Biochemistry, Edinburgh 
University. 
The method used is a variation of the Edman degradation 
method (Mendes and Lai 1975), whereby the amino acids 
are sequentially removed from the N- terminus of the 
peptide. The amino acids are reacted with phenyliso- 
thiocyanate to form the relatively unstable 
phenylthiocarbamyl derivative which isomerizes to give 
the phenylthiohydantoin (PTH) derivative of the amino 
acid. Each derivatised amino acid as individually 
analysed and the retention time obtained for each is 
compared to that of standard amino acids treated under 
identical conditions. The amount of each amino acid is 
measured (in pmols) at each liberation step, and from 
this the sequence of the peptide is determined. Table 
(176) 
Table 6.4.2. The results of seguenc i.nq the synthetic 
peptz.de corresponding to the red and green cone 
pzymç:=ti 
The 'retention time for each amino acid was compared 
to that of an internal standard DPI (data not shown). 
The concentration of other amino acids present was not 
significant (data not shown) and the expected sequence 
was obtained for the peptide. 





pmo]s , amino 
acid 
1st 11..48 671.01 ALA 
2nd 7.03 368.97 GLN 
3rd 7.03 348.96 GLN 
4th 22.30 217.54 TRP 
5th 6.72 178.64 SER 
6th 24.58 310.95 LEU 
7th 7.03 210.10 GLN 
8th 14.47 SIG ARG 
9th 24.58 218.65 LEU 
10th 11.48 183.01 ALA 
11th B.02 42.41 GLY 
SIG at a significant level, no numerical value 
obtained. 
(177) 
6.4.2. shows the retention times and the amount of the 
major amino acid liberated at each sequential step. No 
other amino acids were detected at a significant level. 
In conclusion, the expected sequence was indeed observed 
and there was little evidence of contaminating 
sequences. 
(178) 
6.4.5. Haptenisinq_ the antigen. 
To increase its antigenicitiy, it was decided to 
conjugate the undecapeptide to a larger protein. In 
many cases small proteins or peptides have in many cases 
produced an immmune response in animals after being 
haptenised to a larger protein (Goding 1983 and Weiss et 
al 1987). 
It was neccessary to conjugate the peptide to a protein 
which itself is not present in the bovine retina so that 
antibodies raised against the protein conjugated to the 
peptide would not be detected in the screening process 
and so would not be confused with any anti -peptide 
antibodies produced. 
Another criterion for choosing a suitable protein to 
conjugate to the hapten is that it should contain the 
chemical structures necessary tb allow conjugation to be 
carried out easily. 
in vivo, the N- terminus of the cone pigment protein is 
at the luminal face of the cone photoreceptor, those 
amino acids towards the C- terminus of the protein being 
embedded in the membrane (Nathans et al 1986). To mimic 
this, the peptide was conjugated via its free carboxyl 
terminus, leaving its amino terminus free in solution. 
The alcohol soluble compound N- ethoxy- carbonyl -2- 
ethoxy-1,2-dihydroquinoline (EEDQ) was used to link the 
peptide and the protein molecules. 
(179) 
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Figure 6.4.2. The reaction which takes place 
between EEDQ, the hapten and the protein to be 
conjucated. See text for experimental detail. 
Two molecules were chosen for conjugating to the peptide 
(both absent from the bovine neural retina), egg albumin 
and polylysine (the latter containing a large number of 
free amino groups available for conjugation to the 
peptide). 
EEDQ was added to a mixture of polylysine /ovalbumin and 
peptide with the latter in excess. In the 
polylysine /peptide mixture there were many more free 
amino groups on polylysine molecules than on peptide 
molecules (due to the large number of free amino groups 
on a single polylysine molecule, approximately 120). The 
addition of EEDQ to these should favour the coupling of 
the free carboxyl groups of the peptide molecules 
(present in excess of the free carboxyl groups of the 
polylysine molecules), to the free amino groups of the 
polylysine molecules (present in excess of the free 
amino groups of the peptide molecules) (Figure 6.4.2.). 
Some head -to -tail coupling would be inevitable and 
unavoidable but should have been minimised by the high 
ratio of peptide:polylysine molecules present. The EEDQ 
was added in excess to push the conjugation reaction 
towards completion. In ovalbumin, there are less free 
amino groups than in polylysine, so the likelihood of 
the desired conjugation taking place is less. It should 
be noted however that only a proportion of the reaction 
products need be the desired structure to be used for 
immunising mice. Monoclonal antibodies may be selected 
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Figure 6.4.3 The absorbance profiles between 200nm 
and 400nm, of the peptide, EEDQ, polylysine and 
the peptide- polylysine conjugate. 
1.peptide- polylysine conjugate (undiluted) 
2.peptide (0.1mg /m]., 10. ethanol) 
3.EEDG1 (1mg /ml , 100% ethanol) 
4.polylysine (1mg /ml, 25% ethanol ) 
Wig) 
photoreceptor cells in the retina, whereas those 
monoclonal antibodies raised against any other product 
of the conjugation procedure should not be detected in 
the screening process and so would be discarded. 
0.4 moles of the peptide (in ethanol), was added to 
either 0.1 moles of ovalbumin or to 0.1 moles of 
polylysine (both in solution in distilled water). For 
the polylysine /peptide mixture, this gave an approximate 
ratio of free carboxyl groups on peptide:free amino 
groups on hapten molecules of 1:30. To each of these 
mixtures was added 1 mole of EEDQ (in ethanol) to give a 
final 50% ethanol solution. The mixtures were incubated 
overnight at room temperature and then dialysed against 
50% ethanol to remove unreacted EEDQ and peptide from 
the mixture (material with MW under 12 KDalton). 
The absorbance spectra (200- 400nm) of the reactants and 
the products of the polylysine- peptide conjugation 
procedure were measured (Figure 6.4.3.). The polylysine 
and the EEDQ were found, as expected, to have little or 
no absorbance at 2B0nm and a higher absorbance towards 
the 200nm region, whereas the peptide had a higher 
absorbance at 280nm (due to the presence of tryptophan). 
The reaction products had a higher absorbance value at 
280nm than did the reactants and this was taken to 
indicate the presence of peptide in the final mixture. 
This was assumed to have been conjugated to the 
polylysine since the unreacted peptide should have been 
removed in the dialysis. 
(183) 
These measurements were not carried out for the 
ovalbumin mixture since in this case both the hapten and 
the ovalbumin absorb light at 280nm. 
(184) 
6.4.6. Production of monoclonal antibodies 
Mice were each immunised (3.1.1.) with a total of 
30nmoles of each peptide conjugate (6.4.5.), and three 
cell fusions were carried out as described in Section 
3.1.4. 
In the first fusion, the wells from 5 96 -well plates 
were screened for anti -retinal antibodies using unfixed 
bovine neural retina sections. The ability of an anti - 
peptide antibody to bind to the native protein depends 
on the ability of the peptide to attain the conformation 
that the identical sequence assumes in the native 
protein (Westhof et al 1984). To maximise the 
possibility of detecting cone -specific antibodies, 
changes in the structure of the proteins present in 
tissue sections were minimised by using unfixed tissue 
sections. Fixation of tissue may cause small changes in 
the structure of the proteins. Such changes may not 
affect the binding of antibodies with relatively high 
affinities to their antigen, but those with relatively 
low affinity may no longer bind the antigen if its 
structure is altered. This would be especially true 
for anti -peptide antibodies, which may have a high 
affinity for the synthetic antigen but would have a 
lower affinity for the native proteins. 
Four groups of 6 wells contained antibody with 
immunoreactivity against specific cell layers of the 
retina, three of these with the outer retina and one 
with the outer plexiform layer only and these were 
(185) 
expanded into 24 -well plates. A large number of the 
wells contained antibody with very general specificity 
which bound to all the cell layers of the retina. Four 
of these groups of 6 wells were also expanded into a 24- 
well plate. When screened individually, those wells 
previously containing antibody with immunoreactivity 
against specific layers of the retina, were found to no 
longer contain antibody secreting cells. One of the 24 
wells containing the general anti -retinal antibody was 
further expanded and cloned. This was named Bl and was 
used in further experiments. 
The second fusion was abandoned on Day 2 when it became 
obvious that the NSO cells had reverted to a HAT - 
insensitive state. 
In the third fusion, the wells from six 96 -well plates 
were screened and ten groups of 6 wells containing anti - 
retinal antibodies were expanded into 24 -well plates. 
These were screened individually and 9 cell lines were 
further expanded. All of these cells lines secreted 
antibody with immunoreactivity against all the cell 
layers of the retina and no cone -specific antibodies 
were produced. For this reason these cell lines were 
not cloned and one was used in further experiments. 
This was named B2. 
(186) 
fable 6.1.3. The results of dot blotting 
experiments using different antigen solutions for the 





1001.A3 no Mab B1 E12 
IPM ( -) ( + +) ( -i -+ +) ( + + +) 
FD ( +) ( +) ( + +) ( +) 
Oval (t- +) ( + +) ( + + + +) ( + +) 
Oval- -pep ( -+) (-) ( + +) ( +) 
P -lys -pep (-) (-) ( +) ( +) 
IRBF' ( -) ( -) (-a) ( -) 
al001.A3* ( -) (-41. ( +) ( + +) 
PNA ** 
( -) ( -+) ( +) ( -) 
TD = trypsin- digest 
Oval = lmg /ml ovalbumin 
Oval -pep = peptide conjugated to ovalbumin 
P -lys -pep = peptide conjugated to polylysine 
* High molecular weight material isolated from 
IPM by gel filtration 
* *PNA- binding material isolated from IPM by gel 
filtration 
( -) no binding 
( -+) little binding 
( +) binding (strength of binding denoted by 
the number of +'s) 
(1137) 
6.4.7. Competitive binding studies 
Tissue sections of the bovine neural retina were 
treated with the antibodies (2.2.1.) B1 and B2 except 
that the "anti- peptide antibodies" were preincubated and 
incubated in 100V1 aliquots of ovalbumin or polylysine 
(1mg /ml)(w /v). This was done in an attempt to compete 
out antibody binding to the tissue sections with 
antigen in solution. Should the monoclonal antibodies 
bind to the ovalbumin or polylysine molecules, then the 
tissue sections should not bind to antibody and no 
fluorescence would be detected. 
Staining patterns and intensity of staining were 
identical to tissue sections stained to visualise anti - 
peptide antibody binding. This indicated that either 
the monoclonal antibodies were binding to antigenic 
sites in the retina which are not present on 
ovalbumin /polylysine molecules, or else they bind to the 
retina with a higher affinity than the antigenic sites 
present on these molecules. 
6.4.B. Immunodotting of anti -peptide antibodies 
Immunodotting experiments were carried out (3.2.1.) 
using polylysine, ovalbumin or the peptide -protein 
conjugates as the antigen solutions (1mg /ml)(w /v). 
Control dots using antibody diluting solution (2.2.1.) 
to replace the B1 or B2 antibody culture media, showed 
non -specific binding occurring (Table 6.4.3.). This 
must be between the polylysine / ovalbumin and a component 
(1BB) 
of the incubation solutions. No conclusions can be 
drawn from these immunodotting experiments in which the 
81 and 82 antibodies showed immunoreactivity with both 
the ovalbumin and the polylysine (Table 6.4.3.). This 
suggested the ovalbumin and the polylysine may bind non- 
specifically to component(s) present in the 2nd antibody 
solution or in the streptavidin -HRP conjugate solution. 
81 and B2 both showed immunoreactivity with the IPM, 
which was not seen in the control dot experiments. 82 
showed immunoreactivity with every antigen solution it 
was tested against, whereas 81 showed weak immuno- 
reactivity against some of these (Table 6.4.3.). From 
the intensity of staining it seems the 82' culture medium 
has a much higher antibody titre than does 81, and binds 
with less specificity to a wider range of substances 
than 81. The non -specific binding makes it difficult to 
distinguish any specific immunoreactivity of the 
antibodies. 
6.4.9. Discussion 
The staining patterns of the antibodies 81 and B2 on 
tissue sections of the bovine neural retina indicate 
that the "anti- peptide" antibodies bind many components 
of cells within the retina, other than the cone 
photoreceptors. This is most probably due to non- 
specific binding of the antibodies to the tissue, rather 
than the presence of cone -like proteins throughout the 
retina. 
(189) 
It was assumed that the synthetic undecapeptide would 
adopt the same conformation in vitro as does the 
corresponding sequence of the native protein in vivo. 
This may not be the case and antibodies may have been 
produced with strong immunoreactivity against the 
synthetic peptide but with very weak immunoreactivity 
against the sequence in vivo. Such antibodies would not 
have been detected in the screening process used. It 
should be noted that the synthetic peptide corresponds 
to the N- terminus of a human protein and that the 
monoclonal antibodies produced were tested for their 
immunoreactivity against bovine retina. It was assumed 
that differences in the primary structure of the 
protein, between species would be minimal (as is the 
case between human and bovine rhodopsin) (Nathans et al 
1986), and that an antibody with immunoreactivity 
against the protein in one species would cross -react 
with the protein of the other species. It proved 
impossible to obtain human retinas and so no human 
tissue sections could be treated with the "anti- peptide" 
antibodies. Differences in the structure of the protein 
between the species, may cause a reduction in binding of 
the monoclonal antibodies to the bovine tissue being 
tested. 
(190) 
SECTION 7; SUMMARY 
Section 7 Final remarks and conclusions. 
Three methods have been discussed by which attempts were 
made to produce monoclonal antibodies specific for 
molecules present on the surfaces of the rod and cone 
photoreceptor cells, or present in the IPM but 
associated with the photoreceptor cells. 
In the first method a crude antigen mixture was used to 
immunise mice. This method seemed least likely to 
succeed in producing the cell- specific monoclonal 
antibodies required, as it very much depended on luck as 
to whether the desired antibodies were produced. 
The second and third methods involved the purification 
of antigen, or the chemical synthesis of pure antigen 
for immunisation of mice. These approaches seemed more 
likely to be successful as the chances of producing less 
specific antibodies should have been reduced. In 
practice, however, the use of crude antigen mixtures 
resulted in the production of two interesting monoclonal 
antibodies whereas the use of the purer antigen mixtures 
and the synthetic antigen failed to result in the 
production of any interesting antibodies. The first 
method was the easiest to carry out in that no 
purification steps of the antigen were needed and the 
selection of photoreceptor and IPM -specific antibodies 
was carried out in the screening process. The initial 
selection process was based on treatment of tissue 
sections with the putative antibody- containing culture 
(191) 
supernatants. This allowed antibodies which bound 
specifically to the photo- receptors or to the IPM to be 
identified and the cells producing them to be expanded 
and cloned for further antigen analysis to be carried 
out. This seemed the most efficient screening process 
available. It made possible the screening of six 
hundred culture supernatants simultaneously. The use of 
tissue sections also rules out, or at least reduces, the 
possibility of false positives in that it would be 
unlikely that non -specific binding would be limited to a 
specific area within the tissue sections, whereas a 
false positive dot blot or Western blot is quite likely 
to occur and not be recognised as such immediately, 
leading to much unnecessary work and frustration. Some 
workers have used immune precipitation techniques in 
their initial screening. This would appear an excellent 
method (albeit tedious) and would select only high 
affinity antibodies. It does, however assume that the 
antigen is suitable for detecting by the methods to be 
used (usually gel electrophoresis and Western blotting) 
and that it is present as a single soluble species and 
not as an aggregate. In my case it is unlikely that 
such a screening method would have resulted in the 
detection of any useful antibodies as those antibodies 
which were detected by screening on sections appeared to 
have low affinity for the antigen or to bind to 
molecules not suitable for SDS -PAGE detection methods. 
This of course assumes that all the antibodies present 
(192) 
were in fact detected by the tissue section method (that 
is, not masked by aldehyde fixation) although one would 
expect high affinity monoclonal antibodies to be 
detected by all screening methods. 
The general approach taken in this project to detect 
cell- specific molecules of the retina was carried out 
using bovine tissue, due to a readily available supply. 
There are questions to be asked about the direct 
relevance of work carried out using this tissue with 
respect to human tissue and human retinal abnormalities. 
The lack of availability of human tissue was a great 
drawback, as no direct comparisons could be made between 
the species. Such problems may be solved in the future 
by the use of immortal cell lines derived from human 
retinal cell types, such as photoreceptor cells. Such 
cell lines may provide a model system for the study of 
these cells without the need for biopsy or autopsy 
tissues. 
This project was carried out with the aim of producing 
monoclonal antibodies against molecules on, or 
associated with, the surfaces of the photoreceptor cells 
with the view to characterising these molecules. 
Further studies would then be possible to consider the 
role these molecules play in the development of the 
adult tissue or in tissues affected by disease. 
(193) 
The locations and quantities of the molecules could be 
compared in normal adult tissue, developing tissue and 
diseased tissue in different species in which the 
antibodies cross -react. Monoclonal antibodies raised 
specifically against cone or rod cells can be used as 
markers to distinguish unequivocally between these cell 
types. 
Two interesting monoclonal antibodies have been raised. 
The first, 1001.A1, binds the interstitial retinol 
binding protein (IRBP), the major glycoprotein of the 
interphotoreceptor matrix (IPM). This glycoprotein is 
synthesised by the rod photoreceptor cells and secreted 
into the IPM. In reality, many different monoclonal 
antibodies were raised against this glycoprotein and 
these may prove to be very useful tools for the 
identification of specific fragments within the 
polypeptide structure. Antigenic analysis has not yet 
been carried out. Digestion of the purified IRBP 
molecules with cyanogen bromide or proteolytic enzymes 
followed by characterisation of the antibody- binding 
specificities with respect to the purified peptide 
fragments would be possible, for example, using 
competitive ELISA techniques. This knowledge may be put 
to use in studies whereby the effects of smaller, 
defined fragments of the complete molecule are being 
tested, for instance in their ability to induce 
experimental uveitis. Here polyclonal antibodies could 
(194) 
not be used as they will not differentiate between the 
isolated fragments. However, should the antibodies all 
be specific for a particular fragment of the full length 
polypeptide, this may have important implications with 
respect to immunological studies of the retina and RPE 
with respect to this molecule. 
The second monoclonal antibody, 1001.A3, which was 
raised against a soluble chondroitin sulphate 
proteoglycan within the IPM proved to be very 
interesting. Immunohistochemistry revealed the antigen 
to be present around the inner and outer segments of the 
photoreceptor cells. It is not clear from the 
histochemical data obtained whether the antigen is 
specific for the rod photoreceptors or whether it is 
associated also with the cone photoreceptor cells. The 
antigen is mostly soluble and much of it is removed by 
washing the retina. The insoluble fraction remains 
associated with the photoreceptors but not specifically 
with the cones. Washed bovine retina treated with 
antibodies raised against chondroitin -6- sulphate 
molecules shows a similar binding pattern. There is 
also a soluble fraction of chondroitin -6- sulphate 
molecules, present in IPM. In primates, chondroitin -6- 
sulphate molecules are associated specifically with the 
cone photoreceptors, whereas in rodents, chondroitin -6- 
sulphate molecules are associated with the photo- 
receptors in a more general manner, not specifically 
(195) 
with the cones. It may be that in primates, the 1001.Á3 
antigen is associated only with the cone photoreceptors 
whereas in non -primates, the 1001.Á3 antigen is more 
generally distributed, as are chondroitin-ó- sulphate- 
containing molecules. Double labelling experiments 
using PNA and 1001.Á3 may show the distribution of the 
1001.A3 antigen with respect to the rod and cone 
photoreceptor cells in both washed and control retina. 
There is a very great deal of work still to be done 
making use of the 1001.Á3 monoclonal antibody. Only the 
initial characterisation of the antigen has been carried 
out. One problem associated with the 1001.Á3 antigen is 
that it does not appear to stain with the protein and 
carbohydrate -specific stains used to date and has only 
been identified by the ability of 1001.Á3 to bind to it. 
Enzymatic treatment which degrades the structure of the 
antigen tends to abolish any immunoreactivity and 
therefore the molecule is no longer detectable. This 
has hindered progress in characterising the structure of 
the molecule more fully. It would be helpful to have 
available monoclonal antibodies which recognise 
different structures within the antigen. Antibodies 
specific for the core protein of the molecule for 
example, would be very useful to allow the polypeptide 
structure to be characterised. Future work should 
involve the production of monoclonal antibodies against 
the partially purified 1001.A3 antigen, which has been 
(196) 
subjected to treatment with chondroitìnase ABC or 
hyaluronidase, for example. The availability of 
antibodies against both the complete structure and 
against the enzymatically- treated molecules would be 
very useful and should be relatively easily achieved. 
If it is possible to identify the core protein by means 
of a second antibody, and to remove the 
glycosaminoglycan side chains of the proteoglycan from 
the polypeptide, the purification of the core protein 
should be possible. This should be done with the view 
to obtaining at least a partial sequence of the 
structure. 
The knowledge of a partial amino acid sequence, together 
with monoclonal antibodies raised against the core 
protein, and also the complete structure of the 
proteoglycan molecule would be a very powerful 
combination. For example, cDNA expression libraries of 
the neural retina or of the retinal pigmented epithelium 
(RPE) may be screened with the antibodies in order to 
isolate the gene for this molecule. Antibodies raised 
against the core protein would be much more likely to 
succeed in this detection process due to the fact that 
1001.Á3 recognises post -translational modifications of 
the molecule which may not be produced, or may not be 
produced in the same way, in the expression vectors. 
However, without the knowledge of where the 1001.A3' 
antigen is synthesised one cannot be sure of which cDNA 
library to use. 
(197) 
Experiments involving the culture of pigmented 
epithelium cells or retinal cells, followed by tests to 
establish whether the 1001.A3 antigen is secreted by any 
of these cell types, may establish the source of the 
antigen. 
A partial amino acid sequence of the core protein may 
provide another method to find the cell types involved 
in synthesising the antigen. Various approaches are 
available, such as the construction of a collection of 
oligonucleotide probes for use in in situ hybridisation 
studies. This would allow studies to be carried out on 
the messenger RNA molecules of the core protein and 
hence the site of synthesis may be found. This would 
verify the tissue of origin of the core protein and 
would indicate which expression libraries would be 
suitable for use. These expression libraries could 
also be screened using the oligonucleotides in favour of 
the antibodies. Isolation of the gene would of course 
open up a whole new field of study, enabling gene 
sequencing and chromosome mapping to be carried out. 
Comparisons may be made with other core protein 
structures, possibly leading to clues as to the function 
of the molecule. Chromosomal location would make it 
possible to determine whether the proteoglycan core 
protein is linked to known human disease loci, for 
example retinitis pigmentosa, in which diseases have 
been linked to chromosomal locations but where the 
actual gene involved is unknown. 
(198) 
The 1@01.A3 monoclonal antibody should be tested for 
immunoreactivity with other species. It is known to 
bind specifically to rat tissue, and other species such 
as human and mouse should also be tested. The ability 
to use rodent tissue would open up new investigative 
possibilities. It would be possible to carry out a 
developmental study of the mouse retina, during 
gestation and also during the period after birth in 
which the retina continues to develop. Animal models of 
human disease may also be used, such as the rd mouse and 
the RCS rat. This may prove interesting as 
abnormalities of the composition of the IPM have been 
implicated in such diseases. Changes in the structure 
or quantity of the 1001.A3 antigen could be monitored 
and compared to the normal developmental pattern. 
Finally it may be possible to continue the studies of 
the 1001.A3 antigen by the more direct method of 
immunohistochemistry using electron microscopy. This is 
a very specialised technique involving fixation, 
embedding and sectioning expertise. It may be possible 
to study the structure of the 1001.A3 antigen much more 
closely using the high resolution of electron 
microscopy. Conditions may be found to enable this 
molecule to be studied without loss of immunoreactivity. 
This may lead to the verification of the exact location 
of the antigen with respect to the rod and cone 
photoreceptors, as it woud be possible to distinguish 
(199) 
the rod and cone cells and to find whether binding is 
common to both or restricted to a single type of 
photoreceptor. This method may also elucidate where the 
proteoglycan is synthesised, whether this occurs within 
the photoreceptor cells or within the RPE. 
Several attempts were made to raise monoclonal 
antibodies against the PNA- binding glycoproteins 
associated with the cone photoreceptor cells. No such 
antibodies were raised which led to the conclusion that 
it is possible that these molecules are not particularly 
antigenic and that perhaps the production of antibodies 
against these molecules is not the best approach to take 
towards characterising them. It was found that these 
PNA- binding glycoproteins may be released from the 
retina by treatment with trypsin. Previously it had 
proved difficult to even partially purify these 
molecules from the retina since they are so tightly 
attached, as opposed to the soluble components of the 
IPM which were easily isolated. Further studies however 
indicated that the soluble IPM does in fact contain 
small quantiites of these molecules, normally found 
associated with the cone photoreceptor cells. These are 
present in the IPM in the form of PNA- binding 
glycoproteins and chondroitin -6- sulphate containing 
molecules. A sensible approach would therefore be to 
purify these molecules from the IPM or the trypsin 
digest, using conventional chromatography methods. The 
(200) 
use of conventional chromatography would be especially 
suited to the isolation of the PNA- binding 
glycoproteins. The use of a narrower range gel 
filtration columns and /or combinations of ion exchange, 
reverse phase, or hydrophobic interaction chromatography 
may lead to the purification of these molecules to the 
point whereby it is possible to obtain a partial amino 
acid sequence of the glycoproteins. From this it may be 
possible to take the approach of obtaining oligo- 
nucleotide probes in order to carry out in situ 
hybridisation studies and studies at the gene level, as 
discussed above, with respect to the core protein of the 
100i.Á3 antigen. Another approach would be to 
synthesise synthetic peptides corresponding to sequences 
within the polypeptide backbones of the glycoproteins, 
in order to raise monoclonal or polyclonal antibodies 
against the complete protein. To increase the chances 
of success, it would be important to obtain synthetic 
sequences of 20 -30 amino acids to ensure that any 
antibodies produced against the synthetic peptide, also 
bind to the full length protein with some degree of 
avidity. Such antibodies would allow studies to be 
carried out on the PNA- binding glycoproteins, 
independently of their glycosylation state. It is 
possible that these molecules are also present in non - 
glycosylated forms or with varying degrees of 
glycosylation, and such states would not be 
distinguished by the PNA lectin. Antibodies would also 
(201) 
distinguish between the different PNA- binding 
glycoproteins whose localisation and concentrations may 
be very different within the tissue. PNA would also not 
distinguish between these. 
The final approach taken to raise monoclonal antibodies, 
specific for the photoreceptors was to use a synthetic 
antigen in the form of a synthetic peptide corresponding 
to the amino acid sequence of the N- terminus of cone - 
pigment proteins. No cone -specific monoclonal 
antibodies were produced by this method, probably due to 
the short length of the peptide antigen. Antibodies may 
have been produced with high affinities to the synthetic 
antigen, but which were not detected in the screening 
process due to their low affinities to the full length 
protein in vivo . If such an approach was to be taken 
again, a longer synthetic antigen should be used. This 
may lead to the production of antibodies with high 
affinities to both the synthetic antigen and to the full 
length protein. This has already been proved possible 
with the cone pigment proteins (Lerea et al 1989). 
An alternative approach to raising antibodies against 
proteins such as the cone pigment proteins, of which the 
gene sequence is known, is to produce a synthetic fusion 
protein in bacteria to use as the antigen. This method 
has the advantage that large quantities of the whole 
protein sequence are used, leading to the production of 
high affinity antibodies to the protein in vivo. A 
(202) 
fusion protein may be constructed either by using a 
genomic clone of the gene, or if this is unavailable, by 
using the polymerase chain reaction (PCR) to amplify the 
gene sequence required. RNA (isolated from tissue which 
expresses the gene product) may be used as the starting 
material, to produce a small quantity of cDNA by means 
of the reverse transcriptase enzyme. PCR may then be 
used to produce a large quantity of the gene sequence 
required which can be put directly into an expression 
vector. If a promoter such as that of the /3- 
ga.lactosidase gene or the protein A gene is used, 
expression of the fusion protein in E. coli cells may be 
maximised by induction of the promoter. 
Fusion proteins have been made successfully for example, 
of the inhibitory sub -unit of rod cGMF phospho- 
diesterase. In this case large amounts of the protein, 
corresponding to that of approximately 2500 bovine eyes 
were purified (Brown and Stryer 1989). 
In conclusion, as discussed above, the production of 
cell -specific monoclonal antibodies may provide very 
useful tools which enable the distribution of a 
particular molecule to be studied. Such antibodies may 
also be used to screen cDNA expression libraries. This 
may determine which cDNA clones are cell- specific where 
the antigen may not be known, or may determine those 
specific for a known protein, for example IRBP (Barrett 
(203) 
et al 1985). Gene analysis of the antigen is then 
possible. In this way molecular biology techniques and 













acetic acid: glacial acetic acid 
BSA: bovine serum albumin 
cDNA: cloned deoxyribonucleic acid 
cGMP: cyclic guanosine monophosphate 
COQ: carbon dioxide 
dGDP: deoxyguanosine diphosphate 
dGTP: deoxyguanosine triphosphate 
dTDP: deoxythiamine diphosphate 
dTMP: deoxythiamine monophosphate 
dTTP: deoxythiamine monophosphate 
DNA: deoxyribonucleic acid 
EDTA: ethylenediamine tetra acetic acid 
FITC: fluorocein isothiocyanate 
GDP: guanosine diphosphate 
GTP: guanosine 5'- triphosphate 
HCl: hydrochloric acid 
HEPES: N-( 2- hydroxyethyl)piperazine -N " -2- ethane 
sulphonic acid 
H =O =: hydrogen peroxide 
HPLC: high performance liquid chromatography 
KDa: Kilo daltons 
M: Molar 
Mab: monoclonal antibody 
MES: morpholino- ethane -sulphonic acid 
mg: milligramme 
mM: millimolar 
Mr: molecular weight. 
NH -: ammonia 
nm: nanometre 
OS outer segments 
pI: isoelectric point 
pMols: pico moles 
PMSF: phenylmethylsulphonyl fluoride 
RT: relative mobility with respect to the 
tracker dye 
RNA: ribonucleic acid 
RPE retinal pigmented epithelium 
SDS: sodium dodecyl sulphate 
TBS: tris buffered saline 
TWEEN 20: polyoxyethylenesorbitan monolaurate 
U: international enzyme unit 





It should be noted that throughout the text the Greek 
character p is denoted u. 
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